<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006722.pub2" GROUP_ID="DEPRESSN" ID="162806050415030270" MERGED_FROM="" MODIFIED="2008-11-05 22:31:55 +0100" MODIFIED_BY="Rachel Churchill" NOTES="&lt;p&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-05 21:28:04 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2008-11-05 22:31:55 +0100" MODIFIED_BY="Rachel Churchill">
<TITLE>Psychostimulants for depression</TITLE>
<CONTACT MODIFIED="2008-11-05 22:31:55 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="12236" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Bridget</FIRST_NAME><LAST_NAME>Candy</LAST_NAME><POSITION>Cochrane Research Fellow </POSITION><EMAIL_1>b.candy@medsch.ucl.ac.uk</EMAIL_1><EMAIL_2>bridget@metaclarity.com</EMAIL_2><ADDRESS><DEPARTMENT>Marie Curie Palliative Care Research Unit, Department of Mental Health Sciences</DEPARTMENT><ORGANISATION>Royal Free &amp; University College Medical School </ORGANISATION><ADDRESS_1>Hampstead Campus </ADDRESS_1><ADDRESS_2>Rowland Hill Street </ADDRESS_2><CITY>London</CITY><ZIP>NW3 2PF </ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7794 0500 ext 38667 </PHONE_1><PHONE_2> </PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-05 22:31:55 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="12236" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Bridget</FIRST_NAME><LAST_NAME>Candy</LAST_NAME><POSITION>Cochrane Research Fellow </POSITION><EMAIL_1>b.candy@medsch.ucl.ac.uk</EMAIL_1><EMAIL_2>bridget@metaclarity.com</EMAIL_2><ADDRESS><DEPARTMENT>Marie Curie Palliative Care Research Unit, Department of Mental Health Sciences</DEPARTMENT><ORGANISATION>Royal Free &amp; University College Medical School </ORGANISATION><ADDRESS_1>Hampstead Campus </ADDRESS_1><ADDRESS_2>Rowland Hill Street </ADDRESS_2><CITY>London</CITY><ZIP>NW3 2PF </ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7794 0500 ext 38667 </PHONE_1><PHONE_2> </PHONE_2></ADDRESS></PERSON><PERSON ID="AEE175AD82E26AA2013FC4378D9C2239" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Louise</FIRST_NAME><LAST_NAME>Jones</LAST_NAME><POSITION>Head of Marie Curie Palliative Care Research Unit</POSITION><EMAIL_1>l.jones@medsch.ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Marie Curie Palliative Care Research Unit, Department of Mental Health Sciences</DEPARTMENT><ORGANISATION>Royal Free &amp; University College Medical School</ORGANISATION><ADDRESS_1>Hampstead Campus</ADDRESS_1><ADDRESS_2>Rowland Hill Street</ADDRESS_2><CITY>London</CITY><ZIP>NW3 2PF</ZIP><COUNTRY CODE="GB">UK</COUNTRY><FAX_1>+44 207 267 9157</FAX_1></ADDRESS></PERSON><PERSON ID="B8C26FF082E26AA200CD32E55D6D8D44" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Rachael</FIRST_NAME><LAST_NAME>Williams</LAST_NAME><POSITION>Research Statistician</POSITION><EMAIL_1> r.williams@medsch.ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Marie Curie Palliative Care Research Unit, Department of Mental Health Sciences</DEPARTMENT><ORGANISATION>Royal Free &amp; University College Medical School</ORGANISATION><ADDRESS_1>Hampstead Campus</ADDRESS_1><ADDRESS_2>Rowland Hill Street</ADDRESS_2><CITY>London</CITY><ZIP>NW3 2PF</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 020 7794 0500 ext 34882</PHONE_1><PHONE_2>+44 020 7830 2808</PHONE_2></ADDRESS></PERSON><PERSON ID="AEE3521E82E26AA2013FC43729C19530" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Adrian</FIRST_NAME><LAST_NAME>Tookman</LAST_NAME><EMAIL_1>adrian.tookman@royalfree.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Marie Curie Palliative Care Research Unit, Department of Mental Health Sciences</DEPARTMENT><ORGANISATION>Royal Free &amp; University College Medical School</ORGANISATION><ADDRESS_1>Hampstead Campus</ADDRESS_1><ADDRESS_2>Rowland Hill Street</ADDRESS_2><CITY>London</CITY><ZIP>NW3 2PF</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="AEE506D382E26AA2013FC43799769D8E" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Michael</FIRST_NAME><LAST_NAME>King</LAST_NAME><POSITION>Head of Department</POSITION><EMAIL_1>m.king@medsch.ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Marie Curie Palliative Care Research Unit, Department of Mental Health Sciences</DEPARTMENT><ORGANISATION>Royal Free &amp; University College Medical School</ORGANISATION><ADDRESS_1>Hampstead Campus</ADDRESS_1><ADDRESS_2>Rowland Hill Street</ADDRESS_2><CITY>London</CITY><ZIP>NW3 2PF</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 207 830 2397</PHONE_1><FAX_1>+44 207 830 2808</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-05 21:21:57 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 9/30/07&lt;/p&gt;&lt;p&gt;New studies found but not yet included or excluded: 2/15/08&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 6/21/06&lt;/p&gt;" NOTES_MODIFIED="2008-11-05 21:21:57 +0000" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="11" MONTH="2" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="2" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="2" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2008"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="5" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="11" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Marie Curie Palliative Care Research Unit, London</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Royal Free and University College Medical School, London</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-05 21:28:04 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Psychostimulants for depression</TITLE>
<SUMMARY_BODY>
<P>Depression is common and under-treated. The current first-line drug treatment for moderate or severe depression is antidepressants, but there are problems with their use. This review evaluated the evidence from randomised controlled trials (RCTs) evaluating the effectiveness of psychostimulants (PS) in the treatment of depression. Twenty-four RCTs were identified, of which 14 had data for meta-analysis. Five drugs were evaluated, including dexamphetamine, methylphenidate, methylamphetamine, pemoline and modafinil. Modafinil was evaluated separately as its pharmacology differs from other PS. Three small trials of PS involving a total of 62 participants indicated that oral treatment with PS in the short term (up to four weeks) significantly reduced depressive symptoms when compared with placebo, however, the overall quality of the trials was poor, limiting confidence in the findings. Two trials involving 411 participants compared modafinil against placebo when combined with antidepressant treatment at 6-8 weeks, and showed a non-significant difference in reducing depression symptoms. One small trial of 50 participants compared oral modafinil against placebo after 12 weeks of treatment, and also showed a non-significant difference in reducing depression symptoms. No trials examined the longer-term effect of PS. Further well conducted trials with long term follow-up are required to find out which PS may be more effective in the treatment of depression, and whether PS are more effective in certain subgroups of depressed patients.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Depression is common, disabling, costly and under-treated. There are problems in the current first-line drug treatment, antidepressants, for moderate or severe depression. There is a body of research that has evaluated the effect of psychostimulants (PS) in the treatment of depression. This has not been reviewed systematically.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effectiveness of PS in the treatment of depression and to assess adverse events associated with PS.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Databases CCDANCTR-Studies and CCDANCTR-References were searched on 21/6/2006. Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, PsycInfo, AMED, CINAHL, Dissertation Abstracts and the National Health Service Research Register were searched. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials (RCTs) assessing the effectiveness of PS were included. The trial population comprised adults of either sex with a diagnosis of depression. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two review authors extracted the data independently and assessed trial quality. Meta-analysis was considered for trials with comparable key characteristics. The primary outcome was depression symptoms, based on a continuous outcome, using the standardised mean difference (SMD), or a dichotomous measure of clinical response, using odds ratios (OR), with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Twenty-four RCTs were identified. The overall quality of the trials was low. Five drugs were evaluated; dexamphetamine, methylphenidate, methylamphetamine, pemoline and modafinil. Modafinil was evaluated separately as its pharmacology is different to that of the other PS. PS were administered as a monotherapy, adjunct therapy, in oral or intravenous preparation and in comparison with a placebo or an active therapy. Most effects were measured in the short term (up to four weeks). Thirteen trials had some usable data for meta-analyses. Three trials (62 participants) demonstrated that oral PS, as a monotherapy, significantly reduced short term depressive symptoms in comparison with placebo (SMD -0.87, 95% CI -1.40, -0.33, with non-significant heterogeneity. A similar effect was found for fatigue. In the short term PS were acceptable and well tolerated. Tolerance and dependence were under evaluated. No statistically significant difference in depression symptoms was found between modafinil and placebo. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is some evidence that in the short-term, PS reduce symptoms of depression. Whilst this reduction is statistically significant, the clinical significance is less clear. Larger high quality trials with longer follow-up and evaluation of tolerance and dependence are needed to test the robustness of these findings and, furthermore, to explore which PS may be more beneficial and in which clinical situations they are optimal.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-05 21:28:04 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>
<B>Description of condition</B>
<BR/>Depression is a common (<LINK REF="REF-Singleton-2001" TYPE="REFERENCE">Singleton 2001</LINK>), disabling (<LINK REF="REF-Spitzer-1995" TYPE="REFERENCE">Spitzer 1995</LINK>; <LINK REF="REF-Cassano-2002" TYPE="REFERENCE">Cassano 2002</LINK>), costly (<LINK REF="REF-Murray-1997" TYPE="REFERENCE">Murray 1997</LINK>; <LINK REF="REF-Thomas-2003" TYPE="REFERENCE">Thomas 2003</LINK>) and under-treated condition (<LINK REF="REF-Bebbington-2000" TYPE="REFERENCE">Bebbington 2000</LINK>; <LINK REF="REF-Demyttenaere-2004" TYPE="REFERENCE">Demyttenaere 2004</LINK>; <LINK REF="REF-Singleton-2001" TYPE="REFERENCE">Singleton 2001</LINK>; <LINK REF="REF-Wang-2005" TYPE="REFERENCE">Wang 2005</LINK>). The health burden of depression is recognised by the World Health Organisation (WHO) where an international initiative that aims to raise awareness, and improve recognition and treatment of depression has been launched. At a national level, several countries, including European states, the US, and Australia, have programme objectives in depression set as a priority for health in the 21st century. Depression is characterised by depressed mood and/or loss of interest or pleasure in nearly all activities in the presence of other symptoms such as loss of appetite, fatigue and lack of energy, sleep disturbance, restlessness or irritability, feelings of worthlessness or inappropriate guilt, difficulty thinking, concentrating or making decisions and thoughts of death or suicide or attempts at suicide (<LINK REF="REF-APA-2005" TYPE="REFERENCE">APA 2005</LINK>). Only about 30% to 40% of people in the community who meet diagnostic criteria for depression receive any form of medical or psychological treatment (<LINK REF="REF-Lin-1999" TYPE="REFERENCE">Lin 1999</LINK>; <LINK REF="REF-Singleton-2001" TYPE="REFERENCE">Singleton 2001</LINK>) and this falls to 25% or less when only treatments judged to be of minimal adequacy or better are included (<LINK REF="REF-Young-2001" TYPE="REFERENCE">Young 2001</LINK>). Talking therapies are popular and effective but are in short supply in community settings in Europe, USA and elsewhere.</P>
<P>
<B>Description of intervention</B>
<BR/>Depression is associated with disturbances in the neurotransmitter systems/serotonin, noradrenaline and/or dopamine in the central nervous system. Antidepressant drugs elevate the levels of these neurotransmitters in the synaptic cleft by blocking their re-uptake; all have been shown to be effective in the alleviation of depressive symptoms. However, there is still considerable doubt about the precise role of the monoamine neurotransmitters in depression (<LINK REF="REF-Delgado-2000" TYPE="REFERENCE">Delgado 2000</LINK>). There has also been a reluctance to use other chemicals, such as PS, to increase monoamine concentrations and function, usually because of fears of misuse or dependence. </P>
<P>The current first line drug treatment for moderate or severe depression is antidepressants such as selective serotonin reuptake inhibitors (e.g. fluvoxamine, sertraline, citalopram) or tricyclic and related antidepressants (e.g. amitriptyline, imipramine, lofepramil) (<LINK REF="REF-NICE-2004" TYPE="REFERENCE">NICE 2004</LINK>). Monoamine oxidase inhibitors (e.g. phenelzine, moclobemide) may also be useful. However, there are a number of problems with their use:<BR/>(i) There is evidence for the efficacy of antidepressant drugs but it has been argued that their clinical effect may be weak (<LINK REF="REF-Moncrieff-2005" TYPE="REFERENCE">Moncrieff 2005</LINK>); (ii) adherence to treatment may be poor (<LINK REF="REF-Maddox-1994" TYPE="REFERENCE">Maddox 1994</LINK>) and approximately one third of patients who adhere to treatment do not recover; (iii) antidepressants usually have a therapeutic effect within a week and possibly up to three weeks to have full effect; (iv) reduced energy is a core feature of depression but many antidepressants do not alleviate this symptom; (v) fatigue may also be a complication of therapy with antidepressants: this may be particularly important in people with co-morbid physical illness.</P>
<P>
<B>How the intervention might work</B>
<BR/>Psychostimulants (PS) are drugs known to reduce fatigue and promote alertness and wakefulness. They are a possible alternative to antidepressants, although the conditions for which they are used are limited. Currently in the UK they are only approved for use in the treatment of attention-deficit hyperactive disorder (<LINK REF="REF-BNF-2007" TYPE="REFERENCE">BNF 2007</LINK>). With the exception of modafinil and caffeine, PS increase synaptic activity of the monoamine neurotransmitters, dopamine, noradrenaline and serotonin and have an indirect agonist effect by increasing neurotransmitter function/release rather than a direct effect on postsynaptic receptors. All produce a similar increase in monoamine activity. The main advantage of PS over selective serotonin reuptake inhibitors and tricyclic antidepressants may be their time course of action. PS appear to act quickly: some patients report an improved sense of well being within 24 hours. They may also promptly reduce fatigue and increase energy, benefits that may be crucial in those with severe physical illness or in older people (<LINK REF="REF-Nguyen-2005" TYPE="REFERENCE">Nguyen 2005</LINK>).</P>
<P>
<B>Why it is important to do this review</B>
<BR/>Why PS are not considered a treatment option in depression (NICE 2004) may relate in part to uncertainty about their effectiveness and safety. Earlier reviews of the evidence on effectiveness of PS for depression have reported inconsistent results across studies (<LINK REF="REF-Chiarello-1987" TYPE="REFERENCE">Chiarello 1987</LINK>; <LINK REF="REF-Linet-1989" TYPE="REFERENCE">Linet 1989</LINK>; <LINK REF="REF-Masand-1998" TYPE="REFERENCE">Masand 1998</LINK>;<LINK REF="REF-Orr--2007" TYPE="REFERENCE">Orr 2007</LINK>; <LINK REF="STD-Postolache-1999" TYPE="STUDY">Postolache 1999</LINK>; <LINK REF="REF-Satel-1989" TYPE="REFERENCE">Satel 1989</LINK>). In addition there is potential for misuse, dependence and associated withdrawal reactions and under current legislation in the United Kingdom most PS are controlled substances. We believe it is time to review the place of PS in the treatment of depression and to decide whether further research is needed to evaluate their efficacy in particular settings, such as treatment for mood disorders and fatigue in patients with advanced progressive disease.<BR/> </P>
</BACKGROUND>
<OBJECTIVES>
<P>1. To examine the effectiveness of PS in the treatment of depression. <BR/>2. To assess adverse events associated with use of PS as a treatment for depression.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised controlled trials (RCTs) were included. Observational cohort or cross-sectional studies were not included. For any RCTs using a cross-over design, we used data from analysis from the first comparative phase only or where the means and standard deviations were reported for each trial arm separately. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>
<B>Patient characteristics and diagnosis </B>
<BR/>Participants were adults (aged 16 and over) of either sex receiving a psychostimulant (PS) as a treatment for depression. Trials were included if the diagnosis of depression was made according to any edition of the Diagnostic and Statistical Manual for Mental Health (DSM) or the World Health Organisation's International Classification of Diseases (ICD) or when a clinician made the diagnosis. We undertook such a broad definition of depression, as we were aware that some trials evaluating the effect of PS predate the regular use of standardised diagnostic criteria for depression. </P>
<P>
<B>Exclusion criteria</B>
<BR/>Trials whose primary focus was to evaluate treatments in patients with substance dependence were excluded. Trials with children were not included. </P>
<P>
<B>Comorbidity</B>
<BR/>Patients with serious concomitant medical illness were included in the review. It was planned that trials with patients with co-morbid psychiatric diagnoses would also be included.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>
<B>Intervention</B>
<BR/>Trials were included if they evaluated the effectiveness of any type of psychostimulant (PS) for any type of depression. Trials using the PS modafinil were evaluated separately as its pharmacology is completely different from that of the other PS.</P>
<P>
<B>Control conditions</B>
<BR/>PS were evaluated against any type of control or comparison treatment or wait list group. </P>
<P>
<B>Main comparisons</B>
<BR/>Outcomes were presented by comparison as follows: <BR/>1. PS as monotherapy versus placebo<BR/>2. PS as monotherapy versus other treatment (medication, psychological therapy)<BR/>3. PS versus other treatment as adjunctive treatment</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>
<B>Primary outcome</B>
<BR/>The primary outcome measure was the effect of the PS on depressive symptoms or diagnosis using: <BR/>1. continuous measures, such as Hamilton Depression Scale (HAM-D) (<LINK REF="REF-Hamilton-1960" TYPE="REFERENCE">Hamilton 1960</LINK>) or Montgomery-Asberg Scale (<LINK REF="REF-Montgomery-1979" TYPE="REFERENCE">Montgomery 1979</LINK>)<BR/>2. dichotomous measures - the proportion of people who respond to treatment: including a categorisation of the HAM-D score (<LINK REF="REF-Hamilton-1960" TYPE="REFERENCE">Hamilton 1960</LINK>) or another depression scale such as the Montgomery-Asberg Scale (<LINK REF="REF-Montgomery-1979" TYPE="REFERENCE">Montgomery 1979</LINK>) or any other validated depression scale into a 50% response or less. </P>
<P>
<B>Secondary outcomes</B>
<BR/>1. Changes in other symptoms associated with depression including: changes in weight when not dieting or weight gain or changes in appetite; sleep disturbance (insomnia or hypersomnia (daytime sleepiness)); psychomotor agitation or retardation; fatigue or loss of energy; diminished ability to think or concentrate or recurrent thoughts of death or suicidal ideation (DSM-IV features of Depressive Disorders). Such symptoms were captured in validated scales such as for example the Montgomery-Asberg Scale (<LINK REF="REF-Montgomery-1979" TYPE="REFERENCE">Montgomery 1979</LINK>).<BR/>2. Remission criteria.<BR/>3. Social adjustment and functioning, such as the Social Adaptation Self-Evaluation Scale (<LINK REF="REF-Bosc-1997" TYPE="REFERENCE">Bosc 1997</LINK>)<BR/>4. Health related quality of life, measured using the SF-36 (<LINK REF="REF-Ware-1992" TYPE="REFERENCE">Ware 1992</LINK>)<BR/>5. Acceptability - this was evaluated by:<BR/>a). The total number of participants who dropped out due to inefficacy <BR/>b). The total number of participants who dropped out due to side effects<BR/>6. Tolerability - this was evaluated by:<BR/>a) Proportion of randomised participants experiencing some side effects<BR/>b) Proportion of randomised participants experiencing the following side effects;<BR/>
</P>
<UL>
<LI> Appetite changes</LI>
<LI> Insomnia</LI>
<LI> Reduced energy</LI>
<LI> PS misuse and dependence</LI>
<LI> Withdrawal reactions</LI>
<LI> Tolerance</LI>
<LI> Over arousal</LI>
<LI> Increased anxiety or depression</LI>
<LI> Suicidal thoughts</LI>
<LI> Acts of self-harm</LI>
</UL>
<P>
<BR/>Outcomes were presented according to length of treatment, as follows: <BR/>1. short term (4 weeks or less)<BR/>2. medium term (5 to 12 weeks)<BR/>3. long term (13 weeks or longer). </P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>See: Depression, Anxiety and Neurosis Group methods used in reviews.</P>
<P>
<B>1. Electronic databases:</B>
<BR/>The CCDAN registers was searched as below: </P>
<P>a) CCDANCTR-Studies (searched on 21/6/2006)<BR/>Diagnosis = Depress* or Dysthymi* or "Adjustment Disorder*" or "Mood Disorder*" or "Affective Disorder*" or "Affective Symptoms"<BR/>and <BR/>Intervention = amylobarbitone or Caffeine or dextroamphetamine or *amphetamine or methylphenidate or phenmetrazine or amoxetine or dexamfetamine or cocaine or phenylpropanolamine or pemoline or ephedrine or modafinil or methylene or Psychostimulant*) </P>
<P>CCDANCTR-References (searched on 21/6/2006)<BR/>Keyword = Depress* or Dysthymi* or "Adjustment Disorder*" or "Mood Disorder*" or "Affective Disorder*" or "Affective Symptoms"<BR/>and <BR/>Free-Text = amylobarbiton* or caffeine or *amphetamine or methylphenidat* or phenmetrazin* or amoxetin* or dexamfetamin* or cocaine or phenylpropanolamin* or pemolin* or ephedrin* or modafinil or methylen* or psychostimulant* </P>
<P>b) The following databases were searched: </P>
<P>MEDLINE <BR/>PSYINFO <BR/>EMBASE <BR/>AMED <BR/>CINHAL <BR/>The Cochrane Central Register of Controlled Trials (CENTRAL) <BR/>Dissertation Abstracts<BR/>National Health Service Research Register.</P>
<P> Search strategy used to search MEDLINE</P>
<P>
<B>
<I>a) PS</I>
</B>
<BR/>1) psychostimulants or stimulants<BR/>2) central nervous system stimulants (EXPLODE MeSH), all subheadings)<BR/>3) dextroamphetamine (EXPLODE MeSH, all subheadings)<BR/>4) amphetamine (EXPLODE MeSH, all subheadings)<BR/>5) methylphenidate (EXPLODE MeSH, all subheadings)<BR/>6) phenmetrazine (EXPLODE MeSH, all subheadings)<BR/>7) dexamphetamine <BR/>8) dexedrine or methylphenidate hydrochloride<BR/>9) methylphenidate hydrochloride (EXPLODE MeSH, all subheadings)<BR/>10) cocaine (EXPLODE MeSH, all subheadings)<BR/>11) phenylpropanolamine (EXPLODE MeSH, all subheadings)<BR/>12) ritalin or cephalon or concerta or modafinil or provigil or cocaine or seleguine<BR/>13) amphetamine* or diethylpropion or phenmetrazine or phendimetrazine or phenylpropanolamine <BR/>14) ephedrine (EXPLODE MeSH, all subheadings)<BR/>15) modafinil<BR/>16) Caffeine <BR/>17) Central Nervous System Stimulants (EXPLODE MeSH, all subheadings)<BR/>18) #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17.<BR/>
<B>
<I>
<BR/>b) DEPRESSION</I>
</B>
<BR/>19) depressi*<BR/>20) depressed near patient*<BR/>21) depressed near symptom*<BR/>22) depressi* adj3 disorder*<BR/>23) depressi* adj3 symptom*<BR/>24) affective disorder*<BR/>25) mood adj3 disorder*<BR/>26) #19 or #20 or #21 or #22 or #23 or #24 or #25</P>
<P>
<B>
<I>c) FILTER FOR RCT</I>
</B>
<BR/>27) random* in ti, ab<BR/>28) factorial* in ti, ab<BR/>29) (crossover* or cross over* or cross-over*) in ti, ab<BR/>30) placebo* in ti, ab<BR/>31) (doubl* near blind*) in ti, ab<BR/>32) (singl* near blind*) in ti, ab<BR/>33) assign* in ti, ab<BR/>34) allocat* in ti, ab<BR/>35) volunteer* in ti, ab<BR/>36) crossover procedure (EXPLODE MeSH, all subheadings)<BR/>37) double blind procedure (EXPLODE MeSH, all subheadings)<BR/>38) randomized controlled trial (EXPLODE MeSH, all subheadings)<BR/>39) single blind procedure (EXPLODE MeSH, all subheadings)<BR/>40) #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39.</P>
<P>
<B>
<I>d) FILTER FOR HUMAN STUDIES</I>
</B>
<BR/>41) animal in de<BR/>42) animal (EXPLODE MeSH, all subheadings)<BR/>43) nonhuman (EXPLODE MeSH, all subheadings)<BR/>44) animal-experiment (EXPLODE MeSH, all subheadings)<BR/>45)#41 or #42 or #43 or #44 <BR/>46) human in de<BR/>47) human (EXPLODE MeSH, all subheadings)<BR/>48) #46 or #47<BR/>49) #48 and #45<BR/>50) #45 not #49<BR/>51) #40 not #50</P>
<P>
<B>
<I>e) FINAL COMBINATION</I>
</B>
<BR/>52) #18 and #26 and #51</P>
<P>
<B>2. Handsearches </B>
<BR/>The British Library conference proceedings index and the ISI proceeding of the Web of Knowledge were searched for conferences specific toPS. </P>
<P>
<B>3. Personal communication </B>
<BR/>We attempted to contact experts in the field to identify any further trial evaluations that were missed in the main search. </P>
<P>
<B>4. Reference lists </B>
<BR/>Reference lists and forward citations of included trials and relevant systematic reviews were searched. </P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<U>
<BR/>
</U>
<B>Study selection </B>
<BR/>In accordance with the defined inclusion criteria, citations were screened by two of the review authors. Where it was not possible to accept or reject, the full text of the citation was obtained for further evaluation. </P>
<P>Following screening, the full text of eligible citations was assessed for inclusion independently by two of the review authors (BC and LJ). Where differences of opinion existed they were resolved by consensus with the other review authors (RW, MK and AT). If resolution was not possible, we attempted to contact the authors for clarification. Justification for excluding studies at this stage was documented. </P>
<P>
<B>Data extraction and management</B>
<BR/>Data was extracted independently by two review authors (BC and LJ). Where there are any discrepancies, the other review authors (RW, MK and AT) was consulted and discrepancy resolved by consensus</P>
<P>A data extraction form was designed for this review. Where possible, the following information was obtained for each study: <BR/>
</P>
<UL>
<LI>The number of patients eligible, number randomised, and reasons why patients not included in trial.</LI>
<LI>The number of patients evaluated at follow-up(s) and what were the follow-up time points.</LI>
<LI>Patient characteristics including age, sex, co-morbidities, diagnosis of depression.</LI>
<LI>Trial design features on masking, whether parallel or cross-over, features of randomisation, and sample size calculation.</LI>
<LI>PS intervention including dosage, duration and mode.</LI>
<LI>Comparison intervention including dosage, duration and mode.</LI>
<LI>Outcome data at all time points including how it was measured, and the mean or categorical scores of the main and other outcomes.</LI>
<LI>Data from cross-over trials were only included if the researchers presented separately pre-cross over results or the means and standard deviations reported for each trial arm separately.</LI>
</UL>
<P>
<BR/>Where information was lacking, we attempted to make contact with trial authors or trial sponsors.</P>
<P>
<B>Assessment of trial quality</B>
<BR/>Two review authors (BC and LJ) independently assessed the quality of included trials according to criteria described in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>) and supported by <LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>. Four main sources of systematic bias were assessed for each included trial: <BR/>a) selection bias (randomisation sequence and concealment of allocation, and bias at recruitment)<BR/>b) performance bias<BR/>c) detection bias<BR/>d) attrition bias (the completeness of follow up, with less than 10% loss to follow up defined as adequate)</P>
<P>Criteria a) and d) was assessed as adequate, inadequate or unclear, according to <LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>. Criteria b) and c) was assessed by the use of three questions:<BR/>a) were the trial participants aware of their assigned intervention (performance bias)?<BR/>b) were those providing the intervention aware of the assigned intervention (performance bias)?<BR/>c) were those who were assessing outcomes aware of the assigned intervention (detection bias)?</P>
<P>Based on the quality criteria, if was planned that trials would be broadly subdivided into the following three categories:<BR/>a) all quality criteria met: low risk of bias<BR/>b) one or more of the quality criteria only partly met: moderate risk of bias and<BR/>c) one or more criteria not met: high risk of bias.</P>
<P>
<B>Measures of treatment of effect</B>
<BR/>Trials measured treatment effect using either dichotomous data or a psychiatric ordinal rating scale for depression.</P>
<P>
<B>
<I>Dichotomous data</I>
</B>
<BR/>Where dichotomous data was reported, odds ratios (ORs) and their 95% confidence intervals (CI) were generated. </P>
<P>
<B>
<I>Continuous data</I>
</B>
<BR/>Effects measures for ordinal data were assessed as continuous data. The weighted mean difference (WMD) was generated for ordinal data where the data was provided as a mean and standard deviation. Where different scales were used to pool data to measure the same outcome, the standardised mean difference (WMD) was used, together with 95% confidence intervals (CI).</P>
<P>
<B>Dealing with missing data</B>
<BR/>Where data were missing we attempted to contact trial authors. For trials using continuous data in which SDs were not reported, and no information was available from the authors, the SD were calculated via the standard error of the mean (SEM) by multiplying the SEM by the square root of the sample size. In the absence of a SEM it was planned that the SD would be derived from the p-value using the method appropriate to the test conducted. When either of these was undertaken we planned to explore the effects in a sensitivity analysis.</P>
<P>Drop-outs were included in analysis. Responders and remitters to treatment were calculated on the intention-to-treat (ITT) basis. Where participants had withdrawn from the trial before the endpoint, it was assumed they would have experienced the negative outcome by the end of the trial (e.g. failure to respond to treatment). When there was missing data and the method of "last observation carried forward" (LOCF) had been used to do an ITT analysis, then the LOCF data was used, with due consideration of the potential bias and uncertainty introduced. <BR/>
<B>
<U>
<BR/>
</U>
</B>
<B>Data synthesis (meta-analysis)</B>
<BR/>Where trial data were of sufficient quality and sufficiently similar (in diagnostic criteria, intervention, outcome measure, length of follow-up and type of analysis) they were combined in a meta-analysis to provide a pooled effect estimate. A fixed-effects model was used in the first instance. If there was no statistical heterogeneity, a random-effects model was used to check the robustness of the fixed-effect model. If statistical heterogeneity was observed, the random-effects model was used <I>a priori</I>.</P>
<P>
<B>Assessment of heterogeneity</B>
<BR/>Where meta-analysis was possible, statistical heterogeneity was assessed between trials using the chi-squared statistic and I-squared statistic (A chi-squared p-value of less than 0.05 or an I-squared value equal to or more than 50% was considered indicative of substantial variability in effect estimate between trials due to heterogeneity). If heterogeneity was identified subgroup analysis was undertaken to explore the lack of homogeneity. </P>
<P>
<B>Subgroup analysis and investigation of heterogeneity</B>
<BR/>To explore clinical heterogeneity and investigate the effect modification of participants and treatment types, we planned, if sufficient data were available, to perform the following subgroup analyses: </P>
<P>
<B>
<I>Participants:</I>
</B>
<BR/>(1) Gender - male versus female<BR/>(2) Mild or moderate versus severe depression (according to clinical status) <BR/>(3) Depression in medically ill patients</P>
<P>
<B>
<I>Intervention</I>
</B>: <BR/>(3) Type of PS.<BR/>
<B>
<U>
<BR/>
</U>
</B>
<B>Sensitivity analysis</B>
<BR/>We planned to perform a sensitivity analyses in order to explore the influence of the following factors:<BR/>1. Excluding unpublished studies (if there were any);<BR/>2. Taking account of study quality (low-, moderate- or high-risk of bias);<BR/>3. Excluding studies using the following filters: <BR/>(a) diagnostic criteria used for depression<BR/>(b) source of funding (industry versus other)<BR/>(c) scales used for measuring effect (validated versus other)</P>
<P>
<B>Publication bias</B>
<BR/>We planned to explore publication bias by using funnel plots.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-05 21:28:04 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION>
<P>
<B>Results of the search<BR/>
</B>A total of 77 studies were initially identified through the CCDANCTR-Studies and CCDANCTR-References searches. A further 21 references were identified by the additional MEDLINE searches. <B>
<BR/>
</B>
<BR/>
<B>Included studies</B>
<BR/>Twenty-four RCTs published in twenty-three papers were identified that assessed the effectiveness of a PS in the treatment of the symptoms of depression (<LINK REF="STD-Cantello-1989" TYPE="STUDY">Cantello 1989</LINK>; <LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>; <LINK REF="STD-DeBattista-2003" TYPE="STUDY">DeBattista 2003</LINK>; <LINK REF="STD-Elizur-1979" TYPE="STUDY">Elizur 1979</LINK>; <LINK REF="STD-Fava-2005" TYPE="STUDY">Fava 2005</LINK>; <LINK REF="STD-Fernandez-1995" TYPE="STUDY">Fernandez 1995</LINK>; <LINK REF="STD-Hare-1962" TYPE="STUDY">Hare 1962</LINK>; <LINK REF="STD-Hare-1964" TYPE="STUDY">Hare 1964</LINK>; <LINK REF="STD-Kits-1970" TYPE="STUDY">Kits 1970</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Mattes-1985" TYPE="STUDY">Mattes 1985</LINK>; <LINK REF="STD-Overall-1962" TYPE="STUDY">Overall 1962</LINK>; <LINK REF="STD-Patkar-2006" TYPE="STUDY">Patkar 2006</LINK>; <LINK REF="STD-Postolache-1999" TYPE="STUDY">Postolache 1999</LINK>; <LINK REF="STD-Reus-1979" TYPE="STUDY">Reus 1979</LINK>; <LINK REF="STD-Rickels-1970" TYPE="STUDY">Rickels 1970</LINK>; <LINK REF="STD-Rickels-1972" TYPE="STUDY">Rickels 1972</LINK>; <LINK REF="STD-Robin-1958" TYPE="STUDY">Robin 1958</LINK>; <LINK REF="STD-Silberman-1981" TYPE="STUDY">Silberman 1981</LINK>; <LINK REF="STD-Vaishnavi-2006" TYPE="STUDY">Vaishnavi 2006</LINK>; <LINK REF="STD-Wagner-2000" TYPE="STUDY">Wagner 2000</LINK>; <LINK REF="STD-Wallace-1995" TYPE="STUDY">Wallace 1995</LINK>; <LINK REF="STD-Wheatley-1969-a" TYPE="STUDY">Wheatley 1969 a</LINK>; <LINK REF="STD-Wheatley-1969-b" TYPE="STUDY">Wheatley 1969 b</LINK>). The Characteristics of Included Studies table provides details of the included trials in terms of the populations studied, the treatments examined, and the outcome measures used. Key study characteristics are summarised below. </P>
<P>
<B>
<I>Study design</I>
</B>
<BR/>Fifteen of the 24 included trials were of parallel design. The others were of cross-over design. Fifteen trials were performed over 20 years ago. Four trials declared pharmaceutical funding or interests (<LINK REF="STD-DeBattista-2003" TYPE="STUDY">DeBattista 2003</LINK>; <LINK REF="STD-Fava-2005" TYPE="STUDY">Fava 2005</LINK>; <LINK REF="STD-Patkar-2006" TYPE="STUDY">Patkar 2006</LINK>; <LINK REF="STD-Vaishnavi-2006" TYPE="STUDY">Vaishnavi 2006</LINK>). </P>
<P>
<B>
<I>Sample sizes</I>
</B>
<BR/>Most trials (18/24) involved less than 100 participants. In nine trials there were 10 or fewer participants per trial arm.</P>
<P>
<B>
<I>Participants</I>
</B>
<BR/>Just over half of the trials (14/24) were performed on North American populations. Six were performed on UK populations.</P>
<P>Just over half of the trials (13/24) established baseline depression using the validated diagnostic schedule in the Diagnostic Schedule Manual (DSM) or the Research Diagnostic Criteria (RDC). The other trials relied on a clinical diagnosis. </P>
<P>Twelve trials evaluated the effects of a PS on patients with major depression (<LINK REF="STD-Cantello-1989" TYPE="STUDY">Cantello 1989</LINK>; <LINK REF="STD-DeBattista-2003" TYPE="STUDY">DeBattista 2003</LINK>; <LINK REF="STD-Elizur-1979" TYPE="STUDY">Elizur 1979</LINK>; <LINK REF="STD-Fava-2005" TYPE="STUDY">Fava 2005</LINK>; <LINK REF="STD-Fernandez-1995" TYPE="STUDY">Fernandez 1995</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Patkar-2006" TYPE="STUDY">Patkar 2006</LINK>; <LINK REF="STD-Postolache-1999" TYPE="STUDY">Postolache 1999</LINK>; <LINK REF="STD-Reus-1979" TYPE="STUDY">Reus 1979</LINK>; <LINK REF="STD-Silberman-1981" TYPE="STUDY">Silberman 1981</LINK>; <LINK REF="STD-Vaishnavi-2006" TYPE="STUDY">Vaishnavi 2006</LINK>; <LINK REF="STD-Wallace-1995" TYPE="STUDY">Wallace 1995</LINK>). Other trials evaluated effects in patients with mild depression (<LINK REF="STD-Mattes-1985" TYPE="STUDY">Mattes 1985</LINK>; <LINK REF="STD-Rickels-1972" TYPE="STUDY">Rickels 1972</LINK>), or included patients whose depression ranged from mild to moderate (<LINK REF="STD-Rickels-1970" TYPE="STUDY">Rickels 1970</LINK>; <LINK REF="STD-Robin-1958" TYPE="STUDY">Robin 1958</LINK>) or mild to severe (<LINK REF="STD-Wagner-2000" TYPE="STUDY">Wagner 2000</LINK>). In seven other trials the severity of the depression was unclear (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>; <LINK REF="STD-Hare-1962" TYPE="STUDY">Hare 1962</LINK>; <LINK REF="STD-Hare-1964" TYPE="STUDY">Hare 1964</LINK>; <LINK REF="STD-Kits-1970" TYPE="STUDY">Kits 1970</LINK>; <LINK REF="STD-Overall-1962" TYPE="STUDY">Overall 1962</LINK>; <LINK REF="STD-Wheatley-1969-a" TYPE="STUDY">Wheatley 1969 a</LINK>; <LINK REF="STD-Wheatley-1969-b" TYPE="STUDY">Wheatley 1969 b</LINK>). In five trials patients were described as having a partial or non-response to antidepressant therapy (<LINK REF="STD-DeBattista-2003" TYPE="STUDY">DeBattista 2003</LINK>; <LINK REF="STD-Fava-2005" TYPE="STUDY">Fava 2005</LINK>; <LINK REF="STD-Patkar-2006" TYPE="STUDY">Patkar 2006</LINK>; <LINK REF="STD-Vaishnavi-2006" TYPE="STUDY">Vaishnavi 2006</LINK>; <LINK REF="STD-Wallace-1995" TYPE="STUDY">Wallace 1995</LINK>).</P>
<P>Six trials included as part of their eligibility criteria other common symptoms of depression including fatigue reduced energy, hypersomnia and appetite changes (<LINK REF="STD-Elizur-1979" TYPE="STUDY">Elizur 1979</LINK>; <LINK REF="STD-Fava-2005" TYPE="STUDY">Fava 2005</LINK>; <LINK REF="STD-Rickels-1970" TYPE="STUDY">Rickels 1970</LINK>; <LINK REF="STD-Rickels-1972" TYPE="STUDY">Rickels 1972</LINK>; <LINK REF="STD-Robin-1958" TYPE="STUDY">Robin 1958</LINK>; <LINK REF="STD-Wagner-2000" TYPE="STUDY">Wagner 2000</LINK>). Three trials specified that they excluded patients with a history of drug abuse (<LINK REF="STD-Elizur-1979" TYPE="STUDY">Elizur 1979</LINK>; <LINK REF="STD-Silberman-1981" TYPE="STUDY">Silberman 1981</LINK>; <LINK REF="STD-Wagner-2000" TYPE="STUDY">Wagner 2000</LINK>).</P>
<P>In five trials the participants had serious concomitant medical conditions, including Parkinson's disease (<LINK REF="STD-Cantello-1989" TYPE="STUDY">Cantello 1989</LINK>), HIV (<LINK REF="STD-Fernandez-1995" TYPE="STUDY">Fernandez 1995</LINK>; <LINK REF="STD-Wagner-2000" TYPE="STUDY">Wagner 2000</LINK>), traumatic brain injury (<LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>) and chronic, debilitating physical illnesses (unspecified) in older patients (<LINK REF="STD-Wallace-1995" TYPE="STUDY">Wallace 1995</LINK>). </P>
<P>In most trials participants were adults aged less than 70 years. Four trials included people over 70 years of age (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>; <LINK REF="STD-Rickels-1970" TYPE="STUDY">Rickels 1970</LINK>; <LINK REF="STD-Wallace-1995" TYPE="STUDY">Wallace 1995</LINK>; <LINK REF="STD-Wheatley-1969-b" TYPE="STUDY">Wheatley 1969 b</LINK>). Five studies did not state the maximum age of participants (<LINK REF="STD-Hare-1962" TYPE="STUDY">Hare 1962</LINK>; <LINK REF="STD-Hare-1964" TYPE="STUDY">Hare 1964</LINK>; <LINK REF="STD-Overall-1962" TYPE="STUDY">Overall 1962</LINK>; <LINK REF="STD-Rickels-1972" TYPE="STUDY">Rickels 1972</LINK>; <LINK REF="STD-Robin-1958" TYPE="STUDY">Robin 1958</LINK>).</P>
<P>With the exception of two trials that explored the effects of a PS on depression in men with HIV (<LINK REF="STD-Fernandez-1995" TYPE="STUDY">Fernandez 1995</LINK> and <LINK REF="STD-Wagner-2000" TYPE="STUDY">Wagner 2000</LINK>), all trials included male and female participants. Gender was not reported in one trial (<LINK REF="STD-Reus-1979" TYPE="STUDY">Reus 1979</LINK>).</P>
<P>
<B>
<I>Interventions</I>
</B>
<BR/>Just over half of the trials, 14/24, evaluated PS using an oral preparation as a monotherapy and a placebo control (<LINK REF="STD-Elizur-1979" TYPE="STUDY">Elizur 1979</LINK>; <LINK REF="STD-Hare-1962" TYPE="STUDY">Hare 1962</LINK>; <LINK REF="STD-Kits-1970" TYPE="STUDY">Kits 1970</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Mattes-1985" TYPE="STUDY">Mattes 1985</LINK>; <LINK REF="STD-Overall-1962" TYPE="STUDY">Overall 1962</LINK>; <LINK REF="STD-Rickels-1970" TYPE="STUDY">Rickels 1970</LINK>; <LINK REF="STD-Rickels-1972" TYPE="STUDY">Rickels 1972</LINK>; <LINK REF="STD-Robin-1958" TYPE="STUDY">Robin 1958</LINK>; <LINK REF="STD-Vaishnavi-2006" TYPE="STUDY">Vaishnavi 2006</LINK>; <LINK REF="STD-Wagner-2000" TYPE="STUDY">Wagner 2000</LINK>; <LINK REF="STD-Wallace-1995" TYPE="STUDY">Wallace 1995</LINK>; <LINK REF="STD-Wheatley-1969-a" TYPE="STUDY">Wheatley 1969 a</LINK>; <LINK REF="STD-Wheatley-1969-b" TYPE="STUDY">Wheatley 1969 b</LINK>). </P>
<P>Six trials evaluated a PS either as an adjunct or where patients continued on an antidepressant (<LINK REF="STD-DeBattista-2003" TYPE="STUDY">DeBattista 2003</LINK>; <LINK REF="STD-Fava-2005" TYPE="STUDY">Fava 2005</LINK>; <LINK REF="STD-Patkar-2006" TYPE="STUDY">Patkar 2006</LINK>; <LINK REF="STD-Postolache-1999" TYPE="STUDY">Postolache 1999</LINK>) or a barbiturate (<LINK REF="STD-Hare-1964" TYPE="STUDY">Hare 1964</LINK>; <LINK REF="STD-Overall-1962" TYPE="STUDY">Overall 1962</LINK>). Four trials evaluated a PS as an intravenous monotherapy (<LINK REF="STD-Cantello-1989" TYPE="STUDY">Cantello 1989</LINK>; <LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>; <LINK REF="STD-Reus-1979" TYPE="STUDY">Reus 1979</LINK>; <LINK REF="STD-Silberman-1981" TYPE="STUDY">Silberman 1981</LINK>). </P>
<P>Treatment duration ranged from a single dose (<LINK REF="STD-Cantello-1989" TYPE="STUDY">Cantello 1989</LINK>; <LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>; <LINK REF="STD-Reus-1979" TYPE="STUDY">Reus 1979</LINK>; <LINK REF="STD-Silberman-1981" TYPE="STUDY">Silberman 1981</LINK>) to 12 weeks' therapy (<LINK REF="STD-Overall-1962" TYPE="STUDY">Overall 1962</LINK>; <LINK REF="STD-Vaishnavi-2006" TYPE="STUDY">Vaishnavi 2006</LINK>). In the parallel design trials most treatments were of 3-4 weeks duration. In the cross-over trials duration per treatment was commonly two weeks or less. All intravenous therapy interventions consisted of a single injection. </P>
<P>A high proportion of evaluations (10/24) were of the effect of the PS methylphenidate (<LINK REF="STD-Cantello-1989" TYPE="STUDY">Cantello 1989</LINK>; <LINK REF="STD-Fernandez-1995" TYPE="STUDY">Fernandez 1995</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Mattes-1985" TYPE="STUDY">Mattes 1985</LINK>; <LINK REF="STD-Patkar-2006" TYPE="STUDY">Patkar 2006</LINK>; <LINK REF="STD-Postolache-1999" TYPE="STUDY">Postolache 1999</LINK>; <LINK REF="STD-Rickels-1970" TYPE="STUDY">Rickels 1970</LINK>; <LINK REF="STD-Rickels-1972" TYPE="STUDY">Rickels 1972</LINK>; <LINK REF="STD-Robin-1958" TYPE="STUDY">Robin 1958</LINK>; <LINK REF="STD-Wallace-1995" TYPE="STUDY">Wallace 1995</LINK>). Four other types of PS were evaluated:<BR/>1. Dexamphetamine (<LINK REF="STD-Hare-1962" TYPE="STUDY">Hare 1962</LINK>; <LINK REF="STD-Hare-1964" TYPE="STUDY">Hare 1964</LINK>; <LINK REF="STD-Overall-1962" TYPE="STUDY">Overall 1962</LINK>; <LINK REF="STD-Reus-1979" TYPE="STUDY">Reus 1979</LINK>; <LINK REF="STD-Silberman-1981" TYPE="STUDY">Silberman 1981</LINK>; <LINK REF="STD-Wagner-2000" TYPE="STUDY">Wagner 2000</LINK>; <LINK REF="STD-Wheatley-1969-a" TYPE="STUDY">Wheatley 1969 a</LINK>; <LINK REF="STD-Wheatley-1969-b" TYPE="STUDY">Wheatley 1969 b</LINK>)<BR/>2. Methylamphetamine (<LINK REF="STD-Cookson-1986" TYPE="STUDY">Cookson 1986</LINK>; <LINK REF="STD-Kits-1970" TYPE="STUDY">Kits 1970</LINK>)<BR/>3. Modafinil (<LINK REF="STD-DeBattista-2003" TYPE="STUDY">DeBattista 2003</LINK>; <LINK REF="STD-Fava-2005" TYPE="STUDY">Fava 2005</LINK>; <LINK REF="STD-Vaishnavi-2006" TYPE="STUDY">Vaishnavi 2006</LINK>)<BR/>4. Pemoline (<LINK REF="STD-Elizur-1979" TYPE="STUDY">Elizur 1979</LINK>; <LINK REF="STD-Rickels-1970" TYPE="STUDY">Rickels 1970</LINK>)</P>
<P>
<B>
<I>Outcomes</I>
</B>
<BR/>The effects of a PS on depressed mood were commonly evaluated using a version of the Hamilton Depression Scale (HAM-D).</P>
<P>Other symptoms associated with depression such as hypersomnia, fatigue or reduced energy were measured either by a validated psychometric scales, including Epworth Sleepiness Scale and the Brief Fatigue Inventory, or by self-report.</P>
<P>Less than half of the trials, 9/24, set out a priori to measure side effects (<LINK REF="STD-Cantello-1989" TYPE="STUDY">Cantello 1989</LINK>; <LINK REF="STD-DeBattista-2003" TYPE="STUDY">DeBattista 2003</LINK>; <LINK REF="STD-Elizur-1979" TYPE="STUDY">Elizur 1979</LINK>; <LINK REF="STD-Fava-2005" TYPE="STUDY">Fava 2005</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Mattes-1985" TYPE="STUDY">Mattes 1985</LINK>; <LINK REF="STD-Overall-1962" TYPE="STUDY">Overall 1962</LINK>; <LINK REF="STD-Patkar-2006" TYPE="STUDY">Patkar 2006</LINK>; <LINK REF="STD-Vaishnavi-2006" TYPE="STUDY">Vaishnavi 2006</LINK>). Four trials did not report reasons for participants dropping out (<LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Mattes-1985" TYPE="STUDY">Mattes 1985</LINK>; <LINK REF="STD-Patkar-2006" TYPE="STUDY">Patkar 2006</LINK>; <LINK REF="STD-Robin-1958" TYPE="STUDY">Robin 1958</LINK>).</P>
<P>
<B>Excluded studies</B>
<BR/>Seventy-seven trials were excluded commonly because they did not evaluate a PS or were not RCTs. The reasons for exclusion are listed in the Characteristics of excluded studies table.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The overall quality of the trials was poor. Many trials pre-dated the Consort statement, and as they were undertaken at least 20 years ago, it was not possible to contact authors. All trials appeared to be vulnerable to a number of biases that may have affected their results. </P>
<P>
<B>Selection bias</B>
<BR/>Very few trials (four out of the 24 included trials) provided sufficient details on randomisation generation. One trial provided some details on concealment allocation. None of the trials provided details on potential bias at recruitment. </P>
<P>
<B>Detection and performance bias</B>
<BR/>Although all trials were described as double blind, few (4/24) provided any details on who was masked (<LINK REF="STD-Hare-1964" TYPE="STUDY">Hare 1964</LINK>; <LINK REF="STD-Robin-1958" TYPE="STUDY">Robin 1958</LINK>; <LINK REF="STD-Reus-1979" TYPE="STUDY">Reus 1979</LINK>; <LINK REF="STD-Wallace-1995" TYPE="STUDY">Wallace 1995</LINK>).. </P>
<P>
<B>Attrition bias</B>
<BR/>In ten trials there was some risk of attrition bias, as more than 10% of participants were lost to follow-up. Only one of these trials used intention to treat analysis (<LINK REF="STD-Patkar-2006" TYPE="STUDY">Patkar 2006</LINK>). </P>
<P>See Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for further details.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-05 21:28:04 +0000" MODIFIED_BY="[Empty name]">
<P>Thirteen trials had data in a suitable form for meta-analysis (<LINK REF="STD-DeBattista-2003" TYPE="STUDY">DeBattista 2003</LINK>; <LINK REF="STD-Elizur-1979" TYPE="STUDY">Elizur 1979</LINK>; <LINK REF="STD-Fava-2005" TYPE="STUDY">Fava 2005</LINK>; <LINK REF="STD-Fernandez-1995" TYPE="STUDY">Fernandez 1995</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Patkar-2006" TYPE="STUDY">Patkar 2006</LINK>; <LINK REF="STD-Postolache-1999" TYPE="STUDY">Postolache 1999</LINK>; <LINK REF="STD-Rickels-1970" TYPE="STUDY">Rickels 1970</LINK>; <LINK REF="STD-Rickels-1972" TYPE="STUDY">Rickels 1972</LINK>; <LINK REF="STD-Robin-1958" TYPE="STUDY">Robin 1958</LINK>; <LINK REF="STD-Vaishnavi-2006" TYPE="STUDY">Vaishnavi 2006</LINK>; <LINK REF="STD-Wagner-2000" TYPE="STUDY">Wagner 2000</LINK>; <LINK REF="STD-Wheatley-1969-a" TYPE="STUDY">Wheatley 1969 a</LINK>). Trials with unusable data for meta-analysis included all nine cross-over trials, as none provided separately pre-crossover results, or provided a mean difference (with standard deviation) between trial arms.</P>
<P>Analyses were presented according to short-term PS use (trial duration of 4 weeks or less) (<LINK REF="STD-Elizur-1979" TYPE="STUDY">Elizur 1979</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Patkar-2006" TYPE="STUDY">Patkar 2006</LINK>; <LINK REF="STD-Rickels-1970" TYPE="STUDY">Rickels 1970</LINK>; <LINK REF="STD-Rickels-1972" TYPE="STUDY">Rickels 1972</LINK>; <LINK REF="STD-Robin-1958" TYPE="STUDY">Robin 1958</LINK>; <LINK REF="STD-Wagner-2000" TYPE="STUDY">Wagner 2000</LINK>; <LINK REF="STD-Wheatley-1969-a" TYPE="STUDY">Wheatley 1969 a</LINK>) or medium term use (trial duration of 5-12 weeks) (<LINK REF="STD-DeBattista-2003" TYPE="STUDY">DeBattista 2003</LINK>; <LINK REF="STD-Fava-2005" TYPE="STUDY">Fava 2005</LINK>; <LINK REF="STD-Fernandez-1995" TYPE="STUDY">Fernandez 1995</LINK>;<LINK REF="STD-Postolache-1999" TYPE="STUDY">Postolache 1999</LINK>; <LINK REF="STD-Vaishnavi-2006" TYPE="STUDY">Vaishnavi 2006</LINK>). Modafinil was examined separately from other psychostimulants in all meta-analyses, due to its different mode of action. All trials included in the meta-analyses used an oral therapy route.</P>
<P>The fixed effect model (FE) was used in the first instance in analyses, with the random effects model (RE) used to test the robustness of the findings. Unless otherwise stated below, the fixed effects model was used in analyses. Where statistical heterogeneity was observed, the random effects model was used.</P>
<P>
<B>COMPARISON 1: PSYCHOSTIMULANTS VERSUS PLACEBO (Graphs 01 01 to 01 17)<BR/>
</B>Eight trials contributed to this comparison (<LINK REF="STD-Elizur-1979" TYPE="STUDY">Elizur 1979</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Rickels-1970" TYPE="STUDY">Rickels 1970</LINK>; <LINK REF="STD-Rickels-1972" TYPE="STUDY">Rickels 1972</LINK>; <LINK REF="STD-Robin-1958" TYPE="STUDY">Robin 1958</LINK>; <LINK REF="STD-Vaishnavi-2006" TYPE="STUDY">Vaishnavi 2006</LINK>;<LINK REF="STD-Wagner-2000" TYPE="STUDY">Wagner 2000</LINK>; <LINK REF="STD-Wheatley-1969-a" TYPE="STUDY">Wheatley 1969 a</LINK>)</P>
<P>
<B>
<U>Primary outcome</U>
</B>
<BR/>
<B>Reduction in depression symptoms (Graph 01 01 to 01 02)</B>
<BR/>Three short term trials of PS, with a total of 62 participants, were included in the meta-analysis. All trials used a validated depression scale. There was a significant difference in favour of PS (SMD -0.87, 95% CI -1.40, -0.33). The I<SUP>2</SUP> test at 15.5% did not indicate a high degree of heterogeneity. The random effects model did not differ greatly from the fixed effect model.</P>
<P>In one medium term trial of Modafinil, with a total of 50 participants, there was no significant difference in depression scores between Modafinil and placebo (WMD -2.70, 95% CI -7.76, 2.36).</P>
<P>
<B>Clinical response (Graph 01 03)</B>
<BR/>Three short term trials of PS (130 participants) measured improvement in depression symptoms, two by clinical assessment and one using a validated scale. There was no significant difference in improvement in symptoms (OR 1.01, 95% CI 0.48, 2.09). The I<SUP>2 </SUP>test at 23.1% did not indicate a high degree of heterogeneity. The random effects model did not differ greatly from the fixed effect model. One trial measured clinical response as 50% reduction in depression scale. No significant difference was identified between PS and placebo (OR 1.83, 95% CI 0.57, 5.88).</P>
<P>
<B>
<U>Secondary outcomes<BR/>
</U>1. Changes in other symptoms associated with depression<U>
<BR/>
</U>
<I>Cognitive functioning (Graph 01 04)</I>
<BR/>
</B>Two short term trials of PS, with a total of 42 participants, were included in this analysis, with cognitive functioning measured by Mini-Mental State Examination and Trail Making Test A. No overall significant difference was observed between PS and control (SMD 0.42, 95% CI -0.20, 1.04). The I<SUP>2 </SUP>test at 16% indicated a low degree of heterogeneity. The random effects model did not differ from the fixed effects model.<BR/>
<B>
<I>
<BR/>Fatigue (Graph 01 05 to 01 06)</I>
<BR/>
</B>Of the two short term trials of PS recording fatigue scores, there was a significant difference between the PS and placebo groups that favoured PS (SMD -1.80, 95% CI -2.54, -1.06). The trials were homogenous with an I<SUP>2</SUP> of 0%. The random effects model did not differ from the fixed effects model. There was no significant difference in fatigue scores between modafinil and placebo in the one medium term trial included in this analysis (WMD 0.24, 95% CI -1.44,1.92.)</P>
<P>
<B>
<I>Hypersomnia (Graph 01 07)</I>
</B>
<BR/>In one medium term trial of PS that recorded hypersomnia mean scores, there was no significant difference between the PS and placebo groups (WMD -5.00, 95% CI -10.87, 0.87). In one medium term trial of modafinil that recorded hypersomnia mean scores, using the Epworth Sleepiness Scale, there was no significant difference between the modafinil and placebo groups (WMD -0.24, 95% CI -3.06, 2.58).</P>
<P>
<B>
<I>Other symptoms associated with depression</I>
<BR/>
</B>See Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. There were no data on other symptoms associated with depression including: changes in weight when not dieting, weight gain, changes in appetite; psychomotor agitation or retardation; recurrent thoughts of death or suicidal ideation.<BR/>
<B>
<BR/>2. Remission<BR/>
</B>No studies were included in this outcome</P>
<P>
<B>3. Social adjustment and functioning<BR/>
</B>In one trial of PS with a total of 22 participants, there was no significant difference in the short term on physical functioning (WMD 10.90, 95% CI 0.67, 21.13). No trials evaluated social adjustment or social functioning.</P>
<P>
<B>4. Health-related quality of life (Graph 01 08)<BR/>
</B>Two short term trials of PS with a total of 42 participants were included in the analysis. No significant overall effect was observed in mean at follow up between PS and control (SMD 0.57, 95% CI -0.05, 1.20). The I<SUP>2</SUP> test at 0% did not indicate heterogeneity. The random effects model did not greatly differ from the fixed effects model.</P>
<P>
<B>5. Acceptability<BR/>
<I>Dropouts due to side effects (Graph 01 09)</I>
<BR/>
</B>Two short term trials of PS with a total of 68 participants were included in this analysis of short term effect. No overall significant difference was observed between PS and control (OR 1.63, 95% CI 0.26, 10.25). The I<SUP>2</SUP> test at 34.3% did not indicate significant heterogeneity. The random effects model did not greatly differ from the fixed effect model. One small medium term trial with a sample of 9 showed no significant difference between the two groups for dropout rates due to side effects (OR 6.43, 95% CI 0.23, 181.82).<BR/>
<B>
<BR/>Dropouts due to inefficacy</B>
<BR/>No studies included these data</P>
<P>
<B>6. Tolerability<BR/>
<I>Proportion of participants experiencing some side effects (Graph 01 10 to 01 11)</I>
<BR/>
</B>Two short term trials of PS with a total of 185 participants were included in this analysis. No overall significant difference was observed between PS and control, using a random effects model (OR 1.78, 95% CI 0.57, 5.55). The I<SUP>2</SUP> test at 46% indicated some heterogeneity. The random effects model did not greatly differ from the fixed effects model. Two medium term trials of PS with a total of 90 participants were included in this analysis. A significant difference favouring the control group was observed between PS and control, using a random effects model (OR 7.22, 95% CI 2.21, 23.57).<B>
<BR/>
<I>
<BR/>Dizziness (Graph 01 12)</I>
<BR/>
</B>Two short term trials of PS with a total of 190 participants were included in this analysis. No overall significant difference was observed between PS and placebo control (OR 1.31, 95% CI 0.40, 4.24). The I<SUP>2</SUP> test at 0% did not indicate heterogeneity. The random effects model did not greatly differ from the fixed effects model.</P>
<P>
<B>
<I>Drowsiness (Graph 01 13)</I>
<BR/>
</B>Two short term trials of PS with a total of 190 participants were included in this analysis. No overall significant difference was observed between PS and placebo control (OR 0.41, 95% CI 0.12, 1.37). The I<SUP>2</SUP> test at 0% did not indicate heterogeneity. The random effects model did not greatly differ from the fixed effects model.</P>
<P>
<B>
<I>Headache (Graph 01 14)</I>
<BR/>
</B>Two short term trials of PS with a total of 115 participants were included in this analysis. No significant difference was observed between PS and placebo control (OR 1.06, 95% CI 0.34, 3.35). The I<SUP>2</SUP> test at 0% did not indicate heterogeneity. The random effects model did not greatly differ from the fixed effects model.</P>
<P>
<B>
<I>Insomnia (Graph 01 15)<BR/>
</I>
</B>One short term trial of PS with 95 participants was included in this analysis. No significant difference was observed between PS and placebo control (OR 1.89, 95% CI 0.66, 5.38). The I<SUP>2</SUP> test at 0% did not indicate heterogeneity. The random effects model did not greatly differ from the fixed effects model.</P>
<P>
<B>
<I>Nausea (Graph 01 16)</I>
<BR/>
</B>Two short term trials of PS with a total of 190 participants were included in this analysis. No significant difference was observed between treatments (OR 1.52, 95% CI 0.31, 7.57). The I<SUP>2</SUP> test at 0% did not indicate heterogeneity. The random effects model did not greatly differ from that in the fixed effects model.<BR/>
<B>
<I>
<BR/>Tremor (Graph 01 17)</I>
</B>
<BR/>Two short term trials of PS with a total of 115 participants showed no significant difference between PS and placebo control (OR 2.83 95% CI 0.51, 15.67). The I<SUP>2</SUP> test at 0% did not indicate heterogeneity. The random effects model did not greatly differ from the fixed effects model.</P>
<P>
<B>
<I>Assessment of other side effects</I>
<BR/>
</B>No trials evaluated PS misuse and dependence, withdrawal reactions, over arousal, suicidal thoughts and acts of self-harm.</P>
<P>
<B>
<BR/>COMPARISON 2: PSYCHOSTIMULANTS VERSUS ANTIDEPRESSANTS (Graphs 02 01 to 02 02)<BR/>
</B>Two trials contributed to this comparison (<LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Fernandez-1995" TYPE="STUDY">Fernandez 1995</LINK>).</P>
<P>
<B>
<U>Primary outcome</U>
</B>
<BR/>
<B>Reduction in depression symptoms (Graph 02 01)</B>
<BR/>In one small short term trial of PS with a total of 20 participants, there was no significant difference in depression scores between the PS and antidepressant groups (WMD -4.30, 95% CI --8.79, 9.19).</P>
<P>
<B>
<U>Secondary outcomes<BR/>
</U>Tolerability<BR/>
<I>Proportion of participants experiencing side effects (Graph 02 02)</I>
<U>
<BR/>
</U>
</B>In one small medium term trial of PS with a total of 15 participants, there was no significant difference between the PS and antidepressant groups in the number of participants experiencing side effects (OR 1.43, 95% CI 0.10, 20.44)<BR/>
<B>
<I>
<BR/>Headache</I>
</B>
<BR/>In one trial there was no significant difference between treatment arms (OR 0.23, 95% CI 0.01, 5.73).</P>
<P>
<B>
<I>Insomnia</I>
</B>
<BR/>In one trial there was no significant difference between treatment arms (OR 0.25, 95% CI 0.02, 3.10).</P>
<P>
<B>
<I>Nausea</I>
</B>
<BR/>In one trial there was no significant difference between treatment arms (OR 4.00, 95% CI 0.27, 58.56).</P>
<P>
<B>Other secondary outcomes</B>
<BR/>No other secondary outcomes were included in this comparison.</P>
<P>
<B>COMPARISON 3: PSYCHOSTIMULANTS VERSUS PLACEBO AS ADJUNCT TO ANTIDEPRESSANT TREATMENT<BR/>
</B>Four trials contributed to this comparison (<LINK REF="STD-DeBattista-2003" TYPE="STUDY">DeBattista 2003</LINK>
<B>
<I>; </I>
</B>
<LINK REF="STD-Fava-2005" TYPE="STUDY">Fava 2005</LINK>
<B>
<I>; </I>
</B>
<LINK REF="STD-Patkar-2006" TYPE="STUDY">Patkar 2006</LINK>;<LINK REF="STD-Postolache-1999" TYPE="STUDY">Postolache 1999</LINK>)</P>
<P>
<B>
<U>Primary outcome<BR/>
</U>Reduction in depression symptoms (Graph 03 01 to 03 02)<I>
<BR/>
</I>
</B>In one short term trial of PS with a total of 50 participants, there was no significant difference in the mean depression score between PS versus placebo as adjunct to antidepressant treatment (WMD -1.60, 95% CI -5.96, 2.76). In two short term trials of modafinil with a total of 411 participants, there was no statistical difference in depression scores between modafinil and placebo (WMD -0.09, 95% CI -1.07, 0.89). The I<SUP>2</SUP> test at 0% did not indicate heterogeneity. The random effects model did not greatly differ from the fixed effects model.</P>
<P>In two medium term trials of modafinil, with a total of 443 participants, there was no significant difference in mean depression scores between modafinil and placebo (WMD -0.80, 95% CI-1.88, 0.28). The I<SUP>2</SUP> test at 48.5% indicated a moderate degree of heterogeneity. The random effects model did not greatly differ from the fixed effects model.<BR/>
<BR/>
<B>Clinical response (Graph 03 03)</B>
<BR/>In one short term trial of PS with a total of 60 participants, there was a non-significant difference in 50% response rate (OR 1.83, 95% CI 0.57, 5.88) and in clinical improvement (OR 2.19, 95% CI 0.72, 2.34) between PS and placebo. In one medium term trial of PS with a total of 9 participants, there was no significant difference in clinical improvement between PS combined with adjunct AD treatment versus placebo with AD treatment (OR 1.10, 95% CI 0.31, 3.91).</P>
<P>
<B>
<U>Secondary outcomes</U>
<I>
<BR/>
</I>1. Changes in other symptoms associated with depression</B>
<BR/>
<B>
<I>Fatigue (Graph 03 04 to 03 05)</I>
</B>
<BR/>Of the two short term trials of modafinil recording mean fatigue scores, there was no significant difference between treatment and control, using a random effects model (WMD -0.04, 95% CI -0.79, 0.87). The I<SUP>2</SUP> test at 82.3% indicated a high degree of heterogeneity. Of the two medium term trials of modafinil recording mean fatigue scores, there was no significant difference between treatment and control (WMD -0.31, 95% CI -0.67, 0.05). The I<SUP>2</SUP> test at 44.1% indicated a moderate degree of heterogeneity.</P>
<P>
<B>
<I>Hypersomnia</I> (Graph 03 06 to 03 07)</B>
<BR/>Of the two short term trials of modafinil recording mean hypersomnia scores, there was no significant difference between treatment and control (WMD -0.79, 95% CI -1.63, 0.06). The I<SUP>2 </SUP>test at 0% did not indicate heterogeneity. The random effects model did not differ from the fixed effects model. Of the two medium term trials of modafinil recording mean hypersomnia scores, there was a significant difference between treatment and control (WMD -1.27, 95% CI -2.14, -039). I<SUP>2</SUP> test at 0% did not indicate heterogeneity. The random effects model did not differ from the fixed effects model.</P>
<P>
<B>
<I>Other symptoms associated with depression</I>
</B>
<BR/>See Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. There were no data on other symptoms associated with depression including: changes in weight when not dieting, weight gain, changes in appetite; psychomotor agitation or retardation; recurrent thoughts of death and suicidal ideation.<BR/>
<B>
<BR/>2. Remission</B>
<BR/>No studies were included in this outcome</P>
<P>
<B>3. Social adjustment and functioning</B>
<BR/>No studies were included in this outcome</P>
<P>
<B>4. Health-related quality of life </B>
<BR/>No studies were included in this outcome</P>
<P>
<B>
<I>5. Acceptability<BR/>Dropouts due to side effects (Graph 03 08 to 03 09)</I>
</B>
<BR/>In one small medium term trial of PS with a total of 9 participants, there was no significant difference in dropout rates due to side effects between the PS and placebo groups (OR 6.43, 95% CI 0.23, 181.82).</P>
<P>Two medium term trials of modafinil with a total of 450 participants were included in this analysis. No overall significant difference was observed between modafinil and placebo (OR 1.31, 95% CI 0.54, 3.18). The I<SUP>2</SUP> test at 0% did not indicate heterogeneity. The random effects model did not greatly differ from the fixed effect model.<BR/>
<B>
<BR/>Dropouts due to lack of efficacy (Graph 03 10)</B>
<BR/>Two medium term trials of modafinil with a total of 450 participants were included in analysis of the proportion of participants who dropped out due to inefficacy. No significant difference was observed between Modafinil and placebo control (OR 0.97, 95% CI 0.24, 3.96). The I<SUP>2</SUP> test at 0% did not indicate heterogeneity. The random effects model did not greatly differ from the fixed effect model.</P>
<P>
<B>6. Tolerability</B>
<BR/>
<B>
<I>Proportion of participants experiencing side effects (Graph 03 11)<BR/>
</I>
</B>One short term trial of PS comparing PS as an adjunct to ADs against placebo and ADs showed a non-significant difference in the proportion of participants experiencing side effects (OR 1.32, 95% CI 0.47, 3.72)</P>
<P>
<B>
<I>Headache (Graph 03 12)</I>
</B>
<BR/>Two medium term trials of modafinil, with a total of 447 participants, showed a lack of significant difference in the proportion of participants experiencing headaches between the two groups, using a random effects model (OR 1.21, 95% CI 0.50, 2.94). The I<SUP>2</SUP> test at 60% indicated a substantial degree of heterogeneity.</P>
<P>
<B>
<I>Insomnia (Graph 03 13 to 03 14)<BR/>
</I>
</B>One short term trial of PS, involving 60 participants, showed a lack of significant difference in the proportion of participants experiencing insomnia between the two groups (OR 1.00, 95% CI 0.19, 5.40).<B>
<I>
<BR/>
</I>
</B>
<BR/>Two medium term trials of modafinil, with a total of 447 participants, showed a lack of significant difference in the proportion of participants experiencing insomnia between the two groups (OR 1.24, 95% CI 0.62, 2.50). The I<SUP>2</SUP> test at 0% did not indicate heterogeneity.</P>
<P>
<B>
<I>Nausea (Graph 03 15 to 03 16)</I>
</B>
<BR/>One short term trial of PS, with 60 participants, showed no significant difference between treatment groups for nausea (OR 3.22, 95% CI 0.62, 2.50). Two medium term trials of modafinil, with a total of 447 participants, showed no significant difference between the two groups, using a random effects model (OR 1.78, 95% CI 0.20, 15.95). The I<SUP>2</SUP> test at 80% indicated a high degree of heterogeneity.</P>
<P>
<B>
<I>Tremor (Graph 03 17)</I>
</B>
<BR/>One short term trial of PS, with 60 participants, showed no significant difference between treatment groups for tremor (OR 0.48, 95% CI 0.04, 5.63).</P>
<P>
<B>
<I>Upper respiratory tract infection (Graph 03 18)</I>
</B>
<BR/>Two medium term trials, with a total of 447 participants, were included in this analysis. No overall significant difference was observed between PS and placebo control (OR 0.73, 95% CI 0.31, 1.71). The I<SUP>2 </SUP>test at 0% did not indicate heterogeneity. The random effects model did not greatly differ from the fixed effects model.</P>
<P>
<B>
<I>Assessment of other side effects</I>
</B>
<BR/>No trials evaluated PS misuse and dependence, withdrawal reactions, over arousal, suicidal thoughts and acts of self-harm.<BR/>
<B>
<BR/>Other side effects reported in one trial </B>
<BR/>No significant difference was observed between PS and control treatment in asthenia, cardiovascular vital signs, constipation, 'excitement', hypertension, hypertonia, 'infection', loss of appetite, myalgia, nasopharngitis, nervousness, palpitation, restlessness, rhinitis, tachycardia, tolerance, vertigo, and weight changes. See Additional <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> for further details.</P>
<P>
<B>Severity of adverse events</B>
<BR/>None of the side effects were reported as being moderate or severe, bar one person on PS in one trial (<LINK REF="STD-Patkar-2006" TYPE="STUDY">Patkar 2006</LINK>), who had an episode of non-cardiac chest pain.</P>
<P>
<B>Subgroup analysis </B>
<BR/>
<B>
<I>Depression in medically ill patients (Graph 04 01) </I>
</B>
<BR/>In two short term trials of PS with a total of 42 participants, there was a significant difference favouring PS compared with placebo (SMD -0.75, 95% CI -1.39, -0.11). The I<SUP>2</SUP> test at 48.5% indicated a moderate degree of heterogeneity. The random effects model did not differ greatly from the fixed effects model but it was no longer significant.</P>
<P>Because of insufficient trial data, it was not possible to undertake subgroup analyses of gender, severity of depression or type of PS .</P>
<P>
<B>Sensitivity analysis </B>
<BR/>It was not possible to undertake any sensitivity analyses of poorer quality trials or those that used non-validated measures because of the small number of trials included in the review . Secondly, we could not exclude unpublished trials, as all trials were published. Thirdly, it was not possible to exclude industry funded trials, because all data in meta-analyses were either all non-industry funded or, in the case of meta-analyses of trials that used Modafinil, all were industry funded.</P>
<P>
<B>Evidence from trials not included in any meta-analysis of effect of PS on depression</B>
<BR/>Because of limitations in reporting of data, 13 trials could not be included in any of the meta-analyses examining the effect of PS on depression symptoms. Nine of these trials individually found no significant difference in effect between PS and control treatment in reducing depression (See Additional <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>).</P>
<P>
<B>Publication bias</B>
<BR/>The presence of publication bias was not examined in this systematic review, as too few trials with suitable data were found to construct a meaningful funnel plot.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>
<B>Summary of main results</B>
<BR/>The purpose of this systematic review was to conduct an evaluation of the available evidence regarding the effectiveness and safety of psychostimulants (PS) for depression. As a result of heterogeneity in PS intervention and comparative treatments, and the paucity of RCTs with sufficient data for qualitative analysis, few clinically relevant conclusions can be drawn. The meta-analyses of the primary outcome included an analysis of three trials, involving 62 participants, and pooled scores from a validated depression scale. The results obtained using fixed effects models suggest that for people with depression, treatment with oral PS in comparison with a placebo in the short term (up to four weeks) significantly reduces symptoms. Statistical tests did not indicate a high degree of heterogeneity and use of the more conservative random effects statistical model did not change the results. This effect was not replicated in meta-analysis of trials that measured effectiveness by improvement using a dichotomous measure, however not all trials (2/3) used a validated measure to evaluate improvement in depression. The effect was also not replicated in the meta-analysis of trials that used modafinil. The robustness of our findings of the positive effect of PS on depression in the short term could only be explored in one of the four a priori sensitivity and subgroup analyses we planned to undertake. This analysis confirmed the overall findings.</P>
<P>Pooling of outcomes for other symptoms of depression suggested that PS as a monotherapy has a favourable effect in the short term on fatigue. PS were found to be, in the short term, well-tolerated and acceptable to patients. We are unable to comment in this review on the use of modafinil for the relief of somnolence induced by opioid therapy or its effectiveness in the treatment of narcolepsy. There was insufficient evidence for us to make any comment about the potential for dependence on PS. </P>
<P>
<B>Quality of the evidence</B>
<BR/>There are limitations to our review findings. Because of insufficient data, few trials were combined within a meta-analysis. Many of the trials lacked important information on quality, in particular on randomisation procedures. Most trials were relatively small. Apart from all the modafinil trials, few of the trials with analyzable data exceeded 25 patients per group. Furthermore, it cannot be ruled out that there were differences in the diagnostic assessment of the patients and thus in the quality of the diagnosis across the trials. Despite these being potential reasons why PS are little used, no trials evaluated misuse, dependence, withdrawal reactions, and over arousal. In addition, although depression is associated with suicide and deliberate self-harm, these outcomes were not reported. </P>
<P>
<B>Potential biases in the review process</B>
<BR/>As with all systematic reviews, publication bias is a potentially serious source of bias, and in this review there were too few studies to investigate the possibility of publication bias using funnel plots. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is insufficient evidence for this review to recommend the use of psychostimulants (PS) above other more established treatments of depression. Evidence to date suggests clinicians may consider PS appropriate in certain circumstances such as where established treatments for depression have failed and where treatment is required in the short term. The evidence to date does not support the use of modafinil in the treatment of depression. Clinicians should note that although this review did not identify any serious adverse effect, pemoline (which was used in one of the included trials) is no longer licensed in UK and USA because of risk of liver toxicity. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Larger high quality randomised controlled trials with follow-up periods greater than four weeks are needed. Such trials should test the robustness of our findings on short-term effects and explore the effect in certain subgroups of depressed patients, in particular, those with serious concomitant diseases such as patients receiving palliative care. Such trials should consider evaluating the effect of PS on all common depressive symptoms, including both further evaluations of the effect on fatigue and hypersomnia and further exploration of acceptability, tolerability and the potential for dependence and abuse.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors thank Dr M.E. Thase, Dr C. Pae, Dr K.Peindl, Dr K.Gadde and Professor J.Yoon for giving additional information about their trials. We would also like to thank representatives of Norvaris, Cephalon and Janssen-Cilag for their assistance in providing further information on published trials and/or in searching for any relevant unpublished or in progress trials.</P>
<P>We also gratefully acknowledge project funding from Marie Curie Cancer Care, Dr C Stanford for pharmacological advice and the help of Hugh McGuire of the Cochrane Collaboration Depression, Anxiety and Neurosis Group in conducting the database searches.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>BC together with MK: writing of the protocol. BC: data searches and together with LJ data selection and extraction. BC writing the review.<BR/>RW: providing advice and support for statistical analysis and commentary on the findings.<BR/>AK: conceptualised topic area, advised on protocol development, commented on findings and conclusions.<BR/>LJ, MK: methodology advise and commentary on the findings and conclusions.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Cantello-1989" NAME="Cantello 1989" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cantello R, Aguggia M, Gilli M, Delsedime M, Chiardo Cutin I, Riccio A et al</AU>
<TI>Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: Possible role of the "hedonic" dopamine synapse</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1989</YR>
<VL>52</VL>
<PG>724-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cookson-1986" NAME="Cookson 1986" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cookson J, Silverstone T</AU>
<TI>The effects of Methylamphetamine on Mood and Apetite in Depressed patients: A placebo-controlled study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1986</YR>
<VL>1</VL>
<PG>127-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeBattista-2003" NAME="DeBattista 2003" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR</AU>
<TI>Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<PG>1057-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elizur-1979" NAME="Elizur 1979" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elizur A, Wintner I, Davidson S</AU>
<TI>The clinical and psychological effects of pemoline in depressed patients. A controlled study</TI>
<SO>International Pharmacopsychiatry</SO>
<YR>1979</YR>
<VL>14</VL>
<PG>127-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fava-2005" NAME="Fava 2005" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fava M, Thase ME, DeBattista C</AU>
<TI>A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness</TI>
<SO>Journal of clinical psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<PG>85-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernandez-1995" NAME="Fernandez 1995" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez F, Levy JK, Samley RH</AU>
<TI>Effects of methylphenidate in HIV-related depression: A comparative trial with desipramine</TI>
<SO>International Journal of Psychaitry in Medicine</SO>
<YR>1995</YR>
<VL>25</VL>
<PG>53-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hare-1962" NAME="Hare 1962" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hare EH, Dominian J, Sharpe L</AU>
<TI>Phenelzine and dexamphetamine in depressive illness: A comparative trial</TI>
<SO>British Medical Journal</SO>
<YR>1962</YR>
<VL>1</VL>
<PG>9-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hare-1964" NAME="Hare 1964" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hare EH, McCance C, McCormick WO</AU>
<TI>Imipramine and "Drinamyl" in depressive illness: A comparative trial</TI>
<SO>British Medical Journal</SO>
<YR>1964</YR>
<VL>1</VL>
<PG>818-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kits-1970" NAME="Kits 1970" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kits TP, van Praag.</AU>
<TI>A controlled study of the antidepressant effect of P-chloro-n-methylamphetamine, a compound with a selective effect on the central 5-hydroxytryptamine metabolism</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1970</YR>
<VL>46</VL>
<PG>365-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2005" NAME="Lee 2005" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee H, Kim SW, Kim JM, Shin IS, Yang SY, Yoon JS</AU>
<TI>Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury</TI>
<SO>Human Psychopharmacology</SO>
<YR>2005</YR>
<VL>20</VL>
<PG>97-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattes-1985" NAME="Mattes 1985" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattes JA</AU>
<TI>Methylphenidate in mild depression: A double-blind controlled trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1985</YR>
<VL>46</VL>
<PG>525-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Overall-1962" NAME="Overall 1962" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Hollister LE, Pokorny AD, Casey JF, Katz G</AU>
<TI>Drug therapy in depressions: Controlled evaluation of imipramine, isocarboxide, dextroamphetamine-amobarbital and placebo</TI>
<SO>Clinical Pharmacoly Therapy</SO>
<YR>1962</YR>
<VL>3</VL>
<PG>16-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patkar-2006" NAME="Patkar 2006" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patkar AA, Massand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P et al</AU>
<TI>A randomized, double-blind, placebo-controlled trial of augnebtation with an extended release formulation of methylphenidate in outpatients with treatment resistant depression</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>26</VL>
<PG>653-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Postolache-1999" NAME="Postolache 1999" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Postolache TT, Rosenthal RN, Hellerstein DJ, Aromin R, Kelton GM, Muran JC, Londono JH</AU>
<TI>Early augmentation of sertraline with methylphenidate.</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>2</VL>
<PG>123-4.</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reus-1979" NAME="Reus 1979" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reus VI, Silberman E, Post RM, Weingartner H</AU>
<TI>d-Amphetamine: effects on memory in a depressed population</TI>
<SO>Biological Psychiatry</SO>
<YR>1979</YR>
<VL>14</VL>
<PG>345-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rickels-1970" NAME="Rickels 1970" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rickels K, Gordon P, Gansman D, Charles W, Pereira-Ogan J, Hesbacher P</AU>
<TI>Pemoline and methylphenidate in mildly depressed outpatients</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1970</YR>
<VL>11</VL>
<PG>698-710</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rickels-1972" NAME="Rickels 1972" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rickels K, Gingrich RL, McLaughlin FW, Morris RJ, Sablosky L, Silverman H et al</AU>
<TI>Methylphenidate in mildly depressed outpatients</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1972</YR>
<VL>13</VL>
<PG>595-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robin-1958" NAME="Robin 1958" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robin AA, Wiseberg S</AU>
<TI>A controlled trial of methyl phenidate (Ritalin) in the treatment of depressive states</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1958</YR>
<VL>21</VL>
<PG>55-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silberman-1981" NAME="Silberman 1981" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silberman EK, Reus VI, Jimerson DC, Lynott AM, Post RM</AU>
<TI>Heterogenity of Amphetamine response in depressed patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>10</VL>
<PG>1302-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaishnavi-2006" NAME="Vaishnavi 2006" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaishnavi S, Gadde K, Alamy S, Zhang W, Connor K, Davidson JR</AU>
<TI>Modafinil for atypicall depression: effects of open-label and double-blind discontinuation treatment</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>26</VL>
<PG>373-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wagner-2000" NAME="Wagner 2000" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wagner GJ, Rabkin R</AU>
<TI>Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2000</YR>
<VL>61</VL>
<PG>436-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wallace-1995" NAME="Wallace 1995" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wallace AE, Kofoed LL, West AN</AU>
<TI>Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>6</VL>
<PG>929-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wheatley-1969-a" NAME="Wheatley 1969 a" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wheatley D</AU>
<TI>Amphetamines in general practice: their use in depression and anxiety.</TI>
<SO>Seminars in Psychiatry</SO>
<YR>1969</YR>
<VL>1</VL>
<PG>163-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wheatley-1969-b" NAME="Wheatley 1969 b" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wheatley D</AU>
<TI>Amphetamines in general practice: their use in depression and anxiety</TI>
<SO>Seminars in Psychiatry</SO>
<YR>1969</YR>
<VL>1</VL>
<PG>163-73.</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Ballinger-1974" NAME="Ballinger 1974" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ballinger BR, Presly A, Reid AH, Stevenson IH</AU>
<TI>The effects of hypnotics on imipramine treatment</TI>
<SO>Psychopharmacology</SO>
<YR>1974</YR>
<VL>39</VL>
<PG>267-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blashki-1971" NAME="Blashki 1971" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blashki TG, Mowbray R, Davies B</AU>
<TI>Controlled trial of amitriptyline in general practice</TI>
<SO>British Medical Journal</SO>
<YR>1971</YR>
<VL>1</VL>
<PG>133-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Blashki TG, Mowbray R, Davies BM</AU>
<TI>A controlled trial of an antidepressant (amitriptyline) in general practice</TI>
<SO>V World Congress of Psychiatry, Nov 28-Dec 4, Ciudad De Mexico</SO>
<YR>1971</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brooks-2003" NAME="Brooks 2003" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Brooks A, Aharonovich E, Nunes E</AU>
<TI>Early participation in relapse prevention therapy predicts abstinence in a randomized clinical trial of depramine with depressed cocaine abusers</TI>
<SO>Annual Scientific Meeting of the College on Problems of Drug Dependence, Bal Harbour, FL, June 15-19</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buchsbaum-1977" NAME="Buchsbaum 1977" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buchsbaum MS, Van Kammen DP, Murphy DL</AU>
<TI>Individual differences in average evoked responses to d- and l-amphetamine with and without lithium carbonate in depressed patients</TI>
<SO>Psychopharmacology</SO>
<YR>1977</YR>
<VL>51</VL>
<PG>129-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buckman-1973" NAME="Buckman 1973" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Buckman J, Hain JD, Smith BM, Stevenson I</AU>
<TI>Controlled Interviews using drugs II. Comparisons between restricted and freer conditions</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1973</YR>
<VL>29</VL>
<PG>623-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Camacho-2006" NAME="Camacho 2006" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Camacho A, Ng B</AU>
<TI>Methylphenidate for alpha-interferon induced depression</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2006</YR>
<VL>20</VL>
<PG>687-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capstick-1965" NAME="Capstick 1965" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Capstick N, Corbett M, PAre C, Linford Rees W</AU>
<TI>A comparative trial of diazepam (valium) and amylobarbitone</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1965</YR>
<VL>111</VL>
<PG>517-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carlson-1995" NAME="Carlson 1995" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carlson GA, Rapport MD, Kelly KL, Pataki CS</AU>
<TI>Methylphenidate and desipramine in hospitalized children with comorbid behaviour and mood disorders: separate and combined effects on behavior and mood</TI>
<SO>Journal of Child and Adolescent Psychopharmacology</SO>
<YR>1995</YR>
<VL>5</VL>
<PG>191-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carlson-2004" NAME="Carlson 2004" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carlson PJ, Merlock MC, Suppes T</AU>
<TI>Adjunctive stimulant use in patients with bipolar disorder</TI>
<SO>Bipolar Disorders</SO>
<YR>2004</YR>
<VL>6</VL>
<PG>416-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carroll-1995" NAME="Carroll 1995" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carroll KM, Nich C, Rounsaville BJ</AU>
<TI>Differential symptom reduction in depressed cocaine abusers treated with psychotherapy and pharmacotherapy</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1995</YR>
<VL>183</VL>
<PG>251-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christensen-1990" NAME="Christensen 1990" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christensen L</AU>
<TI>Dietary treatment of depression</TI>
<SO>Behavior Therapy</SO>
<YR>1990</YR>
<VL>21</VL>
<PG>183-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ciraulo-2005" NAME="Ciraulo 2005" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ciraulo DA, Knapp C, Rotosen J, Sarid-Segal O, Ciraulo AM, LoCastro J et al</AU>
<TI>Nefazodone treatment of cocaine deprendence with comorbid depressive symptoms</TI>
<SO>Addiction</SO>
<YR>2005</YR>
<VL>100</VL>
<PG>23-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clauson-2004" NAME="Clauson 2004" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clauson AS, Elliott ES, Watson BD, Treacy J</AU>
<TI>Coadminstration of Phenelzine and Methylphenidate for treatment resistant depression</TI>
<SO>Annals of Pharmacotherpy</SO>
<YR>2004</YR>
<VL>38</VL>
<PG>508</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coffey-1990" NAME="Coffey 1990" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Coffey CE, Figiel GS, Weiner RD, Saunders WB</AU>
<TI>Caffeine augmentation of ECT</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>147</VL>
<PG>579-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cornelius-1994" NAME="Cornelius 1994" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cornelius JC</AU>
<TI>Fluoxetine versus placebo in depressed alcoholics</TI>
<SO>Psychopharmacology</SO>
<YR>1994</YR>
<VL>30</VL>
<PG>661</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cornelius JR, Perkins KA, Salloum IM, Thase ME, Moss HB</AU>
<TI>Fluoxetine versus placebo to decrease the smoking of depressed alcoholic patients</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1999</YR>
<VL>19</VL>
<PG>183-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cornelius JR, Salloum IM, Cornelius MD, Perel JM, Ehler JG, Jarrett PJ et al</AU>
<TI>Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1995</YR>
<VL>31</VL>
<PG>297-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Black A et al</AU>
<TI>Double-blind fluoxetine in depressed alcoholic smokers.</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1997</YR>
<VL>33</VL>
<PG>165-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM et al</AU>
<TI>Fluoxetine in depressed alcoholics. A double-blind placebo-controlled trial</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1997</YR>
<VL>54</VL>
<PG>700-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Perel J, Thase ME</AU>
<TI>Double-blind fluoxetine in depressed alcoholics</TI>
<SO>149th Annual Meeting of the American Psychiatric Association; Nay 4-9; New York, NY</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cornelius JR, Salloum IM, Haskett RF, Daley DC, Cornelius MD, Thase ME et al</AU>
<TI>Fluoxetine versus placebo in depressed alcoholics: A 1 year follow-up study</TI>
<SO>Addictive Behaviors</SO>
<YR>2000</YR>
<VL>25</VL>
<PG>307-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salloum IM, Thase ME, Haskett RF, Daley DC, Jones Barlock A, Upsher C et al</AU>
<TI>Fluoxetine versus placebo in depressed alcoholic cocaine abusers</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1998</YR>
<VL>34</VL>
<PG>117-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daley-1998" NAME="Daley 1998" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daley DC, Salloum IM, Zuckoff A, Kirisci L, Thase ME</AU>
<TI>Increasing treatment adherence among outpatients with depression and cocaine dependence: Results of a pilot study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>155</VL>
<PG>1611-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Darvill-1959" NAME="Darvill 1959" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Darvill FT, Woolley S</AU>
<TI>Double-blind evaluation of methylphenidate (Ritalin) hydrochloride</TI>
<SO>JAMA</SO>
<YR>1959</YR>
<VL>169</VL>
<PG>1739-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Wit-1987" NAME="de Wit 1987" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Wit, Uhlenhuth EH, Johanson CE</AU>
<TI>The reinforcing properties of amphetamine in overweight subjects and subjects with depression</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1987</YR>
<VL>42</VL>
<PG>127-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duval-1996" NAME="Duval 1996" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duval F, Mokrani MC, Crocq MA, Jautz M, Bailey P, Diep TS et al</AU>
<TI>Effect of anti-depressant medication on morning and evening thyroid function tests during a major depressive episode</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1996</YR>
<VL>53</VL>
<PG>833-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fava-2006" NAME="Fava 2006" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fava M, Rush AJ</AU>
<TI>Current status of augmentation and combination treatment for major depressive disorder: a literature review and a proposal for a novel approach to imporive practice</TI>
<SO>Psychotherpay and Psychosomatics</SO>
<YR>2006</YR>
<VL>75</VL>
<PG>139-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fawcett-1971" NAME="Fawcett 1971" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fawett J, Siomonpoulos V</AU>
<TI>Dextroamphetamine response as a possible predictor of improvement with tricyclic therapy in depression</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1971</YR>
<VL>25</VL>
<PG>247-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fawcett-1972" NAME="Fawcett 1972" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fawsett J, Maas JW, Dekirmenjian H</AU>
<TI>Depression and MHPG Excretion</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1972</YR>
<VL>26</VL>
<PG>246-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fawcett-1987" NAME="Fawcett 1987" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fawcett J, Edwards JH, Kravitz HM, Jeffries H</AU>
<TI>Alprazolam: an antidepressant? Alprazolam, desipramine, and an alprazolam-desipramine combination in the treatment of adult depressed outpatients</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1987</YR>
<VL>7</VL>
<PG>295-310</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kravitz HM, Edwards JH, Fawcett J, Fogg L</AU>
<TI>Challenging the amphetamine challenge test: Report of antidepressant treatment study</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1990</YR>
<VL>20</VL>
<PG>121-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giannini-1986" NAME="Giannini 1986" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giannini AJ, Malone DA, Giannini MC, Price WA, Loiselle RH</AU>
<TI>Treatment of depression in chronic cocaine and phencyclidine abuse with desipramine</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1986</YR>
<VL>26</VL>
<PG>211-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grade-1998" NAME="Grade 1998" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grade C, Redford B, Chrostowski J, Toussaint L, Blakewell B</AU>
<TI>Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1998</YR>
<VL>79</VL>
<PG>1047-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-1960" NAME="Harris 1960" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harris JA, Robin AA</AU>
<TI>A controlled trial of Phenelzine in depressive reactions</TI>
<SO>Journal of Mental Science</SO>
<YR>1960</YR>
<VL>106</VL>
<PG>1432-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hicks-1994" NAME="Hicks 1994" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hicks P, Matthews TK, Riggs M</AU>
<TI>Caffeine and ECT in the treatment of depression</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1994</YR>
<VL>30</VL>
<NO>1</NO>
<PG>106</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hinton-1959" NAME="Hinton 1959" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hinton JM</AU>
<TI>A comparison of Perphenazine, (Fentazin) Sodium Amylobarbitone and a placebo in anxious and depressed out-patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1959</YR>
<VL>105</VL>
<PG>872-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holiday-1965" NAME="Holiday 1965" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holiday AR, Joffe JR</AU>
<TI>A controlled evaluation of protriptyline conpared to a placebo and to methylphenidate hydrochloride</TI>
<SO>The Journal of New Drugs</SO>
<YR>1965</YR>
<VL>5</VL>
<PG>257-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hornig_x002d_Rohan-2002" NAME="Hornig-Rohan 2002" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hornig-Rohan M, Amsterdam JD</AU>
<TI>Venlafaxine versus stimulant therapy in patients with ADD and depression</TI>
<SO>Progress in Neuropsychophramacology</SO>
<YR>2002</YR>
<VL>26</VL>
<PG>585-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hunter-1967" NAME="Hunter 1967" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hunter JW; Owen S; Eksi A; Scott JF</AU>
<TI>A controlled cross-over study of trimipramine and amylobarbitone</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1967</YR>
<VL>113</VL>
<PG>667-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Insel-1983a" NAME="Insel 1983a" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Insel TR, Hamilton JA. Guttmacher LB. Murphy DL</AU>
<TI>D-amphetamine in obsessive-compulsive disorder</TI>
<SO>Psychopharmacology</SO>
<YR>1983</YR>
<VL>80</VL>
<PG>231-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Insel TR, Mueller ES, Gillin JC, Siever LJ, Murphy DL</AU>
<TI>Tricyclic response in obsessive compulsive disorder</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>1985</YR>
<VL>9</VL>
<PG>25-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M</AU>
<TI>Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1983</YR>
<VL>40</VL>
<PG>605-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jefferson JW, Greist JH, Perse TL, Rosenfeld R</AU>
<TI>Fluvoxamine associated mania/hypomania in patients with obsessive compulsive disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1991</YR>
<VL>11</VL>
<PG>391-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zahn TP, Insel TR, Murphy DL</AU>
<TI>Psychophysiological changes during pharmacological treatment of patients with obsessive compulsive disorder</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1984</YR>
<VL>145</VL>
<PG>39-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobson-1958" NAME="Jacobson 1958" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jacobson A</AU>
<TI>The use of ritalin in psychotherapy of depressions of the aged</TI>
<SO>Psychiatric Quarterly</SO>
<YR>1958</YR>
<VL>32</VL>
<PG>474-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joffe-1991" NAME="Joffe 1991" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joffe RT, Swinson RP, Levitt AJ</AU>
<TI>Acute psychostimulant challenge in primary obsessive-compulsive disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1991</YR>
<VL>11</VL>
<PG>237-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaplitz-1975" NAME="Kaplitz 1975" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kapltz SE</AU>
<TI>Withdrawn, apathetic geriatric patients responsive to methylphenidate</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1975</YR>
<VL>23</VL>
<PG>271-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kerenyi-1960" NAME="Kerenyi 1960" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kerenyi AB, Koranyi EK, Sarwer-Foner GJ</AU>
<TI>Depressive states and drugs-III. Use of methylphenidate in open psychiatric settings in office practice</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1960</YR>
<VL>83</VL>
<PG>1249-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klein-1991" NAME="Klein 1991" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW</AU>
<TI>Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects</TI>
<SO>Biological Psychiatry</SO>
<YR>1991</YR>
<VL>30</VL>
<PG>973-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lader-1965" NAME="Lader 1965" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lader MH, Bond AJ, James DC</AU>
<TI>Clinical comparison of anxiolytic drug therapy</TI>
<SO>Psychological Medicine</SO>
<YR>1974</YR>
<VL>4</VL>
<PG>381-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lader-1974" NAME="Lader 1974" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bond AJ, James DC, Lader MH</AU>
<TI>Sedative effects on physiological and psychological measures in anxious patients</TI>
<SO>Psychological Medicine</SO>
<YR>1974</YR>
<VL>4</VL>
<PG>374-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Landman-1958" NAME="Landman 1958" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landman ME, Preisig R, Perlman M</AU>
<TI>A practical mood stimulant</TI>
<SO>The Journal of the Medical Society of New Jersey</SO>
<YR>1958</YR>
<VL>55</VL>
<PG>55-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leonard-2004" NAME="Leonard 2004" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leonard BE, McCartan D, White J, King DJ</AU>
<TI>Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects</TI>
<SO>Human Psychopharmacology</SO>
<YR>2004</YR>
<VL>19</VL>
<PG>151-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Little-1989" NAME="Little 1989" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Little KY</AU>
<TI>Detecting acute drug effects</TI>
<SO>Biological Psychiatry</SO>
<YR>1989</YR>
<VL>25</VL>
<PG>645-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Little-1993" NAME="Little 1993" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Little KY</AU>
<TI>D-Amphetamine versus methylphenidate effects in depressed inpatients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1993</YR>
<VL>54</VL>
<PG>525-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-London-1966" NAME="London 1966" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>London AM, Schreiber ED</AU>
<TI>A controlled study of effects of group discussions and an anorexiant in outpatient treatment of obesity</TI>
<SO>Internal Medicine</SO>
<YR>65</YR>
<VL>1</VL>
<PG>80-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lovett-Doust--1959" NAME="Lovett Doust  1959" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lovett Doust JW, Lewis DJ, Miller A, Sprott D, Wright RLD</AU>
<TI>Controlled asessment of antidepressant drugs including tofranil</TI>
<SO>Canadian Psychiatric Association Journal</SO>
<YR>1959</YR>
<VL>4</VL>
<PG>S191-S194</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masand-1991" NAME="Masand 1991" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masand P, Pickett P, Murray GB</AU>
<TI>Psychostimulants for secondary depression in medical illness</TI>
<SO>Psychosomatics</SO>
<YR>1991</YR>
<VL>32</VL>
<PG>203-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McDowell-2000" NAME="McDowell 2000" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McDowell DM, Levin FR, Seracini AM, Nunes EV</AU>
<TI>Venlafaxine treatment of cocaine abusers with depressive disorders</TI>
<SO>American Journal of Drug and Alcohol Abuse</SO>
<YR>2000</YR>
<VL>26</VL>
<PG>25-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meston-2004" NAME="Meston 2004" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meston CM</AU>
<TI>A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunction</TI>
<SO>Journal of Sex and Marital Therapy</SO>
<YR>2004</YR>
<VL>30</VL>
<PG>57-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Natale-1979" NAME="Natale 1979" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Natale M, Dahlberg CC</AU>
<TI>The effect of psychotomimetics on therapist patient matching of speech "rhythms"</TI>
<SO>Journal of Communication Disorders</SO>
<YR>1979</YR>
<VL>12</VL>
<PG>45-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naylor-1986" NAME="Naylor 1986" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naylor GJ, Martin B, Hopwood SE, Watson Y</AU>
<TI>A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis</TI>
<SO>Biological Psychiatry</SO>
<YR>1986</YR>
<VL>21</VL>
<PG>915-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naylor-1987" NAME="Naylor 1987" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naylor GJ, Smith AH; Connelly P</AU>
<TI>A controlled trial of methylene blue in severe depressive illness</TI>
<SO>Biological Psychiatry</SO>
<YR>1987</YR>
<VL>22</VL>
<PG>657-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niederhofer-2002" NAME="Niederhofer 2002" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niederhofer H</AU>
<TI>Therapy resistant major depression: symptom improvement psychopharmacological combination of antidepressants and methyphenidate</TI>
<SO>Wiener Medizininische Wochenschrift</SO>
<YR>2002</YR>
<VL>152</VL>
<PG>578-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Padala-2005" NAME="Padala 2005" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Padala PR, Petty F, Bhatia SC</AU>
<TI>Methylphenidate may treat apathy independent depression</TI>
<SO>Annals of Pharmacotherpy</SO>
<YR>2005</YR>
<VL>39</VL>
<PG>1947-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pataki-1993" NAME="Pataki 1993" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pataki CS, Carlson GA, Kelly KL, Rapport MD, Biancaniello TM.</AU>
<TI>Side effects of Methylphenidate and Desipramine alone and in combination in children.</TI>
<SO>Journal of the American Academy of Child and Adolescent Psychiatry</SO>
<YR>1993</YR>
<VL>32</VL>
<PG>1065-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Post-1974" NAME="Post 1974" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Post RM, Gillin JC, Wyatt RJ, Goodwin FK</AU>
<TI>The effect of orally adminstered cocaine on sleep of depressed patients</TI>
<SO>Psychopharmacologia</SO>
<YR>1974</YR>
<VL>37</VL>
<PG>59-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quadri-1980" NAME="Quadri 1980" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quadri AA; Shalini K, Channabasavanna SM</AU>
<TI>D-Amphetamine as a predictor for response to imipramine and amitriptyline</TI>
<SO>Indian Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>22</VL>
<PG>182-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Randall-2005" NAME="Randall 2005" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Randall DC, Cafferty FH, Shneerson JM, Smith IE, Llewelyn MB, File SE</AU>
<TI>Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2005</YR>
<VL>19</VL>
<PG>647-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rapport-1993" NAME="Rapport 1993" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rapport MD, Carlson GA, Kelly KL, Pataki C</AU>
<TI>Methylphenidate and desipramine in hospitalised children</TI>
<SO>Journal of American Academic Child and Adolescent Psychiatry</SO>
<YR>1993</YR>
<VL>32</VL>
<PG>333-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rees-1961" NAME="Rees 1961" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rees L, Davies B</AU>
<TI>A controlled trial of phenelzine in the treatment of severe depressive illness</TI>
<SO>Journal of Mental Science</SO>
<YR>1961</YR>
<VL>107</VL>
<PG>560</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riddle-1995" NAME="Riddle 1995" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riddle MA, Lynch KA, Scahill L, de Vries A, Cohen DJ, Leckman JF</AU>
<TI>Methylphenidate discontinuation and reinintiation during long-term treatment of children with Tourette's Disorder and attention deficit disorder: a pilot study</TI>
<SO>Journal of Child and Adolescent Psychopharmacology</SO>
<YR>1995</YR>
<VL>5</VL>
<PG>205-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenquist-1994" NAME="Rosenquist 1994" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenquist PB, McCall WV, Farah A, Reboussin DM</AU>
<TI>Effects of caffeine pretreatment on measures of seizure impact.</TI>
<SO>Convulsive Therapy</SO>
<YR>1994</YR>
<VL>10</VL>
<PG>181-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roy_x002d_Byrne-1983" NAME="Roy-Byrne 1983" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roy-Byrne PP, Gwirtsman HE, Baxter L, Gerner RH</AU>
<TI>Endocrine correlates of mood response to methylphenidate in depression</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1983</YR>
<VL>3</VL>
<PG>266-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmitz-2001" NAME="Schmitz 2001" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmitz JM, Averill P, Stotts AL, Moeller FG, Rhoades HM, Grabowski J</AU>
<TI>Fluoxetine treatment of cocaine-dependent patients with major depressive disorder</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2001</YR>
<VL>63</VL>
<PG>207-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sramek-1995" NAME="Sramek 1995" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sramek JJ, Jasinsky O, Chang S, Shu V, Kashkin K, Kennedy S et al</AU>
<TI>Pilot efficacy trial of ABT-200 in patients with major depressive disorder</TI>
<SO>Depression</SO>
<YR>1995</YR>
<VL>2</VL>
<PG>315-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tremblay-2002" NAME="Tremblay 2002" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tremblay LK, Naranjo CA, Cardenas L, Herrmann N, Busto UE.</AU>
<TI>Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine.</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2002</YR>
<VL>59</VL>
<PG>409-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tremblay-2002b" NAME="Tremblay 2002b" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cardenas L, Tremblay LK, Naranjo CA, Herrmann N, Zack M, Busto UE</AU>
<TI>Brain reward system activity in major depression and comorbid nicotine dependence</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>2002.</YR>
<VL>302</VL>
<PG>1265-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Kammen-1975a" NAME="Van Kammen 1975a" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Kammen DP, Murphy DL</AU>
<TI>Attenuation of the euphoriant and activating effects of d- and l-Amephetamine by lithium carbonate treatment</TI>
<SO>Psychopharmacologia</SO>
<YR>1975</YR>
<VL>44</VL>
<PG>215-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Kammen-1975b" NAME="Van Kammen 1975b" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gillin JC, Van Kammen DP, Graves J, Murphy D</AU>
<TI>Differential effects of D and L amphetamine on the sleep of depressed patients</TI>
<SO>Life Sciences</SO>
<YR>1975</YR>
<VL>17</VL>
<PG>1233-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Kammen-1978" NAME="Van Kammen 1978" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Kammen DP, Murphy DL</AU>
<TI>Prediction of Imipramine antidepressant response by a one-day d-amphetamine trial</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1978</YR>
<VL>135</VL>
<PG>1179-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Praag-1973" NAME="Van Praag 1973" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Praag HM, Korf J</AU>
<TI>4-Chlorampetamines. Chance and Trend in the development of new antidepressants</TI>
<SO>Journal of Clinical Pharmacology and New drugs</SO>
<YR>1973</YR>
<VL>13</VL>
<PG>3-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wheatley-1969c" NAME="Wheatley 1969c" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wheatley D</AU>
<TI>Amphetamines in general practice: their use in depression and anxiety</TI>
<SO>Seminars in Psychiatry</SO>
<YR>1969</YR>
<VL>1</VL>
<PG>163-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woods-1986" NAME="Woods 1986" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woods SW, Tesar GE, Murray GB, Cassem NH</AU>
<TI>Psychostimulant treatment of depressive disorders secondary to medical illness</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1986</YR>
<VL>47</VL>
<PG>12-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ziedonis-1991a" NAME="Ziedonis 1991a" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ziedonis DM, Kosten TR</AU>
<TI>Depression as a prognostic factor for pharmacolgical treatment of cocaine dependence</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1991</YR>
<VL>27</VL>
<PG>337-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ziedonis-1991b" NAME="Ziedonis 1991b" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ziedonis DM, Kosten TR</AU>
<TI>Pharmacotherapy improves treatment outcome in depressed cocaine addicts</TI>
<SO>Journal of Psychoactive Drugs</SO>
<YR>1991</YR>
<VL>23</VL>
<PG>417-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-APA-2005" NAME="APA 2005" TYPE="BOOK">
<AU>American Psychiatric Assocaition</AU>
<SO>Diagnostic and statisticsl manual of mental disorders (DSM-5)</SO>
<YR>2005</YR>
<PB>Americian Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bebbington-2000" NAME="Bebbington 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bebbington PE, Brugha TS, Meltzer H, Jenkins R, Ceresa C, Farell M et al</AU>
<TI>Neurotic disorders and the recipt of psychiatric treatment.</TI>
<SO>Psychological Medicine</SO>
<YR>2000</YR>
<VL>30</VL>
<PG>1369-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BNF-2007" NAME="BNF 2007" TYPE="OTHER">
<TI>British Medical Association and Royal Pharmaecutical Society of Great Britian.</TI>
<SO>British National Formulary 53rd Edition. London: British Medical Assocaition and Royal Pharmaecutical Society od Great Britian, 2007</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bosc-1997" NAME="Bosc 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bosc M; Dubini A, Polin V</AU>
<TI>Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1997</YR>
<VL>7</VL>
<PG>S57 S79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cassano-2002" NAME="Cassano 2002" TYPE="JOURNAL_ARTICLE">
<AU>Cassano P, Fava M</AU>
<TI>Depression and public health. An overview.</TI>
<SO>Journal of Psychosomatic Research</SO>
<YR>2002</YR>
<VL>53</VL>
<PG>849-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chiarello-1987" NAME="Chiarello 1987" TYPE="JOURNAL_ARTICLE">
<AU>Chiarello RJ, Cole JO</AU>
<TI>The use of psychostimulants in general psychiatry</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1987</YR>
<VL>44</VL>
<PG>286-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Delgado-2000" NAME="Delgado 2000" TYPE="JOURNAL_ARTICLE">
<AU>Delgado PL</AU>
<TI>Depression: the case for a monoamine deficiency</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2000</YR>
<VL>61 Suppl 6</VL>
<PG>7-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Demyttenaere-2004" NAME="Demyttenaere 2004" TYPE="JOURNAL_ARTICLE">
<AU>Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP et al</AU>
<TI>Prevalence, severity and unmet need for treatment of mental disorders in the World Health Organisation World Mental Health Surveys.</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<PG>2581-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1960" NAME="Hamilton 1960" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>A rating scale for depression</TI>
<SO>Journal of Neurology, Neurosurgy and Psychiatry</SO>
<YR>1960</YR>
<VL>23</VL>
<PG>56-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" NAME="Higgins 2006" TYPE="BOOK">
<AU>Higgins JPT, Greens S, editors.</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 (updated September 2006)</TI>
<SO>www.cochrane.org/resoures/handbook/hbook.htm (accessed September 30th 2006)</SO>
<YR>2006</YR>
<PB>Wiley</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juni-2001" NAME="Juni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Juni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: Assessing the quality of controlled clincal trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lin-1999" NAME="Lin 1999" TYPE="JOURNAL_ARTICLE">
<AU>Lin E, Parikh SV</AU>
<TI>Sociodemographic, clinical, and attitudinal characteristics of the untreated depressed in Ontario</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1999</YR>
<VL>53</VL>
<PG>153-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Linet-1989" NAME="Linet 1989" TYPE="JOURNAL_ARTICLE">
<AU>Linet LS</AU>
<TI>Treatment of a refractory depression with a coombination of fluoxetine and d-amphetamine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>146</VL>
<PG>803-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maddox-1994" NAME="Maddox 1994" TYPE="JOURNAL_ARTICLE">
<AU>Maddox JC, Levi M, Thompson C</AU>
<TI>The compliance with antidepressants in general practice.</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>1994</YR>
<VL>8</VL>
<PG>48-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Masand-1998" NAME="Masand 1998" TYPE="JOURNAL_ARTICLE">
<AU>Masand PS, Anand VS, Tanquary JF</AU>
<TI>Psychostimulant augmentation of second generation anti-depressants: A case series</TI>
<SO>Depression and Anxiety</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>2</NO>
<PG>89-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moncrieff-2005" NAME="Moncrieff 2005" TYPE="JOURNAL_ARTICLE">
<AU>Moncrieff J, Kirsch I</AU>
<TI>Efficacy of antidepressants in adults</TI>
<SO>BMJ</SO>
<YR>2005</YR>
<VL>331</VL>
<PG>155-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montgomery-1979" NAME="Montgomery 1979" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery SA, Asberg M</AU>
<TI>A new depression scale designed to be sensitive to change</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>134</VL>
<PG>382-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murray-1997" NAME="Murray 1997" TYPE="JOURNAL_ARTICLE">
<AU>Murray CJ, Lopez AD</AU>
<TI>Alternative projections of mortality and disability by cause 1990-2020: Golbal Burden of Disease Study</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<PG>1498-04</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nguyen-2005" NAME="Nguyen 2005" TYPE="JOURNAL_ARTICLE">
<AU>Nguyen B, Tampi RR</AU>
<TI>Psychostimulants in the treatment of depression in the older patient</TI>
<SO>Clinical Geriatrics</SO>
<YR>2005</YR>
<VL>13</VL>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2004" NAME="NICE 2004" TYPE="BOOK">
<AU>National Institute for Clinical Excellence</AU>
<SO>Depression: management of depression in primary and secondary care. Clinical practice guideline No 23</SO>
<YR>2004</YR>
<PB>National Institute for Clinical Excellence</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Orr--2007" NAME="Orr  2007" TYPE="JOURNAL_ARTICLE">
<AU>Orr K; Taylor D</AU>
<TI>Psychostimulants in the treatment of depression</TI>
<SO>CNS Drugs</SO>
<YR>2007</YR>
<VL>21</VL>
<PG>239-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Satel-1989" NAME="Satel 1989" TYPE="JOURNAL_ARTICLE">
<AU>Satel SL, Nelson JC</AU>
<TI>Stimulants in the treatment of depression: a critical overview</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1989</YR>
<VL>50</VL>
<PG>2491-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Singleton-2001" NAME="Singleton 2001" TYPE="BOOK">
<AU>Singleton N, Bumpstead R, O'Brien M, Lee A, Meltzer H</AU>
<SO>Psychiatric morbidity among adults living in private households, 2000.</SO>
<YR>2001</YR>
<PB>The Stationery Office</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spitzer-1995" NAME="Spitzer 1995" TYPE="JOURNAL_ARTICLE">
<AU>Spitzer RL, Kroenke K, Linzer M, Hahn SR, Williams JB, deGruy FV 3rd et al</AU>
<TI>Health-related quality of life in primary care patients with mental disorders.</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>274</VL>
<PG>1511-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2003" NAME="Thomas 2003" TYPE="JOURNAL_ARTICLE">
<AU>Thomas CM, Morris S</AU>
<TI>Cost of depression among adults in England in 2000</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>183</VL>
<PG>514-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2005" NAME="Wang 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC.</AU>
<TI>Twelve-month use of mental health services in the United States.</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2005</YR>
<VL>62</VL>
<PG>629-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ware-1992" NAME="Ware 1992" TYPE="JOURNAL_ARTICLE">
<AU>Ware JE Jr, Sherbourne CD</AU>
<TI>The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection</TI>
<SO>Medical Care</SO>
<YR>1992</YR>
<VL>30</VL>
<PG>473-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Young-2001" NAME="Young 2001" TYPE="JOURNAL_ARTICLE">
<AU>Young AS, Klap R, Sherbourne CD, Wells KB</AU>
<TI>The quality of care for depressive and anxiety disorders in the United Sates.</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2001</YR>
<VL>58</VL>
<PG>55-61</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Cantello-1989">
<CHAR_METHODS>
<P>Double blind randomised controlled cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Four armed trial. The two arms are relevant to this review. Arm 1- Patients with major depression (DSM-III) N=14 male (n=8) and female patients. Arm 2- Patients with major depression (DSM-III) and Parkinsonian N=13 male (n=7) and female patients. </P>
<P>Mean age in those depressed was 59 years, in depressed patients with Parkinsonians disease it was 57 years. </P>
<P>Italy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intravenous one dose each of:<BR/>Drug 1 = methylamphetamine 0.4 mg/kg.<BR/>Drug 2 = placebo</P>
<P>Duration of treatment: one dose of each drug separated by 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Self- rated depressed effect plus dysphoria, Mood- observers global judgement score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cookson-1986">
<CHAR_METHODS>
<P>Double blind randomised controlled cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=21 male (n=5) and female patients with depressive disorder (RDC). </P>
<P>Age range 23-74 </P>
<P>UK</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intravenous one dose each of: <BR/>Drug 1 = methylamphetamine 15 mg .<BR/>Drug 2 = placebo </P>
<P>Duration of treatment: 2 days unclear if treatments separated (for washout)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Self report using visual analogue scale (VAS) for depression, anxiety and hunger at 1,2,4 and 6 hours after.<BR/>Author rating of the overall severity of depression using VAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-DeBattista-2003">
<CHAR_METHODS>
<P>Double blind randomised controlled parallel multi-centred study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N= 136 male (n=41) and female patients with major depression (DSM-IV) and partial response to antidepressant therapy.. </P>
<P>Mean age 45 years.</P>
<P>USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral<BR/>Group 1 = modafinil once daily 100-400 mg<BR/>Group 2 = placebo<BR/>In addition both groups received as part of their regular treatment an unspecified anti-depressant</P>
<P>Duration of treatment: 6 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Depression: Hamilton Depression Scale (HAM-D) 21. Clinical Global Impression of severity (CGI-S) and Clinical Global Impression of Change (CGI-C).<BR/>Fatigue and sleepiness using the Fatigue Severity Scale and the Epworth Sleepiness Scale.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Elizur-1979">
<CHAR_METHODS>
<P>Double blind randomised controlled parallel trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=20 male (n=10) and female psychiatric outpatients suffering from major depression (diagnostic measure not stated). </P>
<P>Mean age 36.5 years in pemoline group and 33.7 in placebo group (range 30-60)</P>
<P>Israel</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral<BR/>Group 1 = pemoline 50mg daily <BR/>Group 2 = placebo </P>
<P>Duration of treatment: 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Modified HAM-D (using 8 target symptoms) and CGI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fava-2005">
<CHAR_METHODS>
<P>Double blind randomised controlled parallel multi-centred study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=314 male (n = 94) and female patients diagnosed with MDD (DSM-IV) , with symptoms of fatigue and excessive sleepiness and were partial responders to antidepressant therapy.</P>
<P>Mean age 42 years (18-65 years)</P>
<P>USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral <BR/>Group 1 = modafinil 100-200mg daily<BR/>Group 2 = placebo<BR/>Patients continued to recieve as part of their regular treatment a selective serotonin reuptake inhibitor (SSRIs) antidepressant. </P>
<P>Duration of treatment: 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Depression, sleepinesss, fatigue, and depression. <BR/>Using the HAM-D 31 and 17, Montgomery-Asberg depression rating scale (MADRS), CGI-S, CGI-I, Brief Fatigue Inventory, and Epworth Sleepiness Scale.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fernandez-1995">
<CHAR_METHODS>
<P>Double blind randomised controlled parallel trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N= 20 male patients with major depressive symptoms (DSM-III-R) and HIV. </P>
<P>Mean age in psychostimulant group: 35.5 years (SD 10.48), in anti-depressant group 2: 34 years (SD 7.91)</P>
<P>USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral<BR/>Group 1 = methylphenidate 5-30mg daily<BR/>Group 2 = desipamine 25mg-150mg daily</P>
<P>Duration of treatment : 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-D 24, Brief Symtpom Inventory Depression scale (BSI), State-Trait Anxiety Inventory (STAI).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hare-1962">
<CHAR_METHODS>
<P>Double blind randomised controlled cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N= 46 male (n=12) and female patients diagnosed with primary depressive illness (diagnostic measure not stated). </P>
<P>Median age of completers 42 years</P>
<P>UK</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral<BR/>Twice daily per drug. <BR/>Drug 1 = dexamphetamine 5mg<BR/>Drug 2 = phenezine 30mg<BR/>Drug 3 placebo</P>
<P>Duration of treatment: 2 weeks on weekdays only</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessor rating of depression, retardation, agitation, anxiety, hypochondria, anorexia and insomnia.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hare-1964">
<CHAR_METHODS>
<P>Double blind randomised controlled cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N= 106 male and female (does not provide baseline proportion) in/day patients diagnosed with primary depressive illness. 32 male and 46 females completed study. </P>
<P>Median age of completers 45 years.</P>
<P>UK</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral <BR/>Drug 1 = dexamphetamine 5 mg and amylobarbitone 50 mg<BR/>Drug 2 = imipramine 75mg increased to 150 mg.</P>
<P>Duration of treatment: Over 6 weeks, 3 weeks per drug. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessor rating of depression, anxiety, insomnia (subject rating) and overall clinical state.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kits-1970">
<CHAR_METHODS>
<P>Double blind randomised controlled parallel trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N= 50 male (n=25) and female inpatients, hospitalised for depressive symptoms.</P>
<P>Mean age 44 years, range 19-69.</P>
<P>The Netherlands</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral<BR/>Group 1 = p-chloro-n-methylamphetamine 90 mg daily<BR/>Group 2 = placebo</P>
<P>Duration of treatment: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Vital syndrome interview- severity of depression, mood, sleep, appetite. Beck Depression Inventory and Zung self-rating scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lee-2005">
<CHAR_METHODS>
<P>Double blind randomised controlled parallel trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=30 male (n=24) and female patients with traumatic brain injury with major depression (DSM-IV). </P>
<P>Mean age of completers in methylphenidate group 35.3 (SD 8.0), in setraline group 33.6 (SD 12.3) and in placebo group 35.5 (SD 7.2) years.</P>
<P>Korea</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral <BR/>Group 1 = methylphenidate to 20mg daily<BR/>Group 2 = placebo<BR/>Group 3 = sertraline to 100mg daily</P>
<P>Duration of treatment 1 week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-D-17, Beck Depression Inventory</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mattes-1985">
<CHAR_METHODS>
<P>Double blind randomised controlled cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=20 male (n=10) and female outpatients mildly depressed (HAM-D, SCL-90). </P>
<P>Mean age 30.7 (range 22-45)</P>
<P>USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral<BR/>Drug 1 = methylphenidate 10 mg up to 60mg daily<BR/>Drug 2 = placebo</P>
<P>Duration of treatment unclear either 3 weeks overall or 3 weeks per treatment<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>POMS, Symptom Distress Checklist-90, California Psychological Inventory, SAD-C (global assessment scale and scales for depressive syndrome)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Overall-1962">
<CHAR_METHODS>
<P>Double blind randomised controlled parallel multi-centred trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=204 male (n=194) and female in-patients with a main psychiatric diagnosis of either (1) neurotic depresive reaction, (2) psychotic depressive reaction, (3) manic-depressive reaction , depressed type, (4) involutional psychotic reaction, depressive type, or (5) schizophrenic reaction, schizo-affective type, depressed. </P>
<P>Age not provided.</P>
<P>USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral<BR/>Group 1 = imipramine 37.5mg TO 300 mg<BR/>Group 2 = isocarboxazide 5mg to 40 mg<BR/>Group 3 = dextroamphetamine 5 mg tp 40 mg and amobarbital 32mg to 256 mg daily<BR/>Group 4 = placebo</P>
<P>Treatment duration: 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>IMPS-31</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Patkar-2006">
<CHAR_METHODS>
<P>Double blind randomised controlled parallel trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=60 male (states about 37% of completers were male) and female outpatients with treatment resistant major depressive disorder (DSM-IV). </P>
<P>Mean age of copmpleters was 48.5 years.</P>
<P>USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral<BR/>Group 1 = methylphenidate 18-54 mg daily <BR/>Group 2 = placebo</P>
<P>Patients remain on preexisiting antidepressant</P>
<P>Duration of treatment: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-D 21, CGI-S, CGI-I, Beck Depression Inventory (BDI-11)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Postolache-1999">
<CHAR_METHODS>
<P>Double blind randomised controlled parallel trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N= 9 male (n = 2) and female out-patients with major depressive disorder (DSM-IV)&gt;</P>
<P>Age range 24-66 years</P>
<P>USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral <BR/>Group 1 = methylphenidate increasing up to 10 mg daily<BR/>Group 2 = placebo<BR/>All patients remained on pre-existing antidepressant of sertraline 200mg daily</P>
<P>Duration of treatment: 9 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-D 21</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Reus-1979">
<CHAR_METHODS>
<P>Double blind randomised controlled cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N= 9 endogenously depressed (8 unipolar and 1 bipolar) (RDC) and had concomitant fatgue or apathy. Does not state if male or female.</P>
<P>Age range 21-40 years.</P>
<P>USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intravenous<BR/>Group 1 = dextroamphetamine 20mg<BR/>Group 2 = placebo</P>
<P>Duration of treatment: one dose separated by 2 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Brief Psychiatric Rating Scale<BR/>Modified Bunney-Hamburg Scale<BR/>Self-rated depression, activated euphoria, anxiety<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rickels-1970">
<CHAR_METHODS>
<P>Double blind randomised controlled parallel trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 120 male (n=23) and female outpatient , private psychiatric practice patients or general practice patients that were mild to moderately depressed (GP or psychiatrist diagnosis) with symptoms of fatigue, apathy or anorexia . </P>
<P>Mean age of those recruited from clinc 41 years, from general practice 56 years and from psychiatric private practice 38 years.</P>
<P>USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral<BR/>Group 1 = pemoline 25 mg<BR/>Group 2 = methylphenidate 5 mg 3 times daily<BR/>Group 3 = placebo<BR/>Duration of treatment: 4 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Zung Depression Scale<BR/>Physican rated fatigue, anorexia, anxiety, depression. sleep disturbances, appetite disturbances</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rickels-1972">
<CHAR_METHODS>
<P>Double blind randomised controlled parallel trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N= 101 male (n=33) and female outpatients that were mildly depressed (GP diagnosed) . </P>
<P>Mean age 32.7yrs</P>
<P>USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral<BR/>Group 1 = methylphenidate 30mg daily (could be decreased or increased to 60mg daily) <BR/>Group 2 = placebo</P>
<P>Duration of treatment: 4 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Zung Depression Scale<BR/>Physician depression scale<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Robin-1958">
<CHAR_METHODS>
<P>Double blind randomised controlled parallel trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N= 45 male (n=14) and female patients with mild or moderate depression (psychiatrist diagnosed). All participants had at least 4 other symptoms of sleep disturbance, loss of appetite and weight loss, impairment of interests, lack of confidence, reduced alertness and retardation or agitation.</P>
<P>Mean age in intervention group 37.5 years, in placebo 39.5 years.</P>
<P>UK</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral<BR/>Group 1 = methylphenidate 10-20 mg<BR/>Group 2 = placebo </P>
<P>Duration of treatment: 4 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Psychiatrist rating, Patient rated improvement, depressive scale of MMPI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Silberman-1981">
<CHAR_METHODS>
<P>Double blind randomised cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 20 male (n =10 of completers) and female patients with major depressive episode (RDC).</P>
<P>Mean age of completers 33.4 years</P>
<P>USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intravenous<BR/>One dose of<BR/>Drug 1 = dextroamphetamine 20mg<BR/>Drug 2 = placebo infusion</P>
<P>Duration of treatment: one dose each cross over separated by at least 2 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Physician BPRS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Vaishnavi-2006">
<CHAR_METHODS>
<P>Double blind randomised controlled parallel trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 50 male (n =7) and female patients with major atypical depressive disorder (DSM-IV). <BR/>(atypical described as a subgroup of depressed patients who have reactive mood with features of hypersomnia, hyperphagia, anergia and regection sensitivity and where convention antidepressant therpay is of limited value.</P>
<P>Mean age 39.48 +/- 9.44</P>
<P>USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral<BR/>Group 1 = modafinil 200mg/d to 400 mg/d<BR/>Group 2 = placebo</P>
<P>Duration of treatment 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-D 29, SCL-90 anxiety, depression and over eating subscales, CGI-S, FSS, BFI, ADDS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wagner-2000">
<CHAR_METHODS>
<P>Double blind randomised controlled parallel trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N =23 male patients with depressive disorder (DSM-IV) AND hiv. </P>
<P>Mean age 41 years (SD 8)</P>
<P>USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral <BR/>Group 1 = dextroamphetamine increased up to maximum dose of 40mg per day.<BR/>Group 2 = placebo</P>
<P>Duration of treatment 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-D-21,<BR/>Brief Symptom Inventory (BSI)<BR/>Clinical Global Impressions, 10 point VAS depression, 7 items CFS, 10 point VAS energy<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wallace-1995">
<CHAR_METHODS>
<P>Double blind randomised controlled cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 16 male (n = 5) and female patients with major depression (DSM-III). </P>
<P>Mean age 72.3 years (SD 9.8)</P>
<P>USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral<BR/>Group 1 = methylphenidate 10mg-20mg DAILY<BR/>Group 2 = placebo</P>
<P>Duration of treatment: 8 days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-D(does not state which version)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wheatley-1969-a">
<CHAR_METHODS>
<P>Double blind randomised controlled parellel trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 70 male (n=9) and female patients with acute depression. How diagnosed not stated.</P>
<P>No patients were aged less than 16 or greater than 70 years</P>
<P>UK<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral <BR/>Group 1 = dexamphetamine 10mg- 30mg daily <BR/>Group 2 = placebo</P>
<P>Duration of treatment 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical assessments on symptoms improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wheatley-1969-b">
<CHAR_METHODS>
<P>Double blind randomised controlled cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 40 male (n = 7) and female patients with chronic depresssion. How depression diagnosed unclear. </P>
<P>No patients aged less than 16 years </P>
<P>UK</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral<BR/>Group 1 = dextroamphetamine 10mg - 30 mg daily <BR/>Group 2 = placebo</P>
<P>Duration of treatment 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical assessments on on symptom improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Ballinger-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Blashki-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brooks-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Buchsbaum-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>No depression outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Buckman-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Camacho-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Capstick-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carlson-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carlson-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carroll-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Christensen-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ciraulo-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Clauson-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Coffey-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>No depression outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cornelius-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Daley-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Darvill-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>No depression outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-de-Wit-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT evaluation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Duval-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fava-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fawcett-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT evaluation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fawcett-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT evaluation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fawcett-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Giannini-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grade-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were not diagnosed with depression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harris-1960">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hicks-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>No depression outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hinton-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Holiday-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT evaluation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hornig_x002d_Rohan-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT evaluation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hunter-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Insel-1983a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jacobson-1958">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT evaluation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Joffe-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No depression outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kaplitz-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No depression outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kerenyi-1960">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT evaluation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klein-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were not diagnosed with depression at baseline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lader-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lader-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Landman-1958">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT evaluation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leonard-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Little-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>A validation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Little-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT evaluation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-London-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were not diagnosed with depression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lovett-Doust--1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT evaluation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Masand-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT evaluation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McDowell-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meston-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No depression outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Natale-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>No depression outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Naylor-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Naylor-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Niederhofer-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Padala-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pataki-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Evalaution in children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Post-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>No depression outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Quadri-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT evaluation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Randall-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were not diagnosed with depression at baseline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rapport-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Evaluation in children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rees-1961">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Riddle-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Evaluation in children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rosenquist-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>No depression outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roy_x002d_Byrne-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT evaluation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schmitz-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sramek-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tremblay-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No depression outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tremblay-2002b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cardenas 2002: Not specifically looking at the effect of d-amphetamines on depression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Kammen-1975a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT evaluation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Kammen-1975b">
<CHAR_REASON_FOR_EXCLUSION>
<P>No depression outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Kammen-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT evaluation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Praag-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT evaluation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wheatley-1969c">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome does not measure effectiveness of PS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Woods-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a RCT evaluation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ziedonis-1991a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ziedonis-1991b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not psychostimulants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cantello-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cookson-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-DeBattista-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Elizur-1979">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fava-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fernandez-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hare-1962">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hare-1964">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kits-1970">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lee-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mattes-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Overall-1962">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Patkar-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Postolache-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Reus-1979">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rickels-1970">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rickels-1972">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Robin-1958">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Silberman-1981">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vaishnavi-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wagner-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wallace-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wheatley-1969-a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wheatley-1969-b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Methodological quality of included trials</TITLE>
<TABLE COLS="6" ROWS="25">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>Sample size</P>
</TH>
<TH>
<P>Recruitment rate</P>
</TH>
<TH>
<P>Randomisation</P>
</TH>
<TH>
<P>Masking</P>
</TH>
<TH>
<P>Attrition</P>
</TH>
</TR>
<TR>
<TD>
<P>1-Cantello 1989</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>States 'randomised sequence'</P>
</TD>
<TD>
<P>Double-blind: No details who is masked</P>
</TD>
<TD>
<P>No loss to follow up</P>
</TD>
</TR>
<TR>
<TD>
<P>2-Cookson 1986</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Double-blind: No details who is masked</P>
</TD>
<TD>
<P>No loss to follow up</P>
</TD>
</TR>
<TR>
<TD>
<P>3-DeBattista 2003</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Double-blind: No details who is masked</P>
</TD>
<TD>
<P>14% of 69 in modafinil group, 12% of 67 in placebo group, unclear if used intention-to-treat analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>4-Elizur 1979</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Double-blind: No details who is masked</P>
</TD>
<TD>
<P>No loss to follow up</P>
</TD>
</TR>
<TR>
<TD>
<P>5-Fava 2005</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Computer generated random numbers</P>
</TD>
<TD>
<P>Double-blind: All site personnel blinded except the research pharmacist</P>
</TD>
<TD>
<P>16% of 155 in placebo group, 15% of 159 in intervention group lost to follow up. No Intention to treat analysis.</P>
</TD>
</TR>
<TR>
<TD>
<P>6-Fernandez 1995</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Double-blind: No details who is masked</P>
</TD>
<TD>
<P>25% of 12 in methylphenidate group, 25% of 8 in desipamine group lost to follow up. No Intention to treat analysis.</P>
</TD>
</TR>
<TR>
<TD>
<P>7-Hare 1962</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provdied</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Double-blind: Patient and interventionist</P>
</TD>
<TD>
<P>1.5% of 46 lost to follow up. No intention to treat analysis.</P>
</TD>
</TR>
<TR>
<TD>
<P>8-Hare 1964</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Double-blind: No details who is masked</P>
</TD>
<TD>
<P>26% of 106 lost to follow up. No intention to treat analysis.</P>
</TD>
</TR>
<TR>
<TD>
<P>9-Kits 1970</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Double-blind: No details who is masked</P>
</TD>
<TD>
<P>No loss to follow-up</P>
</TD>
</TR>
<TR>
<TD>
<P>10-Lee 2005</P>
</TD>
<TD>
<P>Sample size calculation reported but not met</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Double-blind: No details who is masked</P>
</TD>
<TD>
<P>No loss to follow-up</P>
</TD>
</TR>
<TR>
<TD>
<P>11-Mattes 1985</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Double-blind: No details who is masked</P>
</TD>
<TD>
<P>5% of 20 lost to follow-up. No intention-to-treat analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>12-Overall 1962</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Randomised blocks - patients assigned in order of admission</P>
</TD>
<TD>
<P>Double-blind: No details who is masked</P>
</TD>
<TD>
<P>41% of 204 lost to follow-up. No intention-to-treat analysis.</P>
</TD>
</TR>
<TR>
<TD>
<P>13-Patkar 2006</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Double-blind: No details who is masked</P>
</TD>
<TD>
<P>17% of 60 lost to follow up. Used intention-to-treat analysis.</P>
</TD>
</TR>
<TR>
<TD>
<P>14-Postolache 1999</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Double-blind: No details who is masked</P>
</TD>
<TD>
<P>22% of 9 lost to follow-up. No intention-to-treat analysis.</P>
</TD>
</TR>
<TR>
<TD>
<P>15--Reus 1979</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Double-blind: Patients and assessor</P>
</TD>
<TD>
<P>No loss to follow-up</P>
</TD>
</TR>
<TR>
<TD>
<P>16-Rickels 1970</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Patients systematically randomly assigned in sucessive numbers within each of the three healthcare settings</P>
</TD>
<TD>
<P>Double-blind: No details who is masked</P>
</TD>
<TD>
<P>31% of placebo group, 16% of pemoline group, 16% methylphenidate group lost to follow up. No Intention to treat analysis.</P>
</TD>
</TR>
<TR>
<TD>
<P>17-Rickels 1972</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Systematised random order shuffled</P>
</TD>
<TD>
<P>Double-blind: No details who is masked</P>
</TD>
<TD>
<P>Unclear in paper</P>
</TD>
</TR>
<TR>
<TD>
<P>18-Robin 1958</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Sealed envelopes were prepared containing the prescription of placebo or methylphenidate and were throughly shuffled.</P>
</TD>
<TD>
<P>Double-blind: Patient and clinican</P>
</TD>
<TD>
<P>23% of 22 in intervention group lost to follow up, no loss to follow-up in control group</P>
</TD>
</TR>
<TR>
<TD>
<P>19-Silberman 1981</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Double-blind. Patient masked, no details on who else is masked</P>
</TD>
<TD>
<P>No loss to follow up</P>
</TD>
</TR>
<TR>
<TD>
<P>20-Vaishnavi 2006</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Random numbers chosen from a statistical distribution with a computer program and each patient assigned a number. Patients who recieved a higher number from the computer placed in one group, all remaining in another</P>
</TD>
<TD>
<P>Double-blind: No details who is masked</P>
</TD>
<TD>
<P>8% of 24 in modafinil group and 27% in placebo group lost to follow-up. Intention-to-treat analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>21-Wagner 2000</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>Indirect recruitment through newsletters and posters</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Double-blind: No details who is masked</P>
</TD>
<TD>
<P>4% of 23 lost to follow-up. No intention-to-treat analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>22-Wallace 1995</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Double-blind: Patient and assessor</P>
</TD>
<TD>
<P>19% of 16 lost to follow-up. No intention-to-treat analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>23-Wheatley 1969a</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Double blind: No details provided</P>
</TD>
<TD>
<P>No loss to follow up</P>
</TD>
</TR>
<TR>
<TD>
<P>24-Wheatley 1969b</P>
</TD>
<TD>
<P>No sample size calculation</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>No details provided</P>
</TD>
<TD>
<P>Double blind: No details provided</P>
</TD>
<TD>
<P>No loss to follow up</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Other symptoms (other than depressed mood) evaluated in one trial only</TITLE>
<TABLE COLS="3" ROWS="12">
<TR>
<TH>
<P>Symptom (Reference)</P>
</TH>
<TH>
<P>Participants</P>
</TH>
<TH>
<P>Outcome effect</P>
</TH>
</TR>
<TR>
<TD>
<P>Alertness (Robin 1958)</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>OR 1.43, 95% CI 0.45, 5.50</P>
</TD>
</TR>
<TR>
<TD>
<P>Anorexia (Elizur 1979)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>WMD 0.97, 95% CI 0.52,1.42</P>
</TD>
</TR>
<TR>
<TD>
<P>Appetite (Cookson 1986)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>In the responder (defined as a fall in depression rating greater after PS than placebo) group all experienced an increase in appetite following PS, which was generally greater than that experienced after placebo. In the non-responders 1/10 showed a significant elevation of hunger after PS. In the four where response was eqivocal there was litle or no change in appetite.</P>
</TD>
</TR>
<TR>
<TD>
<P>Concentration (Elizur 1979)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>WMD -0.21, 95% CI 0.53,0.11</P>
</TD>
</TR>
<TR>
<TD>
<P>Confidence (Robin 1958)</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>OR 1.58, 95% CI 0.45, 5.50</P>
</TD>
</TR>
<TR>
<TD>
<P>Insomnia (Elizur 1979)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>OR 1.44, 95% CI 1.08, 1,80</P>
</TD>
</TR>
<TR>
<TD>
<P>Libido (Elizur 1979)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>WMD 0.17, 95% CI -0.22,0.56</P>
</TD>
</TR>
<TR>
<TD>
<P>Memory (Elizur 1979)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>WMD -0.18, 95% CI -0.39, 0.03</P>
</TD>
</TR>
<TR>
<TD>
<P>'Range of interests' (Robin 1958)</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>OR 1.23, 95% CI 0.23, 4.31</P>
</TD>
</TR>
<TR>
<TD>
<P>Retardation (Robin 1958)</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>OR 0.78, 95% CI 0.20, 3.02</P>
</TD>
</TR>
<TR>
<TD>
<P>Tension (Elizur 1979)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>WMD -0.17, 95% CI -0.54, 0.20</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" NO="3">
<TITLE>Side effects assessed in one trial only</TITLE>
<TABLE COLS="3" ROWS="38">
<TR>
<TH>
<P>Side effect</P>
</TH>
<TH>
<P>Sample size</P>
</TH>
<TH>
<P>Effect outcome</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>PS VERSUS PLACEBO</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Anxiety</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>OR 2.07, 95% CI 0.18, 24.15</P>
</TD>
</TR>
<TR>
<TD>
<P>Constipation</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>OR 2.30, 95% CI 0.54, 9.80</P>
</TD>
</TR>
<TR>
<TD>
<P>Dizziness</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>OR 2.25, 95% CI 0.17, 29.77</P>
</TD>
</TR>
<TR>
<TD>
<P>Dry mouth</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>OR 3.23, 95% CI 0.80, 13.20</P>
</TD>
</TR>
<TR>
<TD>
<P>'Excitement'</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>OR 1.25, 95% CI 0.44, 3.57</P>
</TD>
</TR>
<TR>
<TD>
<P>Headache</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>OR 0.30, 95% 0.01, 8.33</P>
</TD>
</TR>
<TR>
<TD>
<P>Loss of appetite</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>OR 3.22, 95% CI 0.23, 32.89</P>
</TD>
</TR>
<TR>
<TD>
<P>Nausea</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>OR 3.22, 95% CI 0.32, 32.89</P>
</TD>
</TR>
<TR>
<TD>
<P>Palpitation</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>OR 0.30, 95% CI 0.01, 8.33</P>
</TD>
</TR>
<TR>
<TD>
<P>Restlessness</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>OR 1.00, 95% CI 0.05, 18.57</P>
</TD>
</TR>
<TR>
<TD>
<P>Tachycardia</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>OR 1.25, 95% CI 0.44, 3.57</P>
</TD>
</TR>
<TR>
<TD>
<P>Tremor</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>OR 2.25, 95% 0.17, 29.77</P>
</TD>
</TR>
<TR>
<TD>
<P>Tolerance</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>Reports no addictive tendency was observed (No data provided)</P>
</TD>
</TR>
<TR>
<TD>
<P>Vertigo</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>OR 1.22, 95% CI 0.05, 30.03</P>
</TD>
</TR>
<TR>
<TD>
<P>Weight gain</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>OR 0.27, 95% CI 0.05, 1.39</P>
</TD>
</TR>
<TR>
<TD>
<P>Weight loss</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>OR 3.53, 95% CI 0.67, 18.45</P>
</TD>
</TR>
<TR>
<TD>
<P>PS VERSUS ANTIDEPRESSANT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Headache</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>OR 0.23, 95% CI 0.01, 5.73</P>
</TD>
</TR>
<TR>
<TD>
<P>Insomnia</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>OR 0.25, 95% CI 0.02, 3.10</P>
</TD>
</TR>
<TR>
<TD>
<P>Nausea</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>OR 4.00, 95% 0.27, 58.56</P>
</TD>
</TR>
<TR>
<TD>
<P>MODAFINIL VERSUS PLACEBO</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Anxiety</P>
</TD>
<TD>
<P>136</P>
</TD>
<TD>
<P>OR 1.23, 95% 0.32, 4.79</P>
</TD>
</TR>
<TR>
<TD>
<P>Asthenia</P>
</TD>
<TD>
<P>136</P>
</TD>
<TD>
<P>OR 0.37, 95% CI 0.07, 1.98</P>
</TD>
</TR>
<TR>
<TD>
<P>Cardiovascular</P>
</TD>
<TD>
<P>136; 41</P>
</TD>
<TD>
<P>DeBattista 2003 reported no significant differences in vital signs, including sitting and standing systolic and diastolic blood presure and heart rate (no data provided). Vaishnavi 2006 reported there were no significant differences in pulse (p=0.10), systolic blood pressure (p=0.38) or diastolic blood pressure (p=0.60) () (no further data provided).</P>
</TD>
</TR>
<TR>
<TD>
<P>Diarrhoea -short term</P>
</TD>
<TD>
<P>311</P>
</TD>
<TD>
<P>OR 0.56, 95% CI 0.20, 1.59</P>
</TD>
</TR>
<TR>
<TD>
<P>Diarrhoea - medium term</P>
</TD>
<TD>
<P>136</P>
</TD>
<TD>
<P>OR 0.97, 95% CI 0.27, 3.51</P>
</TD>
</TR>
<TR>
<TD>
<P>Dry mouth</P>
</TD>
<TD>
<P>311</P>
</TD>
<TD>
<P>OR 2.00, 95% CI 0.67, 5.99</P>
</TD>
</TR>
<TR>
<TD>
<P>Hypertension</P>
</TD>
<TD>
<P>311</P>
</TD>
<TD>
<P>OR 0.54, 95% CI 0.16, 1.89</P>
</TD>
</TR>
<TR>
<TD>
<P>Hypertonia</P>
</TD>
<TD>
<P>136</P>
</TD>
<TD>
<P>OR 11.52, 95% CI 0.62, 212.40</P>
</TD>
</TR>
<TR>
<TD>
<P>'Infection'</P>
</TD>
<TD>
<P>136</P>
</TD>
<TD>
<P>OR 0.83, 95% CI 0.28, 2.44</P>
</TD>
</TR>
<TR>
<TD>
<P>Myalgia</P>
</TD>
<TD>
<P>136</P>
</TD>
<TD>
<P>OR 0.23, 95% CI 0.03, 2.13</P>
</TD>
</TR>
<TR>
<TD>
<P>Nasophartngitis</P>
</TD>
<TD>
<P>311</P>
</TD>
<TD>
<P>OR 0.97, 95% CI 0.27, 3.41</P>
</TD>
</TR>
<TR>
<TD>
<P>Nervousness</P>
</TD>
<TD>
<P>136</P>
</TD>
<TD>
<P>OR 5.43, 95% CI 1.48, 19.89</P>
</TD>
</TR>
<TR>
<TD>
<P>Rhinitis</P>
</TD>
<TD>
<P>136</P>
</TD>
<TD>
<P>OR 1.78, 95% CI 0.50, 6.38</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" NO="4">
<TITLE>Outcomes on depressed mood in trials not included in the meta-analysis</TITLE>
<TABLE COLS="4" ROWS="14">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>Trial details</P>
</TH>
<TH>
<P>Effect outcome</P>
</TH>
<TH>
<P>Direction of outcome</P>
</TH>
</TR>
<TR>
<TD>
<P>Cantello 1989</P>
</TD>
<TD>
<P>Depression measured by observers global judgement score. PS: Methylamphetamine</P>
</TD>
<TD>
<P>In group of 13 depressed Parkinsonians no significant difference in self-rated and observer judgement score between PS and placebo. In 14 patients with major depression they was significant relief of depressive symptoms when given PS but not placebo. (pre-cross over outcomes not reported separately)</P>
</TD>
<TD>
<P>Mixed</P>
</TD>
</TR>
<TR>
<TD>
<P>Cookson 1986</P>
</TD>
<TD>
<P>Self-rated 10cm VAS for depression. PS: Methylamphetaime</P>
</TD>
<TD>
<P>PS 7/21 patients showed a fall ( &gt;20mm) in self-rated and observer rated depression which was at least 15mm greater than the changes occuring after placebo. Four patients experienced a similar improvement in mood following both PS and placebo. Ten patients showed no mood elevation in response to either PS or placebo.</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Hare 1962</P>
</TD>
<TD>
<P>Depression measured by clinican on a 5-point scale. PS: Dexamphetamine</P>
</TD>
<TD>
<P>No significant difference between PS and placebo.</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Hare 1964</P>
</TD>
<TD>
<P>Depression measured by clinican on a 5-point scale. PS: Dexamphetamine. Ajunct to amylobarbitone.</P>
</TD>
<TD>
<P>No significant difference between PS and antidepressant.</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Kits 1970</P>
</TD>
<TD>
<P>Depression measured by vital syndrome interview. PS: Methylamphetamine</P>
</TD>
<TD>
<P>A difference in favour of PS was apparent</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Mattes 1985</P>
</TD>
<TD>
<P>Depression measured by psychiatrist completed SADS-C, self completed POMS and patient and psychiatrist completed 8-point scales of global improvement. PS: Methylphenidate</P>
</TD>
<TD>
<P>No evidence of benefit effect between PS and placebo</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Overall 1962</P>
</TD>
<TD>
<P>Depression measured by specifically derived 31 item depression scale from IMPS. PS: Dexamphetamine. Ajunct to amylobarbitone.</P>
</TD>
<TD>
<P>No significant difference between PS and comparison treatments.</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Reus 1979</P>
</TD>
<TD>
<P>Self-rated depression. PS: Dextroamphetamine</P>
</TD>
<TD>
<P>After PS 6/9 reported a better response on PS than on placebo</P>
</TD>
<TD>
<P>Positive</P>
</TD>
</TR>
<TR>
<TD>
<P>Rickels 1970</P>
</TD>
<TD>
<P>Depression measured by Zung Depression Scale. PS: Pemoline and Methylphenidate</P>
</TD>
<TD>
<P>PS produced significantly more improvement than placebo in clinic and general practice patients. No significant difference in private psychiatric patients was observed between PS and placebo.</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>Rickels 1972</P>
</TD>
<TD>
<P>Depression measured by Zung Depression Scale. PS: Methylphenidate</P>
</TD>
<TD>
<P>The mean Zung score was significantly lower inthe PS group than in the placebo group (p&lt;0.05)</P>
</TD>
<TD>
<P>Positive</P>
</TD>
</TR>
<TR>
<TD>
<P>Silberman 1981</P>
</TD>
<TD>
<P>Depression measured by physicans BPRS ratings. PS: Dextroamphetamine</P>
</TD>
<TD>
<P>Mean change score in depressive mood was not significant after PS or after placebo.</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Wallace 1995</P>
</TD>
<TD>
<P>Depression measured by Hamilton Depression Scale. PS: Methylphenidate</P>
</TD>
<TD>
<P>Post hoc multiple comparisons revealed that for 10 subjects who were given the active drug first there was no significant difference between PS and placebo. For the three subjects who recieved placebo first thare was no significant difference</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Wheatley 1969b</P>
</TD>
<TD>
<P>GP rated depression. PS: Dextroamphetamine</P>
</TD>
<TD>
<P>Response to PS (44% improvement) very similar to response to placebo (45%)</P>
</TD>
<TD>
<P>No difference</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Psychostimulants versus placebo</NAME>
<CONT_OUTCOME CHI2="2.3667639055445253" CI_END="-0.33376918069692285" CI_START="-1.3986213876530504" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.8661952841749867" ESTIMABLE="YES" I2="15.49642973197799" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.30624134590450036" P_Q="1.0" P_Z="0.0014294712566252825" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="31" UNITS="" WEIGHT="100.0" Z="3.1886332196545997">
<NAME>Reduction in depression symptoms (short-term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.3667639055445253" CI_END="-0.33376918069692285" CI_START="-1.3986213876530504" DF="2.0" EFFECT_SIZE="-0.8661952841749867" ESTIMABLE="YES" I2="15.49642973197799" ID="CMP-001.01.01" NO="1" P_CHI2="0.30624134590450036" P_Z="0.0014294712566252825" STUDIES="3" TAU2="0.0" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.0" Z="3.1886332196545997">
<NAME>Psychostimulants</NAME>
<CONT_DATA CI_END="-0.17218237166294137" CI_START="-2.0921772073194926" EFFECT_SIZE="-1.132179789491217" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="3.0" ORDER="28397" SD_1="0.37" SD_2="0.47" SE="0.4898036011889058" STUDY_ID="STD-Elizur-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="30.75944885475494"/>
<CONT_DATA CI_END="-0.29556125168017144" CI_START="-2.2585596609678977" EFFECT_SIZE="-1.2770604563240346" ESTIMABLE="YES" MEAN_1="15.7" MEAN_2="22.3" ORDER="28398" SD_1="5.6" SD_2="4.2" SE="0.5007741021701437" STUDY_ID="STD-Lee-2005" TOTAL_1="10" TOTAL_2="10" WEIGHT="29.426511200571472"/>
<CONT_DATA CI_END="0.48677174585838623" CI_START="-1.2008348394898547" EFFECT_SIZE="-0.35703154681573424" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="9.4" ORDER="28399" SD_1="3.9" SD_2="6.1" SE="0.43051979491966846" STUDY_ID="STD-Wagner-2000" TOTAL_1="11" TOTAL_2="11" WEIGHT="39.81403994467358"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.361882402595893" CI_START="-7.7618824025958935" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.7" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.2958189044247309" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="1.0454416632722032">
<NAME>Reduction in depression symptoms (medium term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Psychostimulants</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.361882402595893" CI_START="-7.7618824025958935" DF="0.0" EFFECT_SIZE="-2.7" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="1.0" P_Z="0.2958189044247309" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="26" WEIGHT="100.0" Z="1.0454416632722032">
<NAME>Modafinil</NAME>
<CONT_DATA CI_END="2.361882402595893" CI_START="-7.7618824025958935" EFFECT_SIZE="-2.7" ESTIMABLE="YES" MEAN_1="7.3" MEAN_2="10.0" ORDER="28400" SD_1="7.1" SD_2="10.9" SE="2.5826405191745234" STUDY_ID="STD-Vaishnavi-2006" TOTAL_1="24" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.599148217804711" CI_END="2.0894042608875147" CI_START="0.48387125786008167" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0054862842892767" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="41" I2="23.05171416160187" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.32002247602004186" LOG_CI_START="-0.31527017438546884" LOG_EFFECT_SIZE="0.0023761508172865085" METHOD="MH" NO="3" P_CHI2="0.2726480232535977" P_Q="0.0" P_Z="0.9883022385545723" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0" Z="0.014661495047185816">
<NAME>Clinical response (short term) - any measure/definition</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.599148217804711" CI_END="2.0894042608875147" CI_START="0.48387125786008167" DF="2.0" EFFECT_SIZE="1.0054862842892767" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="41" I2="23.05171416160187" ID="CMP-001.03.01" LOG_CI_END="0.32002247602004186" LOG_CI_START="-0.31527017438546884" LOG_EFFECT_SIZE="0.0023761508172865085" NO="1" P_CHI2="0.2726480232535977" P_Z="0.9883022385545723" STUDIES="3" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0" Z="0.014661495047185816">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="22.303750648286012" CI_START="0.5492349781511471" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="1.3483779011148855" LOG_CI_START="-0.26024181241433425" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="28401" O_E="0.0" SE="0.944911182523068" STUDY_ID="STD-Elizur-1979" TOTAL_1="10" TOTAL_2="10" VAR="0.8928571428571428" WEIGHT="8.379052369077307"/>
<DICH_DATA CI_END="3.91251399405445" CI_START="0.3086464679745851" EFFECT_SIZE="1.098901098901099" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.5924559039167434" LOG_CI_START="-0.5105386885589306" LOG_EFFECT_SIZE="0.04095860767890644" ORDER="28402" O_E="0.0" SE="0.6479044835315" STUDY_ID="STD-Robin-1958" TOTAL_1="17" TOTAL_2="23" VAR="0.41978021978021973" WEIGHT="31.77057356608479"/>
<DICH_DATA CI_END="1.7896714165298597" CI_START="0.20564917171112668" EFFECT_SIZE="0.6066666666666667" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" LOG_CI_END="0.25277330188092145" LOG_CI_START="-0.6868730353500968" LOG_EFFECT_SIZE="-0.21704986673458762" ORDER="28403" O_E="0.0" SE="0.551952909813885" STUDY_ID="STD-Wheatley-1969-a" TOTAL_1="38" TOTAL_2="32" VAR="0.30465201465201464" WEIGHT="59.85037406483791"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.1910291658530592" CI_END="1.0387581681407916" CI_START="-0.19842624151542065" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.4201659633126854" ESTIMABLE="YES" I2="16.038999827198776" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.27512211976884315" P_Q="1.0" P_Z="0.18310182819706938" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="21" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="1.3312650065664462">
<NAME>Improvement in cognitive functioning (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1910291658530592" CI_END="1.0387581681407916" CI_START="-0.19842624151542065" DF="1.0" EFFECT_SIZE="0.4201659633126854" ESTIMABLE="YES" I2="16.038999827198776" ID="CMP-001.04.01" NO="1" P_CHI2="0.27512211976884315" P_Z="0.18310182819706938" STUDIES="2" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="1.3312650065664462">
<NAME>Psychostimulants</NAME>
<CONT_DATA CI_END="1.7176044872112133" CI_START="-0.12040152708393337" EFFECT_SIZE="0.79860148006364" ESTIMABLE="YES" MEAN_1="32.8" MEAN_2="31.0" ORDER="28404" SD_1="2.6" SD_2="1.6" SE="0.46888770120091583" STUDY_ID="STD-Lee-2005" TOTAL_1="10" TOTAL_2="10" WEIGHT="45.30801346899931"/>
<CONT_DATA CI_END="0.9431168966263" CI_START="-0.7297931508202938" EFFECT_SIZE="0.10666187290300314" ESTIMABLE="YES" MEAN_1="64.2" MEAN_2="61.2" ORDER="28405" SD_1="20.2" SD_2="32.5" SE="0.42677060921585674" STUDY_ID="STD-Wagner-2000" TOTAL_1="11" TOTAL_2="11" WEIGHT="54.69198653100069"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.21843885956537112" CI_END="-1.0583647442914783" CI_START="-2.5420437695682403" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.8002042569298593" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.6402320284194841" P_Q="1.0" P_Z="1.97273119751741E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="21" TOTAL_2="21" UNITS="" WEIGHT="100.00000000000001" Z="4.756197867985694">
<NAME>Reduction in fatigue (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.21843885956537112" CI_END="-1.0583647442914783" CI_START="-2.5420437695682403" DF="1.0" EFFECT_SIZE="-1.8002042569298593" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" NO="1" P_CHI2="0.6402320284194841" P_Z="1.97273119751741E-6" STUDIES="2" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.00000000000001" Z="4.756197867985694">
<NAME>Psychostimulants</NAME>
<CONT_DATA CI_END="-0.8827723569376342" CI_START="-3.115498660919779" EFFECT_SIZE="-1.9991355089287066" ESTIMABLE="YES" MEAN_1="3.13" MEAN_2="3.84" ORDER="28406" SD_1="0.35" SD_2="0.33" SE="0.5695835029606678" STUDY_ID="STD-Elizur-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="44.15795336564599"/>
<CONT_DATA CI_END="-0.6501705486527863" CI_START="-2.635622098555278" EFFECT_SIZE="-1.6428963236040321" ESTIMABLE="YES" MEAN_1="18.3" MEAN_2="25.4" ORDER="28407" SD_1="3.9" SD_2="4.4" SE="0.5065020494160811" STUDY_ID="STD-Wagner-2000" TOTAL_1="11" TOTAL_2="11" WEIGHT="55.84204663435403"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0502507326990794E-33" CI_END="1.9186178342499758" CI_START="-1.4386178342499754" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.24000000000000024" ESTIMABLE="YES" I2="100.00000000000001" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="0.7793045799413313" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="0.28022540133430035">
<NAME>Reduction in fatigue (medium term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Psychostimulants</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.0502507326990794E-33" CI_END="1.9186178342499758" CI_START="-1.4386178342499754" DF="0.0" EFFECT_SIZE="0.24000000000000024" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-001.06.02" NO="2" P_CHI2="0.0" P_Z="0.7793045799413313" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0" Z="0.28022540133430035">
<NAME>Modafinil</NAME>
<CONT_DATA CI_END="1.9186178342499758" CI_START="-1.4386178342499754" EFFECT_SIZE="0.2400000000000002" ESTIMABLE="YES" MEAN_1="3.52" MEAN_2="3.28" ORDER="28408" SD_1="2.74" SD_2="2.73" SE="0.8564534080680557" STUDY_ID="STD-Vaishnavi-2006" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.5783286061894306" CI_START="-3.058328606189431" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2400000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.8674452958517791" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="0.16690436851706023">
<NAME>Reduction in hypersomnia (medium term): Epworth Sleepiness Scale</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Psychostimulants</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.5783286061894306" CI_START="-3.058328606189431" DF="0.0" EFFECT_SIZE="-0.2400000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" NO="2" P_CHI2="1.0" P_Z="0.8674452958517791" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0" Z="0.16690436851706023">
<NAME>Modafinil</NAME>
<CONT_DATA CI_END="2.5783286061894306" CI_START="-3.058328606189431" EFFECT_SIZE="-0.2400000000000002" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="6.24" ORDER="28409" SD_1="4.35" SD_2="4.79" SE="1.437949180913551" STUDY_ID="STD-Vaishnavi-2006" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.35826420839134476" CI_END="1.1964774372302314" CI_START="-0.046682637708495234" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.5748973997608681" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="0.5494720666792263" P_Q="1.0" P_Z="0.0698681583178097" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="21" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="1.8127644557641773">
<NAME>Improvement in health-related quality of life (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.35826420839134476" CI_END="1.1964774372302314" CI_START="-0.046682637708495234" DF="1.0" EFFECT_SIZE="0.5748973997608681" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" NO="1" P_CHI2="0.5494720666792263" P_Z="0.0698681583178097" STUDIES="2" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="1.8127644557641773">
<NAME>Psychostimulants</NAME>
<CONT_DATA CI_END="1.2683206712571495" CI_START="-0.5045132779647762" EFFECT_SIZE="0.3819036966461866" ESTIMABLE="YES" MEAN_1="119.4" MEAN_2="109.8" ORDER="28410" SD_1="11.9" SD_2="31.9" SE="0.4522618688929525" STUDY_ID="STD-Lee-2005" TOTAL_1="10" TOTAL_2="10" WEIGHT="49.17201308062077"/>
<CONT_DATA CI_END="1.6334610676927135" CI_START="-0.11025431663786067" EFFECT_SIZE="0.7616033755274264" ESTIMABLE="YES" MEAN_1="7.9" MEAN_2="6.0" ORDER="28411" SD_1="2.4" SD_2="2.4" SE="0.4448335270660019" STUDY_ID="STD-Wagner-2000" TOTAL_1="11" TOTAL_2="11" WEIGHT="50.82798691937923"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.521496523595355" CI_END="10.248550719621235" CI_START="0.2591838104146565" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6298031865042175" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="34.275235960647386" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="1.0106624547602718" LOG_CI_START="-0.5863921296037866" LOG_EFFECT_SIZE="0.21213516257824258" METHOD="MH" NO="9" P_CHI2="0.21739358140367593" P_Q="0.0" P_Z="0.60258963440012" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="33" TOTAL_2="35" WEIGHT="100.0" Z="0.5206801102211114">
<NAME>Acceptability: dropouts due to side effects (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.521496523595355" CI_END="10.248550719621235" CI_START="0.2591838104146565" DF="1.0" EFFECT_SIZE="1.6298031865042175" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="34.275235960647386" ID="CMP-001.09.01" LOG_CI_END="1.0106624547602718" LOG_CI_START="-0.5863921296037866" LOG_EFFECT_SIZE="0.21213516257824258" NO="1" P_CHI2="0.21739358140367593" P_Z="0.60258963440012" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="35" WEIGHT="100.0" Z="0.5206801102211114">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="126.4203674191768" CI_START="0.25986689834289073" EFFECT_SIZE="5.7317073170731705" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.101817048196214" LOG_CI_START="-0.5852490370922128" LOG_EFFECT_SIZE="0.7582840055520007" ORDER="28412" O_E="0.0" SE="1.578395919690063" STUDY_ID="STD-Robin-1958" TOTAL_1="22" TOTAL_2="23" VAR="2.4913336792942395" WEIGHT="24.015932521087162"/>
<DICH_DATA CI_END="9.067665277588004" CI_START="0.012253552343373064" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9574954802701487" LOG_CI_START="-1.911737989709474" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="28413" O_E="0.0" SE="1.6854019432007687" STUDY_ID="STD-Wagner-2000" TOTAL_1="11" TOTAL_2="12" VAR="2.8405797101449273" WEIGHT="75.98406747891283"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8549094809741717" CI_END="5.545922492992659" CI_START="0.5688257677034405" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.7761372750157371" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="30" I2="46.08901349327222" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.7439737958042645" LOG_CI_START="-0.24502073837192276" LOG_EFFECT_SIZE="0.2494765287161709" METHOD="MH" NO="10" P_CHI2="0.1732136576998784" P_Q="0.0" P_Z="0.3227549672157415" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.3428628043438679" TOTALS="SUB" TOTAL_1="109" TOTAL_2="76" WEIGHT="99.99999999999999" Z="0.9888123632130397">
<NAME>Tolerability: proportion of participants experiencing side effects (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8549094809741717" CI_END="5.545922492992659" CI_START="0.5688257677034405" DF="1.0" EFFECT_SIZE="1.7761372750157371" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="30" I2="46.08901349327222" ID="CMP-001.10.01" LOG_CI_END="0.7439737958042645" LOG_CI_START="-0.24502073837192276" LOG_EFFECT_SIZE="0.2494765287161709" NO="1" P_CHI2="0.1732136576998784" P_Z="0.3227549672157415" STUDIES="2" TAU2="0.3428628043438679" TOTAL_1="109" TOTAL_2="76" WEIGHT="99.99999999999999" Z="0.9888123632130397">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="18.451788392519774" CI_START="0.8269544793113823" EFFECT_SIZE="3.90625" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" LOG_CI_END="1.266038465419865" LOG_CI_START="-0.08251839604356419" LOG_EFFECT_SIZE="0.5917600346881504" ORDER="28414" O_E="0.0" SE="0.792148975887743" STUDY_ID="STD-Rickels-1970" TOTAL_1="63" TOTAL_2="27" VAR="0.6275000000000001" WEIGHT="34.77994139906782"/>
<DICH_DATA CI_END="2.646220264945964" CI_START="0.514360474500752" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="28" LOG_CI_END="0.42262599097364073" LOG_CI_START="-0.2887324117124142" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="28415" O_E="0.0" SE="0.41785544701867244" STUDY_ID="STD-Rickels-1972" TOTAL_1="46" TOTAL_2="49" VAR="0.1746031746031746" WEIGHT="65.22005860093216"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.32138864525527094" CI_END="23.57033021577111" CI_START="2.209918032056752" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="7.217236158347923" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="1.372365666948704" LOG_CI_START="0.3443761655920685" LOG_EFFECT_SIZE="0.8583709162703863" METHOD="MH" NO="11" P_CHI2="0.5707744429966712" P_Q="0.0" P_Z="0.0010636029247380568" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="42" WEIGHT="100.00000000000001" Z="3.2731386440160635">
<NAME>Tolerability: proportion of participants experiencing side effects (medium term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.32138864525527094" CI_END="23.57033021577111" CI_START="2.209918032056752" DF="1.0" EFFECT_SIZE="7.217236158347923" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="4" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="1.372365666948704" LOG_CI_START="0.3443761655920685" LOG_EFFECT_SIZE="0.8583709162703863" NO="1" P_CHI2="0.5707744429966712" P_Z="0.0010636029247380568" STUDIES="2" TAU2="0.0" TOTAL_1="48" TOTAL_2="42" WEIGHT="100.00000000000001" Z="3.2731386440160635">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="45.56998299262816" CI_START="0.3264769930419966" EFFECT_SIZE="3.857142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.6586788664975438" LOG_CI_START="-0.4861474182080827" LOG_EFFECT_SIZE="0.5862657241447304" ORDER="28416" O_E="0.0" SE="1.259881576697424" STUDY_ID="STD-Elizur-1979" TOTAL_1="10" TOTAL_2="10" VAR="1.5873015873015874" WEIGHT="22.971698739657622"/>
<DICH_DATA CI_END="33.509119556530294" CI_START="2.258788085204985" EFFECT_SIZE="8.7" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="3" LOG_CI_END="1.5251630170097317" LOG_CI_START="0.35387548822750514" LOG_EFFECT_SIZE="0.9395192526186185" ORDER="28417" O_E="0.0" SE="0.6880200923734557" STUDY_ID="STD-Wheatley-1969-a" TOTAL_1="38" TOTAL_2="32" VAR="0.47337164750957855" WEIGHT="77.02830126034239"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.001891380901547246" CI_END="4.235849079380749" CI_START="0.4027483441942798" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3061321537185513" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.6269404780738379" LOG_CI_START="-0.3949662364053691" LOG_EFFECT_SIZE="0.11598712083423444" METHOD="MH" NO="12" P_CHI2="0.9653109367536468" P_Q="0.0" P_Z="0.6563815136523359" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="114" TOTAL_2="76" WEIGHT="99.99999999999999" Z="0.4449145431468254">
<NAME>Tolerability: dizziness (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.001891380901547246" CI_END="4.235849079380749" CI_START="0.4027483441942798" DF="1.0" EFFECT_SIZE="1.3061321537185513" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="0.6269404780738379" LOG_CI_START="-0.3949662364053691" LOG_EFFECT_SIZE="0.11598712083423444" NO="1" P_CHI2="0.9653109367536468" P_Z="0.6563815136523359" STUDIES="2" TAU2="0.0" TOTAL_1="114" TOTAL_2="76" WEIGHT="99.99999999999999" Z="0.4449145431468254">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="30.933675735973" CI_START="0.048291291770303404" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.4904315287002987" LOG_CI_START="-1.3161311772624984" LOG_EFFECT_SIZE="0.0871501757189002" ORDER="28418" O_E="0.0" SE="1.6485888261920003" STUDY_ID="STD-Rickels-1970" TOTAL_1="68" TOTAL_2="27" VAR="2.7178451178451177" WEIGHT="14.183024606027093"/>
<DICH_DATA CI_END="4.661456336271251" CI_START="0.3737887634905457" EFFECT_SIZE="1.32" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6685216205518709" LOG_CI_START="-0.42737375814017114" LOG_EFFECT_SIZE="0.1205739312058499" ORDER="28419" O_E="0.0" SE="0.6437343702133197" STUDY_ID="STD-Rickels-1972" TOTAL_1="46" TOTAL_2="49" VAR="0.41439393939393937" WEIGHT="85.8169753939729"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.20593816768743645" CI_END="1.3712674910852516" CI_START="0.12176910897967147" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.40862944162436543" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.1371221802242335" LOG_CI_START="-0.9144628718116824" LOG_EFFECT_SIZE="-0.3886703457937245" METHOD="MH" NO="13" P_CHI2="0.6499698390336668" P_Q="0.0" P_Z="0.14738724488680557" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="114" TOTAL_2="76" WEIGHT="99.99999999999999" Z="1.4488221911096753">
<NAME>Tolerability: drowsiness (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.20593816768743645" CI_END="1.3712674910852516" CI_START="0.12176910897967147" DF="1.0" EFFECT_SIZE="0.40862944162436543" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="0.1371221802242335" LOG_CI_START="-0.9144628718116824" LOG_EFFECT_SIZE="-0.3886703457937245" NO="1" P_CHI2="0.6499698390336668" P_Z="0.14738724488680557" STUDIES="2" TAU2="0.0" TOTAL_1="114" TOTAL_2="76" WEIGHT="99.99999999999999" Z="1.4488221911096753">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="3.6606756725441527" CI_START="0.090923170053759" EFFECT_SIZE="0.5769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.563561253092437" LOG_CI_START="-1.0413254309227102" LOG_EFFECT_SIZE="-0.23888208891513676" ORDER="28420" O_E="0.0" SE="0.9427183825077077" STUDY_ID="STD-Rickels-1970" TOTAL_1="68" TOTAL_2="27" VAR="0.8887179487179487" WEIGHT="32.99492385786802"/>
<DICH_DATA CI_END="1.7039891482983458" CI_START="0.0622762171164208" EFFECT_SIZE="0.32575757575757575" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.23146682467413535" LOG_CI_START="-1.205677775926662" LOG_EFFECT_SIZE="-0.4871054756262634" ORDER="28421" O_E="0.0" SE="0.8441858523734141" STUDY_ID="STD-Rickels-1972" TOTAL_1="46" TOTAL_2="49" VAR="0.7126497533474278" WEIGHT="67.00507614213197"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.13.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6669117411253671" CI_END="3.3504607206052857" CI_START="0.33634756403215166" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.061564553741785" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.525104530815622" LOG_CI_START="-0.4732117133096333" LOG_EFFECT_SIZE="0.025946408752994365" METHOD="MH" NO="14" P_CHI2="0.4141307090704832" P_Q="0.0" P_Z="0.9188522475225741" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="56" TOTAL_2="59" WEIGHT="100.0" Z="0.10187959373251126">
<NAME>Tolerability: headache (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6669117411253671" CI_END="3.3504607206052857" CI_START="0.33634756403215166" DF="1.0" EFFECT_SIZE="1.061564553741785" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="0.525104530815622" LOG_CI_START="-0.4732117133096333" LOG_EFFECT_SIZE="0.025946408752994365" NO="1" P_CHI2="0.4141307090704832" P_Z="0.9188522475225741" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="59" WEIGHT="100.0" Z="0.10187959373251126">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="8.33159693509127" CI_START="0.010916862780006007" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9207282515421643" LOG_CI_START="-1.9619021485436698" LOG_EFFECT_SIZE="-0.5205869485007527" ORDER="28422" O_E="0.0" SE="1.693271366261031" STUDY_ID="STD-Elizur-1979" TOTAL_1="10" TOTAL_2="10" VAR="2.8671679197994986" WEIGHT="25.376298494806026"/>
<DICH_DATA CI_END="4.661456336271251" CI_START="0.3737887634905457" EFFECT_SIZE="1.32" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6685216205518709" LOG_CI_START="-0.42737375814017114" LOG_EFFECT_SIZE="0.1205739312058499" ORDER="28423" O_E="0.0" SE="0.6437343702133197" STUDY_ID="STD-Rickels-1972" TOTAL_1="46" TOTAL_2="49" VAR="0.41439393939393937" WEIGHT="74.62370150519398"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.14.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.380303943603694" CI_START="0.6609140309952837" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.7308068104807627" LOG_CI_START="-0.17985502809757656" LOG_EFFECT_SIZE="0.27547589119159305" METHOD="MH" NO="15" P_CHI2="1.0" P_Q="0.0" P_Z="0.23570875496463928" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="46" TOTAL_2="49" WEIGHT="100.0" Z="1.1857811593104337">
<NAME>Tolerability: insomnia (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.380303943603694" CI_START="0.6609140309952837" DF="0.0" EFFECT_SIZE="1.8857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="0.7308068104807627" LOG_CI_START="-0.17985502809757656" LOG_EFFECT_SIZE="0.27547589119159305" NO="1" P_CHI2="1.0" P_Z="0.23570875496463928" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="49" WEIGHT="100.0" Z="1.1857811593104337">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="5.380303943603694" CI_START="0.6609140309952837" EFFECT_SIZE="1.8857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.7308068104807627" LOG_CI_START="-0.17985502809757656" LOG_EFFECT_SIZE="0.27547589119159305" ORDER="28424" O_E="0.0" SE="0.5349272718297191" STUDY_ID="STD-Rickels-1972" TOTAL_1="46" TOTAL_2="49" VAR="0.28614718614718615" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.02400018681933996" CI_END="7.572172431867824" CI_START="0.30659334001628924" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.523672417898816" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.8792204950640845" LOG_CI_START="-0.5134372833550618" LOG_EFFECT_SIZE="0.18289160585451142" METHOD="MH" NO="16" P_CHI2="0.8768844522260965" P_Q="0.0" P_Z="0.606701972341275" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="114" TOTAL_2="76" WEIGHT="100.0" Z="0.5147868573375416">
<NAME>Tolerability: nausea (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.02400018681933996" CI_END="7.572172431867824" CI_START="0.30659334001628924" DF="1.0" EFFECT_SIZE="1.523672417898816" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.8792204950640845" LOG_CI_START="-0.5134372833550618" LOG_EFFECT_SIZE="0.18289160585451142" NO="1" P_CHI2="0.8768844522260965" P_Z="0.606701972341275" STUDIES="2" TAU2="0.0" TOTAL_1="114" TOTAL_2="76" WEIGHT="100.0" Z="0.5147868573375416">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="30.933675735973" CI_START="0.048291291770303404" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.4904315287002987" LOG_CI_START="-1.3161311772624984" LOG_EFFECT_SIZE="0.0871501757189002" ORDER="28425" O_E="0.0" SE="1.6485888261920003" STUDY_ID="STD-Rickels-1970" TOTAL_1="68" TOTAL_2="27" VAR="2.7178451178451177" WEIGHT="27.763946918364255"/>
<DICH_DATA CI_END="10.286073067336527" CI_START="0.2613314738618567" EFFECT_SIZE="1.6395348837209303" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0122496050160215" LOG_CI_START="-0.5828082821923972" LOG_EFFECT_SIZE="0.21472066141181217" ORDER="28426" O_E="0.0" SE="0.9369448986101064" STUDY_ID="STD-Rickels-1972" TOTAL_1="46" TOTAL_2="49" VAR="0.8778657430315026" WEIGHT="72.23605308163575"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05089519194590802" CI_END="15.665999519361666" CI_START="0.5124331689054514" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="1.194958108882282" LOG_CI_START="-0.2903627668930214" LOG_EFFECT_SIZE="0.4522976709946303" METHOD="MH" NO="17" P_CHI2="0.821512831815303" P_Q="0.0" P_Z="0.23260938815472887" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="56" TOTAL_2="59" WEIGHT="100.0" Z="1.1936641568820558">
<NAME>Tolerability: tremor (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.05089519194590802" CI_END="15.665999519361666" CI_START="0.5124331689054514" DF="1.0" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="1.194958108882282" LOG_CI_START="-0.2903627668930214" LOG_EFFECT_SIZE="0.4522976709946303" NO="1" P_CHI2="0.821512831815303" P_Z="0.23260938815472887" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="59" WEIGHT="100.0" Z="1.1936641568820558">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="29.767271480010887" CI_START="0.17006933280396677" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.4737390282818577" LOG_CI_START="-0.7693739920591327" LOG_EFFECT_SIZE="0.3521825181113625" ORDER="28427" O_E="0.0" SE="1.3176156917368247" STUDY_ID="STD-Elizur-1979" TOTAL_1="10" TOTAL_2="10" VAR="1.7361111111111112" WEIGHT="46.91358024691358"/>
<DICH_DATA CI_END="33.41143900882333" CI_START="0.33565482323123524" EFFECT_SIZE="3.3488372093023258" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.523895180820203" LOG_CI_START="-0.47410710778887666" LOG_EFFECT_SIZE="0.5248940365156631" ORDER="28428" O_E="0.0" SE="1.1736364345998103" STUDY_ID="STD-Rickels-1972" TOTAL_1="46" TOTAL_2="49" VAR="1.377422480620155" WEIGHT="53.086419753086425"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.17.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Psychostimulants versus antidepressants</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.19169697623131476" CI_START="-8.791696976231316" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.300000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.060611833159483" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.00000000000001" Z="1.8763164964421708">
<NAME>Reduction in depression symptoms (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.19169697623131476" CI_START="-8.791696976231316" DF="0.0" EFFECT_SIZE="-4.300000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="1.0" P_Z="0.060611833159483" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.00000000000001" Z="1.8763164964421708">
<NAME>Psychostimulants</NAME>
<CONT_DATA CI_END="0.19169697623131476" CI_START="-8.791696976231316" EFFECT_SIZE="-4.300000000000001" ESTIMABLE="YES" MEAN_1="15.7" MEAN_2="20.0" ORDER="28429" SD_1="5.6" SD_2="4.6" SE="2.2917242417009946" STUDY_ID="STD-Lee-2005" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="20.43732308757533" CI_START="0.09985732073547865" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="1.310424010619781" LOG_CI_START="-1.0006200906482947" LOG_EFFECT_SIZE="0.15490195998574316" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.7927507180739862" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="6" TOTAL_2="9" WEIGHT="100.0" Z="0.26274034540503477">
<NAME>Tolerability: number of participants experiencing side effects (medium term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.43732308757533" CI_START="0.09985732073547865" DF="0.0" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="1.310424010619781" LOG_CI_START="-1.0006200906482947" LOG_EFFECT_SIZE="0.15490195998574316" NO="1" P_CHI2="1.0" P_Z="0.7927507180739862" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="9" WEIGHT="100.0" Z="0.26274034540503477">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="20.437323087575322" CI_START="0.09985732073547869" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="1.310424010619781" LOG_CI_START="-1.0006200906482947" LOG_EFFECT_SIZE="0.15490195998574316" ORDER="28430" O_E="0.0" SE="1.3575187449376684" STUDY_ID="STD-Fernandez-1995" TOTAL_1="6" TOTAL_2="9" VAR="1.8428571428571427" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Psychostimulants versus placebo as adjunct to antidepressant treatment</NAME>
<CONT_OUTCOME CHI2="1.3826827518100002" CI_END="0.7932202736103148" CI_START="-1.1228366966836867" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1648082115366859" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.5009037715228131" P_Q="0.5086616238252327" P_Z="0.7359889919218148" Q="0.4368194053380292" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="236" TOTAL_2="225" UNITS="" WEIGHT="200.0" Z="0.33716968125305674">
<NAME>Reduction in depression symptoms (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.762546192313698" CI_START="-5.962546192313697" DF="0.0" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" NO="1" P_CHI2="1.0" P_Z="0.47224379810122974" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="22" WEIGHT="100.0" Z="0.7188330477254898">
<NAME>Psychostimulants</NAME>
<CONT_DATA CI_END="2.762546192313698" CI_START="-5.962546192313697" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="14.1" ORDER="28431" SD_1="7.7" SD_2="7.9" SE="2.2258297737738575" STUDY_ID="STD-Patkar-2006" TOTAL_1="28" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.945863346471971" CI_END="0.889911363105699" CI_START="-1.0740881965665543" DF="1.0" EFFECT_SIZE="-0.09208841673042767" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" NO="2" P_CHI2="0.3307746578248526" P_Z="0.8541716179694234" STUDIES="2" TAU2="0.0" TOTAL_1="208" TOTAL_2="203" WEIGHT="100.0" Z="0.18379839170134404">
<NAME>Modafinil</NAME>
<CONT_DATA CI_END="2.019839847537766" CI_START="-1.0398398475377655" EFFECT_SIZE="0.4900000000000002" ESTIMABLE="YES" MEAN_1="13.43" MEAN_2="12.94" ORDER="28432" SD_1="4.1" SD_2="4.7" SE="0.7805448771533289" STUDY_ID="STD-DeBattista-2003" TOTAL_1="65" TOTAL_2="63" WEIGHT="41.20319022924972"/>
<CONT_DATA CI_END="0.7806619583965635" CI_START="-1.7806619583965635" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="10.3" ORDER="28433" SD_1="5.66" SD_2="5.33" SE="0.653410964945408" STUDY_ID="STD-Fava-2005" TOTAL_1="143" TOTAL_2="140" WEIGHT="58.79680977075027"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.30402321456248504" CI_END="0.27963762398942127" CI_START="-1.878475337083457" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7994188565470178" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="0.5813712473681827" P_Q="1.0" P_Z="0.1464907422937064" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="224" TOTAL_2="219" UNITS="" WEIGHT="99.99999999999999" Z="1.4520390689979605">
<NAME>Reduction in depression symptoms (medium term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Psychostimulants</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.30402321456248504" CI_END="0.27963762398942127" CI_START="-1.878475337083457" DF="1.0" EFFECT_SIZE="-0.7994188565470178" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.02" NO="2" P_CHI2="0.5813712473681827" P_Z="0.1464907422937064" STUDIES="2" TAU2="0.0" TOTAL_1="224" TOTAL_2="219" WEIGHT="99.99999999999999" Z="1.4520390689979605">
<NAME>Modafinil</NAME>
<CONT_DATA CI_END="1.6173617341420665" CI_START="-2.2973617341420662" EFFECT_SIZE="-0.33999999999999986" ESTIMABLE="YES" MEAN_1="12.26" MEAN_2="12.6" ORDER="28434" SD_1="5.7" SD_2="5.9" SE="0.998672296828659" STUDY_ID="STD-DeBattista-2003" TOTAL_1="68" TOTAL_2="67" WEIGHT="30.391082341360914"/>
<CONT_DATA CI_END="0.29333710338971986" CI_START="-2.29333710338972" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="9.8" ORDER="28435" SD_1="5.61" SD_2="5.96" SE="0.6598779944893874" STUDY_ID="STD-Fava-2005" TOTAL_1="156" TOTAL_2="152" WEIGHT="69.60891765863907"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.882051583882576" CI_START="0.5684536120951001" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8285714285714285" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.769528828824115" LOG_CI_START="-0.24530496955689196" LOG_EFFECT_SIZE="0.2621119296336115" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.31132700352936704" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.012441530464877">
<NAME>Clinical response (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.882051583882576" CI_START="0.5684536120951001" DF="0.0" EFFECT_SIZE="1.8285714285714285" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.769528828824115" LOG_CI_START="-0.24530496955689196" LOG_EFFECT_SIZE="0.2621119296336115" NO="1" P_CHI2="1.0" P_Z="0.31132700352936704" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="23" WEIGHT="100.0" Z="1.012441530464877">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="5.882051583882575" CI_START="0.5684536120951003" EFFECT_SIZE="1.8285714285714285" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.769528828824115" LOG_CI_START="-0.24530496955689185" LOG_EFFECT_SIZE="0.2621119296336115" ORDER="28436" O_E="0.0" SE="0.5961183966773235" STUDY_ID="STD-Patkar-2006" TOTAL_1="27" TOTAL_2="23" VAR="0.3553571428571428" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.662989498064175" CI_END="0.8708019199678181" CI_START="-0.794361255369259" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.03822033229927956" ESTIMABLE="YES" I2="82.34148235058818" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="0.017326589246394408" P_Q="1.0" P_Z="0.928308086930164" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.2974586049915001" TOTALS="SUB" TOTAL_1="219" TOTAL_2="218" UNITS="" WEIGHT="100.0" Z="0.08997373457838673">
<NAME>Reduction in fatigue symptoms (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.04.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Psychostimulants</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.662989498064175" CI_END="0.8708019199678181" CI_START="-0.794361255369259" DF="1.0" EFFECT_SIZE="0.03822033229927956" ESTIMABLE="YES" I2="82.34148235058818" ID="CMP-003.04.02" NO="2" P_CHI2="0.017326589246394408" P_Z="0.928308086930164" STUDIES="2" TAU2="0.2974586049915001" TOTAL_1="219" TOTAL_2="218" WEIGHT="100.0" Z="0.08997373457838673">
<NAME>Modafinil</NAME>
<CONT_DATA CI_END="0.8993155452849898" CI_START="6.844547150105518E-4" EFFECT_SIZE="0.4500000000000002" ESTIMABLE="YES" MEAN_1="5.04" MEAN_2="4.59" ORDER="28437" SD_1="1.2" SD_2="1.4" SE="0.22924683760984044" STUDY_ID="STD-DeBattista-2003" TOTAL_1="63" TOTAL_2="66" WEIGHT="51.55533321167995"/>
<CONT_DATA CI_END="0.1368608524048157" CI_START="-0.9368608524048164" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="7.2" ORDER="28438" SD_1="2.3" SD_2="2.5" SE="0.2739136313929776" STUDY_ID="STD-Fava-2005" TOTAL_1="156" TOTAL_2="152" WEIGHT="48.44466678832004"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.7900218338383902" CI_END="0.05212416098640793" CI_START="-0.6705240844480381" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3091999617308151" ESTIMABLE="YES" I2="44.13475963834061" I2_Q="0.0" ID="CMP-003.05" NO="5" P_CHI2="0.18092364002903405" P_Q="1.0" P_Z="0.09349906704653958" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="224" TOTAL_2="219" UNITS="" WEIGHT="100.0" Z="1.6772220588433848">
<NAME>Reduction in fatigue symptoms (medium term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Psychostimulants</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7900218338383902" CI_END="0.05212416098640793" CI_START="-0.6705240844480381" DF="1.0" EFFECT_SIZE="-0.3091999617308151" ESTIMABLE="YES" I2="44.13475963834061" ID="CMP-003.05.02" NO="2" P_CHI2="0.18092364002903405" P_Z="0.09349906704653958" STUDIES="2" TAU2="0.0" TOTAL_1="224" TOTAL_2="219" WEIGHT="100.0" Z="1.6772220588433848">
<NAME>Modafinil</NAME>
<CONT_DATA CI_END="0.3737887337520095" CI_START="-0.5737887337520106" EFFECT_SIZE="-0.10000000000000053" ESTIMABLE="YES" MEAN_1="4.63" MEAN_2="4.73" ORDER="28439" SD_1="1.3" SD_2="1.5" SE="0.24173338769956748" STUDY_ID="STD-DeBattista-2003" TOTAL_1="68" TOTAL_2="67" WEIGHT="58.16000765383702"/>
<CONT_DATA CI_END="-0.041399707605339287" CI_START="-1.15860029239466" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="7.1" ORDER="28440" SD_1="2.6" SD_2="2.4" SE="0.2850053862218021" STUDY_ID="STD-Fava-2005" TOTAL_1="156" TOTAL_2="152" WEIGHT="41.83999234616297"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0028010594380457423" CI_END="0.05919738346334502" CI_START="-1.6296951587802542" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7852488876584546" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" NO="6" P_CHI2="0.9577916585514532" P_Q="1.0" P_Z="0.06836906362052686" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="222" TOTAL_2="215" UNITS="" WEIGHT="100.0" Z="1.8225665638456259">
<NAME>Reduction in hypersomnia (short term): Epworth Sleepiness Scale</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.06.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Psychostimulants</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0028010594380457423" CI_END="0.05919738346334502" CI_START="-1.6296951587802542" DF="1.0" EFFECT_SIZE="-0.7852488876584546" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.02" NO="2" P_CHI2="0.9577916585514532" P_Z="0.06836906362052686" STUDIES="2" TAU2="0.0" TOTAL_1="222" TOTAL_2="215" WEIGHT="100.0" Z="1.8225665638456259">
<NAME>Modafinil</NAME>
<CONT_DATA CI_END="0.8046929858320835" CI_START="-2.3046929858320837" EFFECT_SIZE="-0.75" ESTIMABLE="YES" MEAN_1="7.85" MEAN_2="8.6" ORDER="28441" SD_1="4.4" SD_2="4.6" SE="0.7932252827578993" STUDY_ID="STD-DeBattista-2003" TOTAL_1="66" TOTAL_2="63" WEIGHT="29.502224683092013"/>
<CONT_DATA CI_END="0.2057367417927085" CI_START="-1.80573674179271" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" MEAN_1="11.2" MEAN_2="12.0" ORDER="28442" SD_1="4.4" SD_2="4.6" SE="0.5131404197861962" STUDY_ID="STD-Fava-2005" TOTAL_1="156" TOTAL_2="152" WEIGHT="70.49777531690799"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7429284755649809" CI_END="-0.39303376458836325" CI_START="-2.138217194877432" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2656254797328976" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" NO="7" P_CHI2="0.3887244254395711" P_Q="1.0" P_Z="0.004472288040401965" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="224" TOTAL_2="219" UNITS="" WEIGHT="100.0" Z="2.8427732181502883">
<NAME>Reduction in hypersomnia (medium term): Epworth Sleepiness Scale</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.07.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Psychostimulants</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.7429284755649809" CI_END="-0.39303376458836325" CI_START="-2.138217194877432" DF="1.0" EFFECT_SIZE="-1.2656254797328976" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.02" NO="2" P_CHI2="0.3887244254395711" P_Z="0.004472288040401965" STUDIES="2" TAU2="0.0" TOTAL_1="224" TOTAL_2="219" WEIGHT="100.0" Z="2.8427732181502883">
<NAME>Modafinil</NAME>
<CONT_DATA CI_END="-0.2868553015973565" CI_START="-3.353144698402644" EFFECT_SIZE="-1.8200000000000003" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="8.82" ORDER="28443" SD_1="3.9" SD_2="5.1" SE="0.7822310565377187" STUDY_ID="STD-DeBattista-2003" TOTAL_1="68" TOTAL_2="67" WEIGHT="32.3933511869387"/>
<CONT_DATA CI_END="0.061246768336493895" CI_START="-2.0612467683364937" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="11.5" ORDER="28444" SD_1="4.7" SD_2="4.8" SE="0.5414623823230799" STUDY_ID="STD-Fava-2005" TOTAL_1="156" TOTAL_2="152" WEIGHT="67.6066488130613"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.604616255393145" CI_START="0.13149907456419072" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.881077303547452" LOG_CI_START="-0.881077303547452" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>Acceptability: dropouts due to side effects (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.604616255393145" CI_START="0.13149907456419072" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="0.881077303547452" LOG_CI_START="-0.881077303547452" LOG_EFFECT_SIZE="0.0" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="7.604616255393145" CI_START="0.13149907456419072" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.881077303547452" LOG_CI_START="-0.881077303547452" LOG_EFFECT_SIZE="0.0" ORDER="28445" O_E="0.0" SE="1.0350983390135313" STUDY_ID="STD-Patkar-2006" TOTAL_1="30" TOTAL_2="30" VAR="1.0714285714285714" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7204445637886223" CI_END="3.4740358127440163" CI_START="0.6435499401527355" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4952309317894248" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.5408342911395603" LOG_CI_START="-0.19141774574296294" LOG_EFFECT_SIZE="0.17470827269829864" METHOD="MH" NO="9" P_CHI2="0.42306836025425254" P_Q="0.0" P_Z="0.3496558799332914" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="233" TOTAL_2="226" WEIGHT="200.0" Z="0.9352570018041568">
<NAME>Acceptability: dropouts due to side effects (medium term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="181.8195660977102" CI_START="0.22729418785454555" DF="0.0" EFFECT_SIZE="6.428571428571429" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-003.09.01" LOG_CI_END="2.259640617010452" LOG_CI_START="-0.6434116694882785" LOG_EFFECT_SIZE="0.8081144737610868" NO="1" P_CHI2="1.0" P_Z="0.2751940165691221" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="4" WEIGHT="100.0" Z="1.0911792883121132">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="181.8195660977102" CI_START="0.22729418785454555" EFFECT_SIZE="6.428571428571429" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.259640617010452" LOG_CI_START="-0.6434116694882785" LOG_EFFECT_SIZE="0.8081144737610868" ORDER="28446" O_E="0.0" SE="1.7052672834299345" STUDY_ID="STD-Postolache-1999" TOTAL_1="5" TOTAL_2="4" VAR="2.9079365079365083" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9055476946031067" CI_END="3.180477310199093" CI_START="0.5428404135642153" DF="1.0" EFFECT_SIZE="1.3139602803738317" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" I2="0.0" ID="CMP-003.09.02" LOG_CI_END="0.5024923016291117" LOG_CI_START="-0.26532782730820925" LOG_EFFECT_SIZE="0.1185822371604512" NO="2" P_CHI2="0.34129863836477004" P_Z="0.5449171284428863" STUDIES="2" TAU2="0.0" TOTAL_1="228" TOTAL_2="222" WEIGHT="100.0" Z="0.6053941679344652">
<NAME>Modafinil</NAME>
<DICH_DATA CI_END="3.326886786947987" CI_START="0.15405568607174064" EFFECT_SIZE="0.7159090909090909" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5220380221972436" LOG_CI_START="-0.8123222675904176" LOG_EFFECT_SIZE="-0.14514212269658688" ORDER="28447" O_E="0.0" SE="0.7838098394112338" STUDY_ID="STD-DeBattista-2003" TOTAL_1="69" TOTAL_2="67" VAR="0.6143578643578642" WEIGHT="44.83385254413292"/>
<DICH_DATA CI_END="5.49689089111213" CI_START="0.5894241061322001" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.7401171166531589" LOG_CI_START="-0.22957210644654674" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="28448" O_E="0.0" SE="0.5696002496878354" STUDY_ID="STD-Fava-2005" TOTAL_1="159" TOTAL_2="155" VAR="0.3244444444444444" WEIGHT="55.16614745586708"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5238795263530398" CI_END="3.9563168758790845" CI_START="0.23867515295427538" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9717378944376007" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="0.5972910685506335" LOG_CI_START="-0.6221927904466188" LOG_EFFECT_SIZE="-0.012450860947992578" METHOD="MH" NO="10" P_CHI2="0.4691915323003938" P_Q="0.0" P_Z="0.9680753939762357" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="228" TOTAL_2="222" WEIGHT="100.0" Z="0.04002224195840984">
<NAME>Acceptability: dropouts due to lack of efficacy (medium term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Psychostimulants</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5238795263530398" CI_END="3.9563168758790845" CI_START="0.23867515295427538" DF="1.0" EFFECT_SIZE="0.9717378944376007" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-003.10.02" LOG_CI_END="0.5972910685506335" LOG_CI_START="-0.6221927904466188" LOG_EFFECT_SIZE="-0.012450860947992578" NO="2" P_CHI2="0.4691915323003938" P_Z="0.9680753939762357" STUDIES="2" TAU2="0.0" TOTAL_1="228" TOTAL_2="222" WEIGHT="100.0" Z="0.04002224195840984">
<NAME>Modafinil</NAME>
<DICH_DATA CI_END="9.132850849113105" CI_START="0.2389543798315429" EFFECT_SIZE="1.4772727272727273" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9606063651332829" LOG_CI_START="-0.6216850048199465" LOG_EFFECT_SIZE="0.16946068015666813" ORDER="28449" O_E="0.0" SE="0.9294457831791286" STUDY_ID="STD-DeBattista-2003" TOTAL_1="69" TOTAL_2="67" VAR="0.8638694638694637" WEIGHT="49.09504406329954"/>
<DICH_DATA CI_END="5.394735507762782" CI_START="0.043454878440600156" EFFECT_SIZE="0.48417721518987344" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7319701570198679" LOG_CI_START="-1.3619614606214778" LOG_EFFECT_SIZE="-0.31499565180080497" ORDER="28450" O_E="0.0" SE="1.2299857973312005" STUDY_ID="STD-Fava-2005" TOTAL_1="159" TOTAL_2="155" VAR="1.512865061636469" WEIGHT="50.90495593670047"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.721304862873125" CI_START="0.4688300528700535" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.320855614973262" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="0.570695250467659" LOG_CI_START="-0.3289845570213254" LOG_EFFECT_SIZE="0.12085534672316675" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.5984923417139316" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.5265698417254029">
<NAME>Tolerability: proportion of participants experiencing side effects (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.721304862873125" CI_START="0.4688300528700535" DF="0.0" EFFECT_SIZE="1.320855614973262" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" I2="0.0" ID="CMP-003.11.01" LOG_CI_END="0.570695250467659" LOG_CI_START="-0.3289845570213254" LOG_EFFECT_SIZE="0.12085534672316675" NO="1" P_CHI2="1.0" P_Z="0.5984923417139316" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.5265698417254029">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="3.721304862873125" CI_START="0.4688300528700535" EFFECT_SIZE="1.320855614973262" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.570695250467659" LOG_CI_START="-0.3289845570213254" LOG_EFFECT_SIZE="0.12085534672316675" ORDER="28451" O_E="0.0" SE="0.5284763724059014" STUDY_ID="STD-Patkar-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.27928727619130095" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.11.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.504004358281279" CI_END="2.9368422213835625" CI_START="0.5022623251719828" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2145226234102677" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="32" I2="60.06396727334816" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="0.4678806151564084" LOG_CI_START="-0.29906939716108977" LOG_EFFECT_SIZE="0.0844056089976593" METHOD="MH" NO="12" P_CHI2="0.1135575175828043" P_Q="0.0" P_Z="0.6661759661139144" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.24926710989570608" TOTALS="SUB" TOTAL_1="227" TOTAL_2="220" WEIGHT="100.0" Z="0.43140218025082294">
<NAME>Tolerability: headache (medium term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.12.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Psychostimulants</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.504004358281279" CI_END="2.9368422213835625" CI_START="0.5022623251719828" DF="1.0" EFFECT_SIZE="1.2145226234102677" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="32" I2="60.06396727334816" ID="CMP-003.12.02" LOG_CI_END="0.4678806151564084" LOG_CI_START="-0.29906939716108977" LOG_EFFECT_SIZE="0.0844056089976593" NO="2" P_CHI2="0.1135575175828043" P_Z="0.6661759661139144" STUDIES="2" TAU2="0.24926710989570608" TOTAL_1="227" TOTAL_2="220" WEIGHT="100.0" Z="0.43140218025082294">
<NAME>Modafinil</NAME>
<DICH_DATA CI_END="5.21351193161447" CI_START="0.8049866461643018" EFFECT_SIZE="2.048611111111111" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.7171303718020071" LOG_CI_START="-0.09421132403618031" LOG_EFFECT_SIZE="0.31145952388291337" ORDER="28452" O_E="0.0" SE="0.47658612834151826" STUDY_ID="STD-DeBattista-2003" TOTAL_1="69" TOTAL_2="67" VAR="0.2271343377275581" WEIGHT="42.60261417763494"/>
<DICH_DATA CI_END="1.5517642180313602" CI_START="0.4374502398974937" EFFECT_SIZE="0.823905109489051" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.19082573329653554" LOG_CI_START="-0.3590713409662247" LOG_EFFECT_SIZE="-0.08412280383484458" ORDER="28453" O_E="0.0" SE="0.32301226345636336" STUDY_ID="STD-Fava-2005" TOTAL_1="158" TOTAL_2="153" VAR="0.1043369223432031" WEIGHT="57.39738582236507"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.402535691427877" CI_START="0.18509826813114538" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.13" LOG_CI_END="0.7325976446971534" LOG_CI_START="-0.7325976446971533" LOG_EFFECT_SIZE="0.0" METHOD="MH" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.00000000000001" Z="0.0">
<NAME>Tolerability: insomnia (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.402535691427877" CI_START="0.18509826813114538" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-003.13.01" LOG_CI_END="0.7325976446971534" LOG_CI_START="-0.7325976446971533" LOG_EFFECT_SIZE="0.0" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.00000000000001" Z="0.0">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="5.402535691427877" CI_START="0.18509826813114538" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7325976446971534" LOG_CI_START="-0.7325976446971533" LOG_EFFECT_SIZE="0.0" ORDER="28454" O_E="0.0" SE="0.8606629658238704" STUDY_ID="STD-Patkar-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.7407407407407407" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.13.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.36477305947930544" CI_END="2.497323445933175" CI_START="0.6185808470419911" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2428984079654972" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="0.39747479452872037" LOG_CI_START="-0.20860353107184476" LOG_EFFECT_SIZE="0.09443563172843779" METHOD="MH" NO="14" P_CHI2="0.5458675329242055" P_Q="0.0" P_Z="0.5413448518063375" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="227" TOTAL_2="220" WEIGHT="100.0" Z="0.6107805847094743">
<NAME>Tolerability: insomnia (medium term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.14.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Psychostimulants</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.36477305947930544" CI_END="2.497323445933175" CI_START="0.6185808470419911" DF="1.0" EFFECT_SIZE="1.2428984079654972" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" I2="0.0" ID="CMP-003.14.02" LOG_CI_END="0.39747479452872037" LOG_CI_START="-0.20860353107184476" LOG_EFFECT_SIZE="0.09443563172843779" NO="2" P_CHI2="0.5458675329242055" P_Z="0.5413448518063375" STUDIES="2" TAU2="0.0" TOTAL_1="227" TOTAL_2="220" WEIGHT="100.0" Z="0.6107805847094743">
<NAME>Modafinil</NAME>
<DICH_DATA CI_END="3.775915316251128" CI_START="0.592733363352247" EFFECT_SIZE="1.496031746031746" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.5770222456638354" LOG_CI_START="-0.22714062681533795" LOG_EFFECT_SIZE="0.17494080942424875" ORDER="28455" O_E="0.0" SE="0.47236925196468466" STUDY_ID="STD-DeBattista-2003" TOTAL_1="69" TOTAL_2="67" VAR="0.22313271020167572" WEIGHT="52.16175922474842"/>
<DICH_DATA CI_END="2.824654589864766" CI_START="0.33096835306164035" EFFECT_SIZE="0.9668874172185431" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4509653481245732" LOG_CI_START="-0.4802135311420379" LOG_EFFECT_SIZE="-0.014624091508732315" ORDER="28456" O_E="0.0" SE="0.5469790830909993" STUDY_ID="STD-Fava-2005" TOTAL_1="158" TOTAL_2="153" VAR="0.2991861173390703" WEIGHT="47.838240775251585"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="32.889319573224824" CI_START="0.3156865567336114" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.2222222222222223" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.15" LOG_CI_END="1.5170548887258732" LOG_CI_START="-0.5007439118066108" LOG_EFFECT_SIZE="0.5081554884596312" METHOD="MH" NO="15" P_CHI2="1.0" P_Q="0.0" P_Z="0.3235538608141464" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.9871811358639">
<NAME>Tolerability: nausea (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="32.889319573224824" CI_START="0.3156865567336114" DF="0.0" EFFECT_SIZE="3.2222222222222223" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-003.15.01" LOG_CI_END="1.5170548887258732" LOG_CI_START="-0.5007439118066108" LOG_EFFECT_SIZE="0.5081554884596312" NO="1" P_CHI2="1.0" P_Z="0.3235538608141464" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.9871811358639">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="32.889319573224824" CI_START="0.3156865567336114" EFFECT_SIZE="3.2222222222222223" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5170548887258732" LOG_CI_START="-0.5007439118066108" LOG_EFFECT_SIZE="0.5081554884596312" ORDER="28457" O_E="0.0" SE="1.1852650036979324" STUDY_ID="STD-Patkar-2006" TOTAL_1="30" TOTAL_2="30" VAR="1.40485312899106" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.15.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.129072083621997" CI_END="15.95334014321997" CI_START="0.19816021796274141" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.7780093813065838" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" I2="80.50329604075617" I2_Q="0.0" ID="CMP-003.16" LOG_CI_END="1.2028516249419323" LOG_CI_START="-0.70298352872761" LOG_EFFECT_SIZE="0.2499340481071611" METHOD="MH" NO="16" P_CHI2="0.02352834120325753" P_Q="0.0" P_Z="0.6072064322618016" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="2.019681011814692" TOTALS="SUB" TOTAL_1="227" TOTAL_2="220" WEIGHT="100.0" Z="0.5140651665041912">
<NAME>Tolerability: nausea (medium term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.16.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Psychostimulants</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.129072083621997" CI_END="15.95334014321997" CI_START="0.19816021796274141" DF="1.0" EFFECT_SIZE="1.7780093813065838" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" I2="80.50329604075617" ID="CMP-003.16.02" LOG_CI_END="1.2028516249419323" LOG_CI_START="-0.70298352872761" LOG_EFFECT_SIZE="0.2499340481071611" NO="2" P_CHI2="0.02352834120325753" P_Z="0.6072064322618016" STUDIES="2" TAU2="2.019681011814692" TOTAL_1="227" TOTAL_2="220" WEIGHT="100.0" Z="0.5140651665041912">
<NAME>Modafinil</NAME>
<DICH_DATA CI_END="2.4580946179592846" CI_START="0.1292407330833207" EFFECT_SIZE="0.5636363636363636" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.390598595908747" LOG_CI_START="-0.8886005872286893" LOG_EFFECT_SIZE="-0.24900099565997116" ORDER="28458" O_E="0.0" SE="0.75140793231301" STUDY_ID="STD-DeBattista-2003" TOTAL_1="69" TOTAL_2="67" VAR="0.564613880742913" WEIGHT="48.49576354504359"/>
<DICH_DATA CI_END="18.50066098703468" CI_START="1.4868364755543033" EFFECT_SIZE="5.244755244755245" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" LOG_CI_END="1.2671872450459138" LOG_CI_START="0.17226320680736248" LOG_EFFECT_SIZE="0.7197252259266382" ORDER="28459" O_E="0.0" SE="0.6431638000227264" STUDY_ID="STD-Fava-2005" TOTAL_1="158" TOTAL_2="153" VAR="0.41365967365967365" WEIGHT="51.504236454956406"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.627939778925991" CI_START="0.04141051521604122" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.4827586206896552" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.17" LOG_CI_END="0.7503494416731447" LOG_CI_START="-1.3828893661145807" LOG_EFFECT_SIZE="-0.316269962220718" METHOD="MH" NO="17" P_CHI2="1.0" P_Q="0.0" P_Z="0.5611318666743456" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.5811611274663572">
<NAME>8Tolerability: tremor (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.627939778925991" CI_START="0.04141051521604122" DF="0.0" EFFECT_SIZE="0.4827586206896552" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.17.01" LOG_CI_END="0.7503494416731447" LOG_CI_START="-1.3828893661145807" LOG_EFFECT_SIZE="-0.316269962220718" NO="1" P_CHI2="1.0" P_Z="0.5611318666743456" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.5811611274663572">
<NAME>Psychostimulants</NAME>
<DICH_DATA CI_END="5.6279397789259935" CI_START="0.04141051521604121" EFFECT_SIZE="0.4827586206896552" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7503494416731449" LOG_CI_START="-1.382889366114581" LOG_EFFECT_SIZE="-0.316269962220718" ORDER="28460" O_E="0.0" SE="1.2530750353969133" STUDY_ID="STD-Patkar-2006" TOTAL_1="30" TOTAL_2="30" VAR="1.5701970443349755" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.17.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Modafinil</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9087459149833974" CI_END="1.7109942408227032" CI_START="0.3148442163577685" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7339595635622435" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="0.23324854771577605" LOG_CI_START="-0.5019042802147913" LOG_EFFECT_SIZE="-0.13432786624950763" METHOD="MH" NO="18" P_CHI2="0.3404475122202897" P_Q="0.0" P_Z="0.4738350287655413" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="227" TOTAL_2="220" WEIGHT="100.0" Z="0.7162531924423589">
<NAME>Tolerability: upper respiratory tract infection (medium term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.18.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Psychostimulants</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9087459149833974" CI_END="1.7109942408227032" CI_START="0.3148442163577685" DF="1.0" EFFECT_SIZE="0.7339595635622435" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" I2="0.0" ID="CMP-003.18.02" LOG_CI_END="0.23324854771577605" LOG_CI_START="-0.5019042802147913" LOG_EFFECT_SIZE="-0.13432786624950763" NO="2" P_CHI2="0.3404475122202897" P_Z="0.4738350287655413" STUDIES="2" TAU2="0.0" TOTAL_1="227" TOTAL_2="220" WEIGHT="100.0" Z="0.7162531924423589">
<NAME>Modafinil</NAME>
<DICH_DATA CI_END="4.79424069037061" CI_START="0.3158067027730978" EFFECT_SIZE="1.23046875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6807198335933028" LOG_CI_START="-0.5005786566378009" LOG_EFFECT_SIZE="0.09007058847775094" ORDER="28461" O_E="0.0" SE="0.6939005806835846" STUDY_ID="STD-DeBattista-2003" TOTAL_1="69" TOTAL_2="67" VAR="0.4814980158730159" WEIGHT="29.831240070741288"/>
<DICH_DATA CI_END="1.597176959208127" CI_START="0.17117647385304915" EFFECT_SIZE="0.5228758169934641" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.20335303645784633" LOG_CI_START="-0.7665559241091567" LOG_EFFECT_SIZE="-0.28160144382565516" ORDER="28462" O_E="0.0" SE="0.569729324563844" STUDY_ID="STD-Fava-2005" TOTAL_1="158" TOTAL_2="153" VAR="0.3245915032679738" WEIGHT="70.16875992925871"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Psychostimulants versus placebo: concomitant serious medical condition</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="21" TOTAL_2="21" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Reduction in depression symptoms (short term)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.29556125168017144" CI_START="-2.2585596609678977" EFFECT_SIZE="-1.2770604563240346" ESTIMABLE="YES" MEAN_1="15.7" MEAN_2="22.3" ORDER="28463" SD_1="5.6" SD_2="4.2" SE="0.5007741021701437" STUDY_ID="STD-Lee-2005" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.48677174585838623" CI_START="-1.2008348394898547" EFFECT_SIZE="-0.35703154681573424" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="9.4" ORDER="28464" SD_1="3.9" SD_2="6.1" SE="0.43051979491966846" STUDY_ID="STD-Wagner-2000" TOTAL_1="11" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>